Document:

Pursuant
    to 17 CFR 229.601(b)(10)(iv), confidential information (indicated by [***]) has been omitted from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed.

   Exhibit 10.6

   

  Execution Version

  	 

  

   

  AEGERION PHARMACEUTICALS. INC.,

   

  THE GUARANTOR PARTIES HERETO

   

  and

   

  GLAS TRUST COMPANY LLC

   

  as Trustee

  
   

  

  
 

  

  INDENTURE

   

  Dated as of September 24, 2019

   

  

  
  

  

  
 

  

  5.00% Convertible Senior Notes due 2025

   

  	 

  

   

  

   

  
    
      
 

  

  CROSS REFERENCE TABLE*

   

  

  

  	
          Trust 

          Indenture 

          Act 

          Section 

        	 	
          Indenture 

          Section 

        
	 	 	 
	310	(a)(1)	 	11.09
	 	(a)(2)	 	11.09
	 	(a)(3)	 	N/A
	 	(a)(4)	 	N/A
	 	(a)(5)	 	N/A
	 	(b)	 	11.09, 11.03
	 	(c)	 	N/A
	311	(a)	 	11.03
	 	(b)	 	11.03
	 	(c)	 	N/A
	312	(a)	 	2.08
	 	(b)	 	N/A
	 	(c)	 	N/A
	313	(a)	 	N/A
	 	(b)(1)	 	N/A
	 	(b)(2)	 	N/A
	 	(c)	 	N/A
	 	(d)	 	N/A
	314	(a)	 	3.02(A)
	 	(b)	 	N/A
	 	(c)(1)	 	12.02(A)
	 	(c)(2)	 	12.02(B)
	 	(c)(3)	 	N/A
	 	(d)	 	N/A
	 	(e)	 	12.02(A), 12.02(B)
	 	(f)	 	N/A
	315	(a)	 	11.01(B)
	 	(b)	 	11.05
	 	(c)	 	11.01(A)
	 	(d)	 	11.01(C)
	 	(e)	 	7.12
	316	(a) (last sentence) 	2.15
	 	(a)(1)(A) 	7.06
	 	(a)(1)(B) 	7.05
	 	(a)(2)	 	N/A
	 	(b)	 	7.08
	 	(c)	 	N/A
	317	(a)(1)	 	7.09
	 	(a)(2)	 	7.10
	 	(b)	 	2.07

   

  

   

  
    
      
 

  

  	
          Trust 

          Indenture 

          Act 

          Section 

        	 	
          Indenture 

          Section 

        
	318	(a)	 	N/A
	 	(b)	 	12.17
	 	(c)	 	N/A

   

  

  N/A means not applicable. 

  * This Cross Reference Table is not part of the Indenture.

   

  
    
      
 

  

  
  

  

  TABLE OF CONTENTS

   

  	 	Page
	 	 
	Article 1.    Definitions; Rules of Construction	1
	 	 	 	 	 
	 	Section 1.01.	 	Definitions	1
	 	Section 1.02.	 	Other Definitions	17
	 	Section 1.03.	 	Rules of Construction	18
	 	 	 	 	 
	Article 2.   The Notes	19
	 	 
	 	Section 2.01.	 	Form, Dating and Denominations	19
	 	Section 2.02.	 	Execution, Authentication and Delivery	20
	 	Section 2.03.	 	Initial Notes and Additional Notes	21
	 	Section 2.04.	 	Method of Payment	21
	 	Section 2.05.	 	Accrual of Interest; Defaulted Amounts; When Payment Date is Not a Business Day

        	22
	 	Section 2.06.	 	Registrar, Paying Agent and Conversion Agent	22
	 	Section 2.07.	 	Paying Agent and Conversion Agent to Hold Property in Trust	23
	 	Section 2.08.	 	Holder Lists	24
	 	Section 2.09.	 	Legends	24
	 	Section 2.10.	 	Transfers and Exchanges; Certain Transfer Restrictions	24
	 	Section 2.11.	 	Exchange and Cancellation of Notes to Be Converted, Redeemed or Repurchased	30
	 	Section 2.12.	 	Replacement Notes	31
	 	Section 2.13.	 	Registered Holders; Certain Rights with Respect to Global Notes	31
	 	Section 2.14.	 	Cancellation	32
	 	Section 2.15.	 	Notes Held by the Company	32
	 	Section 2.16.	 	Temporary Notes	32
	 	Section 2.17.	 	Outstanding Notes	32
	 	Section 2.18.	 	Repurchases by the Company	33
	 	Section 2.19.	 	CUSIP and ISIN Numbers	33
	 	 	 	 	 
	Article 3.   Covenants	34
	 	 
	 	Section 3.01.	 	Payment on Notes	34
	 	Section 3.02.	 	Reports	34
	 	Section 3.03.	 	Additional Interest	34
	 	Section 3.04.	 	Additional Amounts	35
	 	Section 3.05.	 	Compliance and Default Certificates	38
	 	Section 3.06.	 	Stay, Extension and Usury Laws	38
	 	Section 3.07.	 	Corporate Existence	38
	 	Section 3.08.	 	Restriction on Acquisition of Notes by the Company	38
	 	Section 3.09.	 	Further Instruments and Acts	39
	 	Section 3.10.	 	Listing	39
	 	Section 3.11.	 	Restricted Payments	39
	 	Section 3.12.	 	Dispositions	40
	 	Section 3.13.	 	Indebtedness	41

   

  

   

  
    - i -

    
      
 

  

  	Article 4.   Repurchase and Redemption	43
	 	 
	 	Section 4.01.	 	No Sinking Fund	43
	 	Section 4.02.	 	Right of Holders to Require the Company to Repurchase Notes upon a Fundamental Change	43
	 	Section 4.03.	 	Right of the Company to Redeem the Notes	47
	 	 	 	 	 
	Article 5.   Conversion	51
	 	 
	 	Section 5.01.	 	Right to Convert	51
	 	Section 5.02.	 	Conversion Procedures	52
	 	Section 5.03.	 	Settlement upon Conversion	53
	 	Section 5.04.	 	Reserve and Status of Ordinary Shares Issued upon Conversion	56
	 	Section 5.05.	 	Adjustments to the Conversion Rate	56
	 	Section 5.06.	 	Voluntary Adjustments	66
	 	Section 5.07.	 	Adjustments to the Conversion Rate in Connection with a Make-Whole Fundamental Change	66
	 	Section 5.08.	 	Restriction on Conversions	68
	 	Section 5.09.	 	Effect of Ordinary Share Change Event	69
	 	Section 5.10.	 	Responsibility of Trustee	70
	 	 	 	 	 
	Article 6.   Successors	71
	 	 	 	 	 
	 	Section 6.01.	 	When the Company May Merge, Etc.	71
	 	Section 6.02.	 	Successor Corporation Substituted	71
	 	 	 	 	 
	Article 7.   Defaults and Remedies	72
	 	 	 	 	 
	 	Section 7.01.	 	Events of Default	72
	 	Section 7.02.	 	Acceleration	74
	 	Section 7.03.	 	Sole Remedy for a Failure to Report	74
	 	Section 7.04.	 	Other Remedies	75
	 	Section 7.05.	 	Waiver of Past Defaults	76
	 	Section 7.06.	 	Control by Majority	76
	 	Section 7.07.	 	Limitation on Suits	76
	 	Section 7.08.	 	Absolute Right of Holders to Receive Payment and Conversion Consideration	77
	 	Section 7.09.	 	Collection Suit by Trustee	77
	 	Section 7.10.	 	Trustee May File Proofs of Claim	77
	 	Section 7.11.	 	Priorities	78
	 	Section 7.12.	 	Undertaking for Costs	78
	 	 	 	 	 
	Article 8.   Amendments, Supplements and Waivers	78
	 	 	 	 	 
	 	Section 8.01.	 	Without the Consent of Holders	78
	 	Section 8.02.	 	With the Consent of Holders	79
	 	Section 8.03.	 	Notice of Amendments, Supplements and Waivers	81
	 	Section 8.04.	 	Revocation, Effect and Solicitation of Consents; Special Record Dates; Etc.	81
	 	Section 8.05.	 	Notations and Exchanges	81
	 	Section 8.06.	 	Trustee to Execute Supplemental Indentures	82

   

  
    - ii -

    
      
 

  

  	Article 9.   Guarantees	82
	 	 
	 	Section 9.01.	 	Guarantees	82
	 	Section 9.02.	 	Limitation on Guarantor Liability	83
	 	Section 9.03.	 	Execution and Delivery of Guarantee	84
	 	Section 9.04.	 	When Guarantors May Merge, Etc.	84
	 	Section 9.05.	 	Future Guarantors	85
	 	Section 9.06.	 	Application of Certain Provisions to the Guarantors	86
	 	 	 	 	 
	Article 10.   Satisfaction and Discharge	86
	 	 	 	 	 
	 	Section 10.01.	 	Termination of Company’s Obligations	86
	 	Section 10.02.	 	Repayment to Company	87
	 	Section 10.03.	 	Reinstatement	87
	 	 	 	 	 
	Article 11.   Trustee	87
	 	 	 	 	 
	 	Section 11.01.	 	Duties of the Trustee	87
	 	Section 11.02.	 	Rights of the Trustee	89
	 	Section 11.03.	 	Individual Rights of the Trustee	90
	 	Section 11.04.	 	Trustee’s Disclaimer	90
	 	Section 11.05.	 	Notice of Defaults	91
	 	Section 11.06.	 	Compensation and Indemnity	91
	 	Section 11.07.	 	Replacement of the Trustee	92
	 	Section 11.08.	 	Successor Trustee by Merger, Etc.	93
	 	Section 11.09.	 	Eligibility; Disqualification	93
	 	 	 	 	 
	Article 12.   Miscellaneous	94
	 	 	 	 	 
	 	Section 12.01.	 	Notices	94
	 	Section 12.02.	 	Delivery of Officer’s Certificate and Opinion of Counsel as to Conditions Precedent	96
	 	Section 12.03.	 	Statements Required in Officer’s Certificate and Opinion of Counsel	96
	 	Section 12.04.	 	Rules by the Trustee, the Registrar and the Paying Agent	96
	 	Section 12.05.	 	No Personal Liability of Directors, Officers, Employees and Shareholders	96
	 	Section 12.06.	 	Governing Law; Waiver of Jury Trial	97
	 	Section 12.07.	 	Submission to Jurisdiction	97
	 	Section 12.08.	 	No Adverse Interpretation of Other Agreements	97
	 	Section 12.09.	 	Successors	97
	 	Section 12.10.	 	Force Majeure	97
	 	Section 12.11.	 	U.S.A. PATRIOT Act	98
	 	Section 12.12.	 	Calculations; Determinations	98
	 	Section 12.13.	 	Severability	98
	 	Section 12.14.	 	Counterparts	98
	 	Section 12.15.	 	Table of Contents, Headings, Etc.	98
	 	Section 12.16.	 	Withholding Taxes	99
	 	Section 12.17.	 	Trust Indenture Act Controls	99
	 	 	 	 	 
	Exhibits	 	 	 
	 	 	 	 	 
	Exhibit A: Form of Note	A-l

  

   

  
    - iii -

    
      
 

  

  	Exhibit B: Form of Global Note Legend	B-1

   

  

   

  

  
    - iv -

    
      
 

  

  
  INDENTURE, dated as of September 24, 2019, among Aegerion Pharmaceuticals, Inc., a Delaware corporation, as issuer (the “Company”), Amryt Pharma Holdings plc, a company incorporated in England and Wales with company number 12107859 (to be
    renamed on or around the date hereof as Amryt Pharma plc) (the “Parent”), Amryt Pharma plc, a company incorporated in
    England and Wales with company number 05316808 (to be renamed and re-registered on or around the date hereof as Amryt Pharma Holdings Limited) (“Old Parent”), the additional guarantors listed on the signature pages hereto, as guarantors (together with the Parent and Old Parent, the “Guarantors”), and GLAS Trust Company LLC, a limited liability company organized and existing under the laws of the State
    of New Hampshire, as trustee (the “Trustee”).

   

  Each party to this Indenture (as defined below) agrees as follows for the benefit of the other party and for the equal and ratable
    benefit of the Holders (as defined below) of the Company’s 5.00% Convertible Senior Notes due 2025 (the “Notes”).

   

  Article 1.      DEFINITIONS; RULES OF CONSTRUCTION

   

  Section 1.01. Definitions.

   

  “144A Global Note” means a Global Note bearing the
    Private Placement Legend and deposited with or on behalf of, and registered in the name of, the Depositary or its nominee that will be issued in a denomination equal to the outstanding principal amount of the Notes and initially issued in reliance on
    Rule 144A.

   

  “Additional Interest” means any interest
    that accrues on any Note pursuant to Section 3.03.

   

  “Affiliate” has the meaning set forth in Rule 144 as in effect on the Issue Date.

   

  “Applicable Procedures” means, with
    respect to any transfer or exchange of or for beneficial interests in any Global Note, the rules and procedures of the Depositary, Euroclear and Clearstream that apply to such transfer or exchange.

   

  “Attributable Indebtedness” means, at
    any date, (a) in respect of any Capital Lease Obligation (other than a lease resulting from a Sale Leaseback) of any Person, the capitalized amount thereof that would appear on a balance sheet of such Person prepared as of such date in accordance with
    IFRS, and (b) in respect of any Sale Leaseback, the present value, discounted in accordance with IFRS, at the interest rate implicit in the related lease, of the obligations of the lessee for net rental payments over the remaining term of such lease
    (including any period for which such lease has been extended or may, at the option of the lessor be extended).

   

  “Authorized Denomination” means, with respect to a
    Note, a principal amount thereof equal to $1,000 or any integral multiple of $1 in excess thereof.

   

  “Bankruptcy Law” means Title 11, United
    States Code, or any similar U.S. federal or state or non-U.S. law for the relief of debtors.

   

  “Board of Directors” means the board of directors of the Company or a committee
    of

  
    - 1 -

    
      
 

  

  such board duly authorized to act on behalf of such board.

   

  “Business Day” means any day other
    than (i) a Saturday, (ii) a Sunday or (iii) any day on which banking institutions in New York City or London are authorized or required by law or executive order to close or be closed.

   

  “Capital Lease” means, with respect to
    any Person, any leasing or similar arrangement conveying the right to use any property, whether real or personal property, or a combination thereof, by that Person as lessee that, in conformity with IFRS, is required to be accounted for as a capital
    lease on the balance sheet of such Person.

   

  “Capital Lease Obligation” means, with respect to any
    Person, all monetary or financial obligations of such Person and its Subsidiaries under any Capital Leases, and the amount of such obligations shall be the capitalized amount thereof determined in accordance with IFRS, and the stated maturity thereof
    shall be the date of the last payment of rent or any other amount due under such lease prior to the first date on which such lease may be terminated by the lessee without payment of a penalty; provided that any obligations that were not
    required to be included on the balance sheet of such Person as capital lease obligations when incurred but are subsequently re-characterized as capital lease obligations due to a change in accounting rules after the Issue Date shall for all purposes
    hereunder not be treated as a Capital Lease Obligation.

   

  “Capital Stock” of any Person means any
    and all shares of, interests in, rights to purchase, warrants or options for, participations in, or other equivalents of, in each case however designated, the equity of such Person, but excluding any debt securities convertible into such equity.

   

  “Cash Equivalents” means any of the following: (A)
    readily marketable direct obligations of the Government of the United States or any agency or instrumentality thereof or obligations unconditionally guaranteed by the full faith and credit of the Government of the United States, (B) securities with
    maturities of 365 days or less from the date of acquisition that are issued or fully guaranteed by any state, district or territory of the United States, by any political subdivision or taxing authority of any such state, district or territory or by
    any foreign government, the securities of which state, district or territory, taxing authority or foreign government (as the case may be) are rated at least A by S&P or A by Moody’s, (C) commercial paper maturing not more than two hundred and
    seventy (270) days from the date of issue and issued by a corporation (other than an Affiliate of the Company or any Guarantor) organized under the laws of any state of the United States of America or of the District of Columbia and, at the time of
    acquisition thereof, rated A 2 or higher by S&P, P 2 or higher by Moody’s or F2 or higher by Fitch, (D) money market mutual or similar funds that invest substantially all of their assets in one or more type of securities satisfying the requirements
    of clauses (A) through (C) of this definition, (E) Investments, classified in accordance with IFRS as current assets of the Parent or any of its Subsidiaries, in money market investment programs registered under the Investment Company Act of 1940, as
    amended, which are administered by financial institutions having capital of at least $500,000,000, and the portfolios of which are limited solely to Investments of the character, quality and maturity described in clause (A) of this definition, (F)
    agencies (LSE’s), State (municipal bonds), or corporate bonds having a long term rating of at least A- or

  
    - 2 -

    
      
 

  

  A3 from S&P, Moody’s or Fitch, having maturities of not more than fifteen (15) months from the date of acquisition and (G) money market funds
    having a rating of AAAm/Aaa or better from S&P, Moody’s or Fitch.

   

  “Change in Tax Law” means any change
    or amendment in the laws, rules or regulations of a Relevant Taxing Jurisdiction, or any change in an official written interpretation, administration or application of such laws, rules or regulations by any legislative body, court, governmental taxing
    authority or regulatory or administrative authority of such Relevant Taxing Jurisdiction (including the enactment of any legislation and the publication of any judicial decision or regulatory or administrative interpretation or determination) affecting
    taxation, which change or amendment (A) had not been theretofore publicly announced; and (B) becomes effective on or after September 24, 2019 (or, if the Relevant Taxing Jurisdiction was not a Relevant Taxing Jurisdiction on such date, the date on
    which such Relevant Taxing Jurisdiction became a Relevant Taxing Jurisdiction).

   

  “Close of Business” means 5:00 p.m., New York City time.

   

  “Company” means the Person named as
    such in the first paragraph of this Indenture and, subject to Article 6, its successors and assigns.

   

  “Company Order” means a written request
    or order signed on behalf of the Company by one (1) of its Officers and delivered to the Trustee.

   

  “Conversion Date” means, with respect
    to a Note, the first Business Day on which the requirements set forth in Section 5.02(A) to convert such Note are satisfied.

   

  “Conversion Price” means, as of any
    time, an amount equal to (A) one thousand dollars ($1,000) divided by (B) the Conversion Rate in effect at such time.

   

  “Conversion Rate” initially means
    386.75 Ordinary Shares per $1,000 principal amount of Notes; provided, however, that the Conversion Rate is subject to adjustment pursuant to Article 5; provided, further, that
    whenever this Indenture refers to the Conversion Rate as of a particular date without setting forth a particular time on such date, such reference will be deemed to be to the Conversion Rate immediately after the Close of Business on such date.

   

  “Conversion Share” means any Ordinary
    Share issued or issuable upon conversion of any Note.

   

  “Cumulative Credit” means the sum of (without
    duplication) (A) five million dollars ($5,000,000), (B) fifty percent (50%) of the consolidated net income of the Parent for the period from the Issue Date to the end of the Company’s most recently ended fiscal quarter for which financials statements
    have been delivered in accordance with Section 3.02(A) at the time of such Restricted Payment and (C) one hundred percent (100%) of the aggregate net proceeds, of property received by the Company after the Issue Date from the issue or sale of
    Equity Interests (other than any Equity Interests under the CVR Instrument, excluding any such net proceeds used to pay amounts under the CVR Instrument.

  
    - 3 -

    
      
 

  

  “CVR Instrument” means the deed poll
    entered into by the Parent on or around the date of this Indenture constituting certain contingent value rights.

   

  “Daily Cash Amount” means, with
    respect to any VWAP Trading Day, the lesser of (A) the applicable Daily Maximum Cash Amount; and (B) the Daily Conversion Value for such VWAP Trading Day.

   

  “Daily Conversion Value” means, with
    respect to any VWAP Trading Day, one-twentieth (l/20th) of the product of (A) the Conversion Rate on such VWAP Trading Day; and (B) the Daily VWAP per Ordinary Share on such VWAP Trading Day.

   

  “Daily Maximum Cash Amount” means,
    with respect to the conversion of any Note, the quotient obtained by dividing (A) the Specified Dollar Amount applicable to such conversion by (B) twenty (20).

   

  “Daily Share Amount” means, with
    respect to any VWAP Trading Day, the quotient obtained by dividing (A) the excess, if any, of the Daily Conversion Value for such VWAP Trading Day over the applicable Daily Maximum Cash Amount by (B) the Daily VWAP for such VWAP Trading Day. For the
    avoidance of doubt, the Daily Share Amount will be zero for such VWAP Trading Day if such Daily Conversion Value does not exceed such Daily Maximum Cash Amount.

   

  “Daily VWAP” means, for any VWAP Trading
    Day, the per share volume-weighted average price of the Ordinary Shares on the Relevant Stock Exchange in respect of the period from the scheduled open of trading until the scheduled close of trading of the primary trading session on such VWAP Trading
    Day (or, if such volume-weighted average price is unavailable, the market value of one Ordinary Share on such VWAP Trading Day, determined, using a volume-weighted average price method, by a nationally recognized independent investment banking firm
    selected by the Company, which may include any of the Investors). The Daily VWAP will be determined without regard to after-hours trading or any other trading outside of the regular trading session. The Daily VWAP for any VWAP Trading Day will be
    expressed in U.S. dollars and, if expressed in a different currency for such VWAP Trading Day as determined above (which, for the avoidance of doubt, will be the case at the time the Notes are initially issued), will be translated to U.S. dollars at
    the Prevailing Exchange Rate on such VWAP Trading Day.

   

  “Deed Poll Constituting Loan Notes” means

    the deed poll to be entered into by the Parent in the form set out in schedule 1 of the CVR Instrument if it elects to satisfy its payment obligations under the CVR Instrument by the issue of loan notes.

   

  “Default” means any event that is (or, after notice, passage of time or both,
    would be) an Event of Default.

   

  “Default Settlement Method” means
    Combination Settlement with a Specified Dollar Amount of $1,000 per $1,000 principal amount of Notes; provided, however, that the Company

  

  

   

  
    - 4 -

    
      
 

  

  may, from time to time, change the Default Settlement Method by sending notice of the new Default Settlement Method to the Holders, the Trustee and the
    Conversion Agent.

   

  “Depositary” means The Depository Trust Company or its successor.

   

  “Depositary Participant” means any member of, or participant in, the Depositary.

   

  “Depositary Procedures” means, with respect to
    any conversion, transfer, exchange or transaction involving a Global Note or any beneficial interest therein, the rules and procedures of the Depositary applicable to such conversion, transfer, exchange or transaction.

   

  “Disposition” or “Dispose” means the sale, transfer, license, lease or other disposition of any asset or property by the Parent or any of its Subsidiaries (including any Spin-Off, Sale Leaseback and any
    sale of Equity Interests, but excluding any issuance by the Company or a Guarantor of its own Equity Interests).

   

  “Disqualified Equity Interests” has the
    meaning set forth in the Senior Secured Credit Facility.

   

  “Equity Interests” means, with respect
    to any Person, all of the shares of Capital Stock of (or other ownership or profit interests in) such Person, all of the warrants, options or other rights for the purchase or acquisition from such Person of shares of Capital Stock of (or other
    ownership or profit interests in) such Person, all of the securities convertible into or exchangeable for shares of Capital Stock of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or acquisition
    from such Person of such shares (or such other interests), and all of the other ownership or profit interests in such Person (including partnership, member or trust interests therein), whether voting or nonvoting, in each case, excluding the Notes, and
    any refinancings thereof.

   

  “Ex-Dividend Date” means, with
    respect to an issuance, dividend or distribution on the Ordinary Shares, the first date on which the Ordinary Shares trade on the Relevant Stock Exchange (or, if there is no Relevant Stock Exchange, on the other applicable exchange or in the applicable
    market), regular way, without the right to receive such issuance, dividend or distribution (including pursuant to due bills or similar arrangements required by the relevant stock exchange). For the avoidance of doubt, any alternative trading convention
    on the applicable exchange or market in respect of the Ordinary Shares under a separate ticker symbol or CUSIP number will not be considered “regular way” for this purpose.

   

  “Exchange Act”
    means the U.S. Securities Exchange Act of 1934, as amended.

   

  “Freely Tradable” means, with respect to
    any Note, that such Note would be eligible to be offered, sold or otherwise transferred pursuant to Rule 144 or otherwise if held by a Person that is not an Affiliate of the Company, and that has not been an Affiliate of the Company during the
    immediately preceding three (3) months, without any requirements as to volume, manner of sale, availability of current public information or notice under the Securities Act (except that, during the six (6) month period beginning on, and including, the
    date that is six (6) months after

  
    - 5 -

    
      
 

  

  the Last Original Issue Date of such Note, any such requirement as to the availability of current public information will be disregarded if the same is satisfied at that time), and such
    Note (x) is not identified by a “restricted” CUSIP or ISIN number; and (y) is not represented by any certificate that bears a restricted note legend.

   

  “Fundamental Change” means any of the following events:

   

  (A)          a “person” or “group” (within the meaning of Section 13(d)(3) of the Exchange Act), other than the Parent or its Wholly Owned
    Subsidiaries, or their respective employee benefit plans, files any report with the SEC indicating that such person or group has become the direct or indirect “beneficial owner” (as defined below) of shares of the Parent’s common equity representing
    more than fifty percent (50%) of the voting power of all of the Parent’s then-outstanding common equity; provided, however, that, for these purposes, no “person” or “group” will be deemed to be the beneficial owner of any securities tendered
    pursuant to a tender or exchange offer made by or on behalf of such “person” or “group” until such tendered securities are accepted for purchase or exchange under such offer:

   

  (B)           the consummation of (i) any sale, lease or other transfer, in one transaction or a series of transactions, of all or substantially
    all of the assets of the Parent and its Subsidiaries, taken as a whole, to any Person, other than solely to one or more of the Parent’s Wholly Owned Subsidiaries; or (ii) any transaction or series of related transactions in connection with which
    (whether by means of merger, consolidation,: share exchange, combination, reclassification, recapitalization, acquisition, liquidation or otherwise) all of the Ordinary Shares are exchanged for, converted into, acquired for, or constitutes solely the
    right to receive, other securities, cash or other property (other than changes resulting solely from a subdivision or combination, or a change in par value, of the Ordinary Shares); provided, however, that any merger, consolidation, share
    exchange or combination of the Parent pursuant to which the Persons that directly or indirectly “beneficially owned” (as defined below) all classes of the Parent’s common equity immediately before such transaction directly or indirectly “beneficially
    own,” immediately after such transaction, more than fifty percent (50%) of all classes of common equity of the surviving, continuing or acquiring company or other transferee, as applicable, or the parent thereof, in substantially the same proportions
    vis-a-vis each other as immediately before such transaction will be deemed not to be a Fundamental Change pursuant to this clause (B);

   

  (C)           the Parent’s shareholders approve any plan or proposal for the liquidation or dissolution of the Parent; or

   

  (D)           the Ordinary Shares cease to be listed on any Permitted Exchange;

   

  provided, however, that a transaction or event described in clause (A) or (B) above will not constitute a Fundamental Change if at least
    ninety percent (90%) of the consideration received or to be received by the holders of Ordinary Shares (excluding cash payments for fractional shares or pursuant to dissenters rights), in connection with such transaction or event, consists of shares of
    common stock or ordinary shares listed (or depositary receipts representing shares of common stock or ordinary shares, which depositary receipts are listed) on any Permitted Exchange, or that will be so listed when issued or exchanged in connection
    with such transaction or event, and such transaction or event constitutes an Ordinary Share Change Event whose Reference Property

  
    - 6 -

    
      
 

  

  consists of such consideration.

   

  Notwithstanding the foregoing, (i) the transactions contemplated by the Plan (including the establishment of a holding company above the Parent)
    shall not be deemed, individually or in the aggregate, to constitute a Fundamental Change and (ii) a Fundamental Change shall not be deemed to occur pursuant to clause (A) or (B) above if (x) Parent becomes a direct or indirect
    wholly-owned subsidiary of a holding company or a holding company becomes the successor to Parent under Section 6.02 pursuant to a transaction that is permitted under Section 6.01 of the Indenture and (y) the direct or indirect holders of the Voting
    Stock of such holding company immediately following that transaction (or a series of related transactions) are substantially the same (and hold in the same proportions) as the holders of Parent’s Voting Stock immediately prior to that transaction.
    “Voting Stock” means, with respect to any specified Person as of any date, the capital stock of such Person that is at the time entitled to vote generally in the election of the board of directors of such Person.

   

  For purposes of clause (A) of the definition of Fundamental Change, no Fundamental Change shall be deemed to occur as a result of any of
    Athyrium Capital Management, LP or its affiliates or Highbridge MSF International Ltd., 1992 Tactical Credit Master Fund, L.P. or Highbridge SCF Special Situations SPV, L.P., or their respective affiliates, or any combination of the foregoing persons,
    becoming the “beneficial owner” of more than 50% of the voting power of all of the Parent’s then-outstanding common equity.

   

  For the purposes of this definition, (x) any transaction or event described in both clause (A) and in clause (B)(i) or (ii) above

    (without regard to the proviso in clause (B)) will be deemed to occur solely pursuant to clause (B) above (subject to such proviso); and (y) whether a Person is a “beneficial owner” and whether shares are “beneficially owned” will be determined in
    accordance with Rule 13d-3 under the Exchange Act.

   

  “Fundamental Change Repurchase Date” means the date
    fixed for the repurchase of any Notes by the Company pursuant to Section 4.02(C).

   

  “Fundamental Change Repurchase Notice” means a notice
    (including a notice substantially in the form of the “Fundamental Change Repurchase Notice” set forth in Exhibit A) containing the information, or otherwise
    complying with the requirements, set forth in Section 4.02(F)(i) and Section 4.02(F)(ii).

   

  “Fundamental Change Repurchase Price” means the cash price payable by the
    Company to repurchase any Note upon its Repurchase Upon Fundamental Change, calculated pursuant to Section 4.02(D).

   

  “Global Note” means a Note that is represented by a
    certificate substantially in the form set forth in Exhibit A, registered in the name of the Depositary or its nominee and bearing the Global Note Legend, duly executed by the Company and authenticated
    by the Trustee, and deposited with the Trustee, as custodian for the Depositary.

   

  “Global Note Legend” means a legend
    substantially in the form set forth in Exhibit B.

  
    - 7 -

    
      
 

  

  “Guarantee” means

    the guarantee by each Guarantor of the Company’s obligations under this Indenture and the Notes pursuant to Article 9.

   

  “Guarantor” means

    the Persons named as such in the first paragraph of this Indenture, each other Person that becomes a Guarantor by executing an amended or supplemental indenture pursuant to Sections 8.01(B) and 9.03 and, subject to Section 9.04, the successors and assigns of the foregoing.

   

  “Holder” means
    a person in whose name a Note is registered on the Registrar’s books.

   

  “IAI Global Note” means

    a Global Note bearing the Private Placement Legend, duly executed by the Company and authenticated by the Trustee, and deposited with the Trustee, as custodian for the Depositary, and initially issued to Institutional Accredited Investors.

   

  “IFRS” means
    International Financial Reporting Standards, as in effect from time to time.

   

  “Immaterial Subsidiaries”
    has the meaning set forth in the Senior Secured Credit Facility.

   

  “Indebtedness” of

    any Person means, without duplication, (a) all obligations of such Person for borrowed money, (b) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (c) all obligations of such Person under conditional sale or
    other title retention agreements relating to property acquired by such Person, (d) all obligations of such Person in respect of the deferred purchase price of property or services (excluding (i) accounts payable and other accrued liabilities incurred
    in the ordinary course of business not past due for more than one hundred twenty (120) days after its stated due date (except for accounts payable contested in good faith), (ii) any earn out obligation until such obligation is both required to be
    reflected as a liability on the balance sheet of such Person in accordance with IFRS and not paid after becoming due and payable, (iii) deferred or equity compensation arrangements entered into in the ordinary course of business and payable to
    directors, officers or employees) and (iv) milestone payments due to Software AG Stiftung in connection with Birkin AG in an aggregate amount not to exceed 38,000,000 Euros which shall be payable solely on the basis of the criteria disclosed pursuant
    to the Senior Secured Credit Facility prior to the Issue Date), (e) all Indebtedness (excluding prepaid interest thereon) of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured
    by) any lien on property owned or acquired by such Person, whether or not the Indebtedness secured thereby has been assumed but, in the case of Indebtedness which is not assumed by such Person, limited to the lesser of (x) the amount of such
    Indebtedness and (y) the fair market value of such property, (f) all guarantees by such Person of Indebtedness of others, (g) all Attributable Indebtedness of such Person, (h) all obligations, contingent or otherwise, of such Person as an account party
    in respect of letters of credit and letters of guaranty (excluding the portion thereof that has been fully cash collateralized in a manner permitted by the Senior Secured Credit Facility), (i) all obligations, contingent or otherwise, of such Person in
    respect of bankers’ acceptances, surety bonds and performance bonds, whether or not matured and (j) all obligations of such Person in

  
    - 8 -

    
      
 

  

  respect of Disqualified Equity Interests. The Indebtedness of any Person shall include the Indebtedness of
    any other entity (including any partnership in which such Person is a general partner) to the extent such Person is directly liable therefor as a result of such Person’s ownership interest in or other relationship with such entity, except to the extent
    the terms of such Indebtedness provide that such Person is not liable therefor. Anything herein to the contrary notwithstanding, obligations in respect of any Indebtedness that has been irrevocably defeased (either covenant or legal) or satisfied and
    discharged pursuant to the terms of the instrument creating or governing such Indebtedness shall not constitute Indebtedness.

   

  “Indenture” means

    this Indenture, as amended or supplemented from time to time.

   

  “Indirect Participant” means

    a Person who holds a beneficial interest in a Global Note through a Participant.

   

  “Institutional Accredited Investor” means an institution that is an “accredited investor” as defined in Rule 501(a)(1), (2), (3) or (7) under the Securities Act.

   

  “Intellectual Property” has

    the meaning set forth in the Senior Secured Credit Facility.

   

  “Internal Revenue Code” means

    the United States Internal Revenue Code of 1986, as amended.

   

  “Investment” in

    any Person, means any loan or advance to such Person, any purchase or other acquisition of any voting Equity Interests or other Equity Interests or Indebtedness or the assets comprising a division or business unit or a substantial part or all of the
    business of such Person, any capital contribution to such Person or any other direct or indirect investment in such Person.

   

  “Investors” means

    existing unsecured creditors of the Company, other than the Department of Justice and other governmental entities and trade creditors, allocated (a) on a pro rata basis based on the respective principal or face amount of the respective unsecured claims
    and (b) dollar for dollar in the case of the existing $22.5 million roll up loans under the Company’s secured bridge financing that was funded in November 2018 (plus accrued fees and interest thereon, estimated to be approximately $500,000) and any
    amounts funded under the debtor-in-possession financing upon the emergence of the Company’s bankruptcy case that are not paid in full in cash on the Plan effective date.

   

  “Interest Payment Date” means,

    with respect to a Note, each April 1 and October 1 of each year, commencing on April 1, 2020 (or commencing on such other date specified in the certificate representing such Note). For the avoidance of doubt the Maturity Date is an Interest Payment
    Date.

   

  “Issue Date” means

    September 24, 2019.

   

  “Last Original Issue Date”
      means (A) with respect to any Notes issued pursuant to the Plan, and any Notes issued in exchange therefor or in substitution thereof, the Issue Date and (B)

  
    - 9 -

    
      
 

  

  with respect to any Notes issued pursuant to Section 2.03(B),
    and any Notes issued in exchange therefor or in substitution thereof, either (i) the date such Notes are originally issued or (ii) such other date as is specified in an Officer’s Certificate delivered to the Trustee before the original issuance of
    such Notes.

   

  “Last Reported Sale Price”
      of the Ordinary Shares for any Trading Day means the closing sale price per share (or, if no closing sale price is reported, the average of the last bid price and the last ask price per share or, if more than one in either case, the
    average of the average last bid prices and the average last ask prices per share) of the Ordinary Shares on such Trading Day as reported in composite transactions for the Relevant Stock Exchange. If the Last Reported Sale Price cannot be determined
    pursuant to the previous sentence, then the Last Reported Sale Price will be the average of the mid-point of the last bid price and the last ask price per Ordinary Share on such Trading Day from each of at least three (3) nationally recognized
    independent investment banking firms selected by the Company, which may include any of the Investors. Neither the Trustee nor the Conversion Agent will have any duty to determine the Last Reported Sale Price. The Last Reported Sale Price will be
    determined without regard to after-hours trading or any other trading outside of the regular trading session. The Last Reported Sale Price for any Trading Day will be expressed in U.S. dollars and, if expressed in a different currency for such Trading
    Day as determined above (which, for the avoidance of doubt, will be the case at the time the Notes are initially issued), will be translated to U.S. dollars at the Prevailing Exchange Rate on such Trading Day.

   

  “Make-Whole Fundamental Change” means (A) a Fundamental Change (determined after giving effect to the proviso immediately after clause (D) of the definition thereof, but without regard to the proviso to clause (B)(ii) of the definition
    thereof); or (B) the sending of a Redemption Notice pursuant to Section 4.03(G); provided, however, that the sending of a Redemption Notice will constitute a Make-Whole Fundamental Change only
    with respect to the Notes called for Redemption pursuant to such Redemption Notice and not with respect to any other Notes.

   

  “Make-Whole Fundamental Change Conversion Period” has the following meaning:

   

  (A)          in the case of a Make-Whole Fundamental Change pursuant to clause (A) of the definition thereof, the period from, and including, the Make-Whole Fundamental Change Effective Date of such Make-Whole Fundamental Change to, and including, the thirty fifth
    (35th) Trading Day after such Make-Whole Fundamental Change Effective Date (or, if such Make-Whole Fundamental Change also constitutes a Fundamental Change, to, but excluding, the related Fundamental Change Repurchase Date); and

   

  (B)           in the case of a Make-Whole Fundamental Change pursuant to clause (B) of the
    definition thereof, the period from, and including, the Redemption Notice Date for the related Redemption, to, and including, the Business Day immediately before the related Redemption Date;

   

  provided, however, that if the Conversion Date for the conversion of a Note occurs during the
    Make-Whole Fundamental Change Conversion Period for both a Make-Whole Fundamental Change occurring pursuant to clause (A) of the definition of “Make-Whole Fundamental

  
    - 10 -

    
      
 

  

  Change” and a Make-Whole Fundamental Change occurring pursuant to clause (B) of such definition,
    then, notwithstanding anything to the contrary in Section 5.07, solely for purposes of such conversion, (x) such Conversion Date will be deemed to occur solely during the Make-Whole Fundamental Change
    Conversion Period for the Make-Whole Fundamental Change with the earlier Make-Whole Fundamental Change Effective Date; and (y) the Make-Whole Fundamental Change with the later Make-Whole Fundamental Change Effective Date will be deemed not to have
    occurred (unless the converting Holder notifies the Company to the contrary concurrently on the Conversion Date); provided, further, that if a Holder provides a notice of waiver of the provisions set forth in Section 5.08(A) during
    any Make-Whole Fundamental Change Conversion Period, such notice shall constitute a Conversion Date occurring during such Make-Whole Fundamental Change Conversion Period and the Company will deliver the relevant Conversion Consideration following the
    completion of the 61 calendar day notice period.

   

  “Make-Whole Fundamental Change Effective Date” means (A) with respect to a Make-Whole Fundamental Change pursuant to clause (A) of the definition thereof, the date on which such Make-Whole Fundamental Change occurs or becomes effective; and
    (B) with respect to a Make-Whole Fundamental Change pursuant to clause (B) of the definition thereof, the applicable Redemption Notice Date.

   

  “Market Disruption Event”
      means, with respect to any date, the occurrence or existence, during the one-half hour period ending at the scheduled close of trading on such date on the Relevant Stock Exchange, of any material suspension or limitation imposed on trading
    (by reason of movements in price exceeding limits permitted by the relevant exchange or otherwise) in the Ordinary Shares or in any options contracts or futures contracts relating to the Ordinary Shares.

   

  “Maturity Date” means

    April 1, 2025.

   

  “Nasdaq” means the NASDAQ Global Market or The NASDAQ Global Select Market (or any of their respective successors).

   

  “Net Cash Proceeds” means:

   

  (A)          with respect to the Disposition of any asset by the Company or any Guarantor or any of their
    Subsidiaries the excess, if any, of (i) the sum of cash and Cash Equivalents received in connection with such Disposition (including any cash or Cash Equivalents received by way of deferred payment pursuant to, or by monetization of, a note receivable
    or otherwise, but only as and when so received) over (ii) the sum of (w) the principal amount of any Indebtedness permitted by this Indenture that is secured by a lien on the asset subject to such Disposition and that is repaid (and is timely repaid)
    in connection therewith (other than the Notes), (x) the reasonable out of pocket expenses actually incurred and paid by the Parent or any of its Subsidiaries in connection with such Disposition (including, reasonable attorney’s, accountant’s and other
    similar professional advisor’s fees, investment banking fees, survey costs, title insurance premiums, and related search and recording charges, transfer taxes, deed or mortgage recording taxes, other customary expenses and brokerage, consultant or
    other customary fees) to third parties (other than the Company, the Guarantors or any of their respective Affiliates), (y)

  
    - 11 -

    
      
 

  

  taxes paid or reasonably estimated to be actually payable or that are actually accrued in connection
    therewith with respect to the current tax year as a result of any gain recognized in connection therewith by such Person or any of the direct or indirect stockholders thereof and attributable to such Disposition; provided that, if the amount
    of any estimated taxes pursuant to this subclause (y) exceeds the amount of taxes actually required to be paid in cash, the aggregate amount of such excess shall constitute Net Cash Proceeds and (z) any reasonable reserve actually maintained in respect
    of (1) the sale price of such asset or assets established in accordance with IFRS, and (2) any liabilities associated with such asset or assets and retained by the Parent or any of its Subsidiaries after such sale or other Disposition thereof,
    including pension and other post employment benefit liabilities and liabilities related against any indemnification obligations associated with such transaction and it being understood that “Net Cash Proceeds” shall include any cash or Cash Equivalents
    (a) received upon the Disposition of any non cash consideration received by such Person in any such Disposition, and (b) received upon the reversal (without the satisfaction of any applicable liabilities in cash in a corresponding amount) of any
    reserve described in subclause (z) above or, if such liabilities have not been satisfied in cash and such reserve not reversed within two (2) years after such Disposition, the amount of such reserve; and

   

  (B)           with respect to the incurrence or issuance of any Indebtedness by the Company, the
    Guarantors or any of their respective Subsidiaries not permitted under Section 3.13, the excess, if any, of (i) the sum of the cash received in connection with such incurrence or issuance over (ii) the
    investment banking fees, underwriting discounts, commissions, costs and other out-of-pocket expenses and other customary expenses (including reasonable attorney’s, accountant’s and other similar professional advisor’s fees), incurred by such Person in
    connection with such incurrence or issuance to third parties (other than the Company, the Guarantors or any of their respective Affiliates).

   

  “Note Agent” means any Registrar, Paying Agent or
    Conversion Agent.

   

  “Notes” means the 5.00% Convertible Senior Notes due 2025 issued by the Company pursuant to this
    Indenture.

   

  “Observation Period” means,

    with respect to any Note to be converted, (A) subject to clause (B) below, if the Conversion Date for such Note occurs on or before the twenty-fifth (25th) Scheduled Trading Day immediately before the Maturity
    Date, the twenty (20) consecutive VWAP Trading Days beginning on, and including, the third (3rd) VWAP Trading Day immediately after such Conversion Date; (B) if such Conversion Date occurs on or after the date the Company has sent a Redemption Notice
    calling such Note for Redemption pursuant to Section 4.03(G) and before the related Redemption Date, the twenty (20) consecutive VWAP Trading Days beginning on, and including, the twenty-first (21st) Scheduled Trading Day immediately before
    such Redemption Date; and (C) subject to clause (B) above, if such Conversion Date occurs after the twenty-fifth (25th) Scheduled Trading Day immediately before the Maturity Date, the twenty (20) consecutive
    VWAP Trading Days beginning on, and including, the twenty-first (21st) Scheduled Trading Day immediately before the Maturity Date.

   

  “Officer” means the Chairman of the Board of Directors, the Chief Executive Officer, the President,
    the Chief Operating Officer, the Chief Financial Officer, the Chief Accounting

  
    - 12 -

    
      
 

  

  Officer, the Treasurer, any Assistant Treasurer, the Controller, the Secretary or any Vice-President of the
    Company; provided, that in the case of an Officer’s Certificate delivered pursuant to Section 3.05, Officer shall mean the Chief Executive Officer, Chief Financial Officer or Chief Accounting Officer.

   

  “Officer’s Certificate” means

    a certificate that is signed on behalf of the Company by one (1) of its Officers and that meets the requirements of Section 12.03.

   

  “Open of Business” means

    9:00 a.m., New York City time.

   

  “Opinion of Counsel” means

    an opinion, from legal counsel (including an employee of, or counsel to, the Company or any of its Subsidiaries) reasonably acceptable to the Trustee, that meets the requirements of Section 12.03, subject

    to customary qualifications and exclusions.

   

  “Ordinary Shares” means

    the ordinary shares of the Parent, subject to Section 5.09.

   

  “Parent” means
    the Person named as such in the first paragraph of this Indenture and, subject to Article 6, its successors and assigns.

   

  “Parent Board” means

    the board of directors of Parent or a committee of such board duly authorized to act on behalf of such board.

   

  “Participant” means,

    with respect to the Depositary, Euroclear or Clearstream, a Person who has an account with the Depositary, Euroclear or Clearstream, respectively (and, with respect to DTC, shall include Euroclear and Clearstream).

   

  “Permitted Exchange” means

    the London Stock Exchange’s AIM Market, the Irish Stock Exchange’s Euronext Growth Market, The New York Stock Exchange or Nasdaq (or any of their respective successors).

   

  “Person” or “person” means any individual, corporation, partnership, limited liability company, joint venture, association, joint-stock company, trust, unincorporated
    organization or government or other agency or political subdivision thereof. Any division or series of a limited liability company, limited partnership or trust will constitute a separate “person” under this Indenture.

   

  “Physical Note” means

    a Note (other than a Global Note) that is represented by a certificate substantially in the form set forth in Exhibit A, registered in the name of the Holder of such Note and duly executed by the
    Company and authenticated by the Trustee.

   

  “Plan” means
    the plan of reorganization filed with respect to the Company’s Chapter 11 bankruptcy case and confirmed by a final order.

   

  “Prevailing Exchange Rate”
      means, for purposes of translating, as of any date, any amount in non-U.S. currency to U.S. dollars, the spot mid rate of exchange between such currencies prevailing as of 9am, New York City time, on such date, as displayed on, or derived

  
    - 13 -

    
      
 

  

  from, Bloomberg page “BFIX” (or, if such page is not available, its equivalent successor page) in respect of
    such currencies. If such rate cannot be determined as provided in the immediately preceding sentence on such date (which, for the purpose of this definition, will be deemed to be the “Affected Day”), then the Prevailing Exchange Rate for such date will be determined mutatis mutandis but with respect to the immediately preceding day on which such rate can be so determined; provided, however, that, if
    such immediately preceding day is before the fifth day before such Affected Day, or, if such rate cannot be so determined, then the Prevailing Exchange Rate will be determined in such other manner as prescribed in good faith by an independent advisor.

   

  “Private Placement Legend”
      means a legend substantially in the form set forth in Exhibit C.

   

  “Redemption” means

    the repurchase of any Note by the Company pursuant to Section 4.03.

   

  “Redemption Date” means

    the date fixed for the repurchase of any Notes by the Company pursuant to a Redemption.

   

  “Redemption Notice Date” means,

    with respect to a Redemption, the date on which the Company sends the Redemption Notice for such Redemption pursuant to Section 4.03.

   

  “Redemption Price” means

    the cash price payable by the Company to redeem any Note upon its Redemption, calculated pursuant to Section 4.03(F).

   

  “Refinancing Indebtedness”
      has the meaning set forth in the Senior Secured Credit Facility.

   

  “Regular Record Date” has

    the following meaning with respect to an Interest Payment Date: (A) if such Interest Payment Date occurs on April 1, the immediately preceding March 16; and (B) if such Interest Payment Date occurs on October 1, the immediately preceding September 16.

   

  “Relevant Stock Exchange”
      means (i) the London Stock Exchange’s AIM Market, or (ii) if the Ordinary Shares are not then listed on the London Stock Exchange’s AIM Market, the principal exchange or other market on which the Ordinary Shares are then listed or admitted
    for trading (and, in the case of this clause (ii), the identity of the Relevant Stock Exchange will be determined in good faith by the Board of Directors); provided that if the Ordinary Shares or American Depositary Receipts representing
    Ordinary Shares (“ADRs”) are at any time listed on Nasdaq, references to the London Stock Exchange’s AIM Market in this definition shall be deemed to be
    replaced with Nasdaq unless, as of any relevant date of determination, the aggregate share trading volume of the Ordinary Shares for the preceding twenty (20) Trading Days on the London Stock Exchange’s AIM Market exceeds that on Nasdaq. For the
    avoidance of doubt, in any case where this definition would result in a reference to or computation based on ADRs, the relevant reference or computation will be appropriately adjusted to reflect the relevant ADR exchange ratio relative to the Ordinary
    Shares.

  
    - 14 -

    
      
 

  

  “Repurchase Upon Fundamental Change” means the repurchase of any Note by the Company pursuant to Section 4.02.

   

  “Responsible Officer” means

    (A) any vice president, assistant vice president, any trust officer or assistant trust officer, or any other officer of the Trustee customarily performing functions similar to those performed by any of the above designated officers and (B) with respect
    to a particular corporate trust matter, any other officer of the Trustee to whom such matter is referred because of his or her knowledge of and familiarity with the particular subject and who shall have direct responsibility for the administration of
    this Indenture.

   

  “Restricted Global Note” means

    a Global Note bearing the Private Placement Legend.

   

  “Restricted Payment” means

    any:

   

  (A)          dividend or other distribution (whether in cash, securities or other property) or any payment
    (whether in cash, securities or other property), in each case, with respect to any capital stock or other Equity Interest of any Person or any of its Subsidiaries, including any sinking fund or similar deposit, on account of the purchase, retraction,
    redemption, retirement, defeasance, acquisition, cancellation or termination of any such capital stock or other Equity Interest, or on account of any return of capital to any Person’s stockholders, partners or members (or the equivalent of any thereof
    and including any thereof acquired through the exercise of warrants or rights of conversion, exchange or purchase); and

   

  (B)           payment of any management or similar type fees by the Company or any Guarantors to any
    parent Affiliate thereof that is not a Guarantor.

   

  “Rule 144” means

    Rule 144 under the Securities Act (or any successor rule thereto), as the same may be amended from time to time.

   

  “Sale Leaseback” means

    any transaction or series of related transactions pursuant to which the Parent or any of its Subsidiaries (a) sells, transfers or otherwise disposes of any property, real or personal, whether now owned or hereafter acquired, and (b) as part of such
    transaction, thereafter rents or leases such property or other property that it intends to use for substantially the same purpose or purposes as the property being sold, transferred or disposed.

   

  “Scheduled Trading Day” means

    any day that is scheduled to be a Trading Day on the Relevant Stock Exchange. If the Ordinary Shares are not so listed or traded, then “Scheduled Trading Day” means a Business Day.

   

  “SEC” means the U.S. Securities and Exchange Commission.

   

  “Securities Act” means

    the U.S. Securities Act of 1933, as amended.

   

  “Security” means

    any Note or Conversion Share.

   

  “Senior Secured Credit Facility” means the Credit Agreement, dated as of September

  
    - 15 -

    
      
 

  

  24, 2019, among the Company, Old Parent, the lenders party thereto and Cantor Fitzgerald Securities, as
    administrative agent.

   

  “Settlement Method” means

    Cash Settlement, Physical Settlement or Combination Settlement.

   

  “Significant Subsidiary” means,

    with respect to any Person, any Subsidiary of such Person that constitutes a “significant subsidiary” (as defined in Rule l-02(w) of Regulation S-X under the Exchange Act) of such Person.

   

  “Special Interest” means

    any interest that accrues on any Note pursuant to Section 7.03.

   

  “Specified Dollar Amount”
      means, with respect to the conversion of a Note to which Combination Settlement applies, the maximum cash amount per $1,000 principal amount of such Note deliverable upon such conversion (excluding cash in lieu of any fractional Ordinary
    Share), as determined by the Company in U.S. dollars.

   

  “Share Price” has

    the following meaning for any Make-Whole Fundamental Change: (A) if the holders of Ordinary Shares receive only cash in consideration for their Ordinary Shares in such Make-Whole Fundamental Change and such Make-Whole Fundamental Change is pursuant to
    clause (B) of the definition of “Fundamental Change,” then the Share Price is the amount of cash paid per Ordinary Share in such Make-Whole Fundamental Change; and (B) in all other cases, the Share Price is the average of the Last Reported Sale
    Prices per Ordinary Share for the five (5) consecutive Trading Days ending on, and including, the Trading Day immediately before the Make-Whole Fundamental Change Effective Date of such Make-Whole Fundamental Change.

   

  “Subsidiary” means,

    with respect to any Person, (A) any corporation, association or other business entity (other than a partnership or limited liability company) of which more than fifty percent (50%) of the total voting power of the Capital Stock entitled (without regard
    to the occurrence of any contingency, but after giving effect to any voting agreement or shareholders’ agreement that effectively transfers voting power) to vote in the election of directors, managers or trustees, as applicable, of such corporation,
    association or other business entity is owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of such Person; and (B) any partnership or limited liability company where (i) more than fifty percent (50%) of
    the capital accounts, distribution rights, equity and voting interests, or of the general and limited partnership interests, as applicable, of such partnership or limited liability company are owned or controlled, directly or indirectly, by such Person
    or one or more of the other Subsidiaries of such Person, whether in the form of membership, general, special or limited partnership or limited liability company interests or otherwise; and (ii) such Person or any one or more of the other Subsidiaries
    of such Person is a controlling general partner of, or otherwise controls, such partnership or limited liability company.

   

  “Tax” means any tax, duty, levy, impost, assessment or other
    governmental charge (including penalties and interest and other similar liabilities related thereto).

  
    - 16 -

    
      
 

  

  “Tax Redemption” means

    the Redemption of any Note pursuant to Section 4.03(C).

   

  “Trading Day” means

    any day on which (A) there is no Market Disruption Event; and (B) trading in the Ordinary Shares generally occurs on the Relevant Stock Exchange. If the Ordinary Shares are not so listed or traded, then “Trading Day” means a Business Day.

   

  “Trust Indenture Act” means

    the U.S. Trust Indenture Act of 1939, as amended.

   

  “Trustee” means

    the Person named as such in the first paragraph of this Indenture until a successor replaces it in accordance with the provisions of this Indenture and, thereafter, means such successor.

   

  “Unrestricted Global Note”
      means a Global Note that does not bear and is not required to bear the Private Placement Legend.

   

  “VWAP Market Disruption Event” means, with respect to any date, (A) the failure by the Relevant Stock Exchange to open for trading during its regular trading session on such date; or (B) the occurrence or existence, for more than one half hour period in
    the aggregate, of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the Relevant Stock Exchange or otherwise) in the Ordinary Shares or in any options contracts or futures contracts relating
    to the Ordinary Shares, and such suspension or limitation occurs or exists at any time before 1:00 p.m., New York City time, on such date.

   

  “VWAP Trading Day” means

    a day on which (A) there is no VWAP Market Disruption Event; and (B) trading in the Ordinary Shares generally occurs on the Relevant Stock Exchange. If the Ordinary Shares are not so listed or traded, then “VWAP Trading Day” means a Business Day.

   

  “Wholly Owned Subsidiary”
      of a Person means any Subsidiary of such Person all of the outstanding Capital Stock or other ownership interests of which (other than directors’ qualifying shares) are owned by such Person or one or more Wholly Owned Subsidiaries of such
    Person.

   

  Section 1.02. Other Definitions.

   

  	Term	 	Defined in 

          Section
	“Additional Amounts”	 	3.04(A)
	“Additional Shares”	 	5.07(A)
	“Business Combination Event” 	 	6.01(A)
	“Cash Settlement” 	 	5.03(A)
	“Combination Settlement” 	 	5.03(A)
	“Conversion Agent” 	 	2.06(A)
	“Conversion Consideration” 	 	5.03(B)
	“Default Interest” 	 	2.05(B)
	“Defaulted Amount” 	 	2.05(B)
	“Event of Default” 	 	7.01(A)

   

  

  

   

  
    - 17 -

    
      
 

  

  	“Expiration Date”	 	5.05(A)(v)
	“Expiration Time”	 	5.05(A)(v)
	“FATCA”	 	3.04(A)(iv)
	“Fundamental Change Notice”	 	4.02(E)
	“Fundamental Change Repurchase Right”	 	4.02(A)
	“Guaranteed Obligations”	 	9.01(A)
	“Guarantor Business Combination Event”	 	9.04(A)
	“Initial Notes”	 	2.03(A)
	“Junior Indebtedness”	 	3.13(C)
	“Ordinary Share Change Event”	 	5.09(A)
	“Paying Agent”	 	2.06(A)
	“Physical Settlement”	 	5.03(A)
	“Redemption Notice”	 	4.03(G)
	“Reference Property”	 	5.09(A)
	“Reference Property Unit”	 	5.09(A)
	“Register	 	2.06(B)
	“Registrar”	 	2.06(A)
	“Relevant Taxing Jurisdiction”	 	3.04(A)
	“Reporting Event of Default”	 	7.03(A)
	“Specified Courts”	 	12.07
	“Spin-Off	 	5.05(A)(iii)(2)
	“Spin-Off Valuation Period”	 	5.05(A)(iii)(2)
	“Stated Interest”	 	2.05(A)
	“Successor Corporation”	 	6.01(A)
	“Successor Person”	 	5.09(A)
	“Tax Redemption Opt-Out Election”	 	4.03(C)(ii)
	“Tax Redemption Opt-Out Election Notice”	 	4.03(C)(ii)(l)
	“Tender/Exchange Offer Valuation Period”	 	5.05(A)(v)
	“Transfer Taxes”	 	3.04(B)

   

  Section 1.03. Rules of Construction.

   

  For purposes of this Indenture:

   

  (A)          “or” is not exclusive;

   

  (B)           “including” means “including without limitation”;

   

  (C)           “will” expresses a command;

   

  (D)           the “average” of a set of numerical values refers to the arithmetic average of such
    numerical values;

   

  (E)           a merger involving, or a transfer of assets by, a limited liability company, limited
    partnership or trust will be deemed to include any division of or by, or an allocation of assets to a series of, such limited liability company, limited partnership or trust, or any unwinding of any such division or allocation;

  
    - 18 -

    
      
 

  

  (F)           words in the singular include the plural and in the plural include the singular, unless the
    context requires otherwise;

   

  (G)           “herein,” “hereof’’ and other words of similar import refer to this Indenture as a whole and
    not to any particular Article, Section or other subdivision of this Indenture, unless the context requires otherwise;

   

  (H)           references to currency mean the lawful currency of the United States of America, unless the
    context requires otherwise;

   

  (I)            the exhibits, schedules and other attachments to this Indenture are deemed to form part of
    this Indenture; and

   

  (J)            the term “interest,” when used with respect to a Note, includes any Additional Interest and Special Interest, unless the context requires otherwise.

   

  For purposes of this Indenture, the following
    terms of the Trust Indenture Act have the following meanings:

   

  (i)            “Commission”
      means the SEC;

   

  (ii)           “indenture securities” means the Notes;

   

  (iii)           “indenture security holder” means a Holder;

   

  (iv)          “indenture to be qualified” means this Indenture;

   

  (v)           “indenture trustee” or “institutional trustee” means the Trustee; and

   

  (vi)           “obligor” on

    the indenture securities means the Company.

   

  All other terms used in this Indenture that are defined by the Trust Indenture Act (including by reference
    to another statute) or the related rules of the SEC, and not defined in this Indenture, have the respective meanings so defined by the Trust Indenture Act or such rules.

   

  Article 2. THE NOTES

   

  Section 2.01. Form, Dating and Denominations.

   

  The Notes and the Trustee’s certificate of authentication will be substantially in the form set forth in Exhibit

      A. The Notes will bear the legends required by Section 2.09 and may bear notations, legends or endorsements required by law, stock exchange rule or usage or the Depositary. Each Note will be
    dated as of the date of its authentication.

   

  Except to the extent otherwise provided in a Company Order delivered to the Trustee in connection with the
    issuance and authentication thereof, the Notes will be issued initially in the form of one or more Global Notes. Global Notes may be exchanged for Physical Notes, and

   

  
    - 19 -

    
      
 

  

  Physical Notes may be exchanged for Global Notes, only as provided in Section 2.10.

   

  The Notes will be issuable only in registered form without interest coupons and only in Authorized
    Denominations.

   

  Each certificate representing a Note will bear a unique registration number that is not affixed to any
    other certificate representing another outstanding Note.

   

  The terms contained in the Notes constitute part of this Indenture, and, to the extent applicable, the
    Company and the Trustee, by their execution and delivery of this Indenture, agree to such terms and to be bound thereby; provided, however, that, to the extent that any provision of any Note conflicts with the provisions of this Indenture, the
    provisions of this Indenture will control for purposes of this Indenture and such Note.

   

  Section 2.02. Execution, Authentication and Delivery.

   

  (A)          Due Execution by the Company. At least one (1) duly authorized Officer will sign the
    Notes on behalf of the Company by manual or facsimile signature. A Note’s validity will not be affected by the failure of any Officer whose signature is on any Note to hold, at the time such Note is authenticated, the same or any other office at the
    Company.

   

  (B)           Authentication by the Trustee and Delivery.

   

  (i)      No Note will be valid until it is authenticated by the Trustee. A Note will be deemed to be
    duly authenticated only when an authorized signatory of the Trustee (or a duly appointed authenticating agent) manually signs the certificate of authentication of such Note.

   

  (ii)      The Trustee will cause an authorized signatory of the Trustee (or a duly appointed
    authenticating agent) to manually sign the certificate of authentication of a Note only if (1) the Company delivers such Note to the Trustee; (2) such Note is executed by the Company in accordance with
    Section 2.02(A); and (3) the Company delivers a Company Order to the Trustee that (a) requests the Trustee to authenticate such Note; and (b) sets forth the name of the Holder of such Note and the date
    as of which such Note is to be authenticated. If such Company Order also requests the Trustee to deliver such Note to any Holder or to the Depositary, then the Trustee will promptly deliver such Note in accordance with such Company Order.

   

  (iii)     The Trustee may appoint an authenticating agent acceptable to the Company to authenticate
    Notes. A duly appointed authenticating agent may authenticate Notes whenever the Trustee may do so under this Indenture, and a Note authenticated as provided in this Indenture by such an agent will be deemed, for purposes of this Indenture, to be
    authenticated by the Trustee. Each duly appointed authenticating agent will have the same rights to deal with the Company as the Trustee would have if it were performing the duties that the authentication agent was validly appointed to undertake.

  
    - 20 -

    
      
 

  

  Section 2.03. Initial Notes and Additional Notes.

   

  (A)          Initial Notes. On the Issue Date, there will be originally issued one hundred twenty
    four million nine hundred ninety-nine thousand nine hundred ninety-seven dollars ($124,999,999) aggregate principal amount of Notes, subject to the provisions of this Indenture (including Section 2.02). Notes

    issued pursuant to this Section 2.03(A), and any Notes issued in exchange therefor or in substitution thereof, are referred to in this Indenture as the “Initial

      Notes.”

   

  (B)           Additional Notes. The Company may, subject to the provisions of this Indenture
    (including Section 2.02), originally issue additional Notes with the same terms as the initial Notes (except, to the extent applicable, with respect to the date as of which interest begins to accrue on
    such additional Notes and the first Interest Payment Date and the Last Original Issue Date of such additional Notes), which additional Notes will, subject to the foregoing, be considered to be part of the same series of, and rank equally and ratably
    with all other, Notes issued under this Indenture; provided, however, that if any such additional Notes are not fungible with other Notes issued under this Indenture for federal income tax or federal securities laws purposes, then such
    additional Notes will be identified by a separate CUSIP number or by no CUSIP number.

   

  Section 2.04. Method of Payment.

   

  (A)          Global Notes. The Company will pay, or cause the Paying Agent to pay, the principal
    (whether due upon maturity on the Maturity Date, Redemption on a Redemption Date or repurchase on a Fundamental Change Repurchase Date or otherwise) of, interest on, and any cash Conversion Consideration for, any Global Note to the Depositary by wire
    transfer of immediately available funds no later than the time the same is due as provided in this Indenture.

   

  (B)           Physical Notes. The Company will pay, or cause the Paying Agent to pay, the
    principal (whether due upon maturity on the Maturity Date, Redemption on a Redemption Date or repurchase on a Fundamental Change Repurchase Date or otherwise) of, interest on, and any cash Conversion Consideration for, any Physical Note no later than
    the time the same is due as provided in this Indenture as follows: (i) if the principal amount of such Physical Note is at least five million dollars ($5,000,000) (or such lower amount as the Company may choose in its sole and absolute discretion) and
    the Holder of such Physical Note entitled to such payment has delivered to the Paying Agent or the Trustee, no later than the time set forth in the immediately following sentence, a written request that the Company make such payment by wire transfer to
    an account of such Holder within the United States, by wire transfer of immediately available funds to such account; and (ii) in all other cases, by check mailed to the address of the Holder of such Physical Note entitled to such payment as set forth
    in the Register. To be timely, such written request must be so delivered no later than the Close of Business on the following date: (x) with respect to the payment of any interest due on an Interest Payment Date, the immediately preceding Regular
    Record Date; (y) with respect to any cash Conversion Consideration, the relevant Conversion Date; and (z) with respect to any other payment, the date that is fifteen (15) calendar days immediately before the date such payment is due.

  
    - 21 -

    
      
 

  

  Section 2.05. Accrual of Interest; Defaulted Amounts; When Payment Date is Not a Business Day.

   

  (A)          Accrual of Interest. Each Note will accrue interest at a rate per annum equal to
    5.00% (the “Stated Interest”), plus any Additional Interest and Special Interest that may accrue pursuant to Sections 3.03 and 7.03, respectively. Stated Interest on each Note will (i) accrue from, and including, the most
    recent date to which Stated Interest has been paid or duly provided for (or, if no Stated Interest has theretofore been paid or duly provided for, the date set forth in the certificate representing such Note as the date from, and including, which
    Stated Interest will begin to accrue in such circumstance) to, but excluding, the date of payment of such Stated Interest; and (ii) be, subject to Sections 4.02(D), 4.03(F) and 5.02(D) (but without duplication of any payment of
    interest), payable semi-annually in arrears on each Interest Payment Date, beginning on the first Interest Payment Date set forth in the certificate representing such Note, to the Holder of such Note as of the Close of Business on the immediately
    preceding Regular Record Date. Stated Interest, and, if applicable, Additional Interest and Special Interest, on the Notes will be computed on the basis of a 360-day year comprised of twelve 30-day months.

   

  (B)           Defaulted Amounts. If the Company fails to pay any amount (a “Defaulted Amount”)
    payable on a Note on or before the due date therefor as provided in this Indenture, then, regardless of whether such failure constitutes an Event of Default, (i) such Defaulted Amount will forthwith cease to be payable to the Holder of such Note
    otherwise entitled to such payment; (ii) to the extent lawful, interest (“Default Interest”) will accrue on such Defaulted Amount at a rate per annum equal to the rate per annum at which Stated Interest accrues, from, and including, such due
    date to, but excluding, the date of payment of such Defaulted Amount and Default Interest; (iii) such Defaulted Amount and Default Interest will be paid on a payment date selected by the Company to the Holder of such Note as of the Close of Business on
    a special record date selected by the Company, provided that such special record date must be no more than fifteen (15), nor less than ten (10), calendar days before such payment date; and (iv) at least
    fifteen (15) calendar days before such special record date, the Company will send notice to the Trustee and the Holders that states such special record date, such payment date and the amount of such Defaulted Amount and Default Interest to be paid on
    such payment date.

   

  (C)           Delay of Payment when Payment Date is Not a Business Day. If the due date for a
    payment on a Note as provided in this Indenture is not a Business Day, then, notwithstanding anything to the contrary in this Indenture or the Notes, such payment may be made on the immediately following Business Day and no interest will accrue on such
    payment as a result of the related delay. Solely for purposes of the immediately preceding sentence, a day on which the applicable place of payment is authorized or required by law or executive order to close or be closed will be deemed not to be a
    “Business Day.”

   

  Section 2.06. Registrar, Paying Agent and Conversion Agent.

   

  (A)          Generally. The Company will maintain (i) an office or agency in the continental
    United States where Notes may be presented for registration of transfer or for exchange (the “Registrar”); (ii) an office or agency in the continental United States where Notes may be presented for
    payment (the “Paying Agent”); and (iii) an office or agency in the continental United States where Notes may be presented for conversion (the “Conversion Agent”).
    If the

  
    - 22 -

    
      
 

  

  Company fails to maintain a Registrar, Paying Agent or Conversion Agent, then the Trustee will act as such.
    For the avoidance of doubt, the Company or any of its Subsidiaries may act as Registrar, Paying Agent or Conversion Agent.

   

  (B)           Duties of the Registrar. The Registrar will keep a record (the “Register”) of the names and addresses of the Holders, the Notes held by each Holder and the transfer, exchange, repurchase, Redemption and conversion of Notes. Absent manifest error, the entries in the Register will
    be conclusive and the Company and the Trustee may treat each Person whose name is recorded as a Holder in the Register as a Holder for all purposes. The Register will be in written form or in any form capable of being converted into written form
    reasonably promptly.

   

  (C)           Co-Agents; Company’s Right to Appoint Successor Registrars, Paying Agents and Conversion
      Agents. The Company may appoint one or more co-Registrars, co-Paying Agents and co-Conversion Agents, each of whom will be deemed to be a Registrar, Paying Agent or Conversion Agent, as applicable, under this Indenture. Subject to Section
      2.06(A), the Company may change any Registrar, Paying Agent or Conversion Agent (including appointing itself or any of its Subsidiaries to act in such capacity) without notice to any Holder. The Company
    will notify the Trustee (and, upon request, any Holder) of the name and address of each Note Agent, if any, not a party to this Indenture and will enter into an appropriate agency agreement with each such Note Agent, which agreement will implement the
    provisions of this Indenture that relate to such Note Agent.

   

  (D)           Initial Appointments. The Company appoints the Trustee as the initial Paying Agent,
    the initial Registrar and the initial Conversion Agent.

   

  Section 2.07. Paying Agent and Conversion Agent to Hold
      Property in Trust.

   

  The Company will require each Paying Agent or Conversion Agent that is not the Trustee to agree in writing
    that such Note Agent will (A) hold in trust for the benefit of Holders or the Trustee all money and other property held by such Note Agent for payment or delivery due on the Notes; and (B) notify the Trustee of any default by the Company in making any
    such payment or delivery. The Company, at any time, may, and the Trustee, while any Default continues, may, require a Paying Agent or Conversion Agent to pay or deliver, as applicable, all money and other property held by it to the Trustee, after which
    payment or delivery, as applicable, such Note Agent (if not the Company or any of its Subsidiaries) will have no further liability for such money or property. If the Company or any of its Subsidiaries acts as Paying Agent or Conversion Agent, then (A)
    it will segregate and hold in a separate trust fund for the benefit of the Holders or the Trustee all money and other property held by it as Paying Agent or Conversion Agent; and (B) references in this Indenture or the Notes to the Paying Agent or
    Conversion Agent holding cash, or other property, or to the delivery of cash or other property to the Paying Agent or Conversion Agent, in each case for payment or delivery to any Holders or the Trustee or with respect to the Notes, will be deemed to
    refer to cash or other property so segregated and held separately, or to the segregation and separate holding of such cash or other property, respectively. Upon the occurrence of any event pursuant to in clause (ix) or (x) of Section

      7.01(A) with respect to the Company (or with respect to any Subsidiary of the Company acting as Paying Agent or Conversion Agent), the Trustee will serve as the Paying Agent or

  
    - 23 -

    
      
 

  

  Conversion Agent, as applicable, for the Notes.

   

  Section 2.08. Holder Lists.

   

  If the Trustee is not the Registrar, the Company will furnish to the Trustee, no later than seven (7)
    Business Days before each Interest Payment Date, and at such other times as the Trustee may request, a list, in such form and as of such date or time as the Trustee may reasonably require, of the names and addresses of the Holders.

   

  Section 2.09. Legends.

   

  (A)          Global Note Legend. Each Global Note will bear the Global Note Legend (or any similar
    legend required by the Depositary for such Global Note).

   

  (B)           Private Placement Legend. Any Restricted Global Note will bear the Private Placement
    Legend.

   

  (C)           Other Legends. A Note may bear any other legend or text, not inconsistent with this
    Indenture, as may be required by applicable law or by any securities exchange or automated quotation system on which such Note is traded or quoted.

   

  (D)           Acknowledgement and Agreement by the Holders. A Holder’s acceptance of any Note
    bearing any legend required by this Section 2.09 will constitute such Holder’s acknowledgement of, and agreement to comply with, the restrictions set forth in such legend.

   

  Section 2.10. Transfers and Exchanges; Certain Transfer
      Restrictions.

   

  (A)          Provisions Applicable to All Transfers and Exchanges.

   

  (i) Subject to this Section 2.10, Physical Notes and
    beneficial interests in Global Notes may be transferred or exchanged from time to time and the Registrar will record each such transfer or exchange in the Register.

   

  (ii) Each Note issued upon transfer or exchange of any other Note (such other Note being referred to as
    the “old Note” for purposes of this Section 2.10(A)(ii)) or portion thereof in accordance with this Indenture will be the valid obligation of the Company, evidencing the same indebtedness, and entitled
    to the same benefits under this Indenture, as such old Note or portion thereof, as applicable.

   

  (iii) The Company, the Guarantors, the Trustee and the Note Agents will not impose any service charge
    on any Holder for any transfer, exchange or conversion of Notes, but the Company, the Guarantors, the Trustee, the Registrar and the Conversion Agent may require payment of a sum sufficient to cover any transfer tax or similar governmental charge that
    may be imposed in connection with any transfer, exchange or conversion of Notes, other than exchanges pursuant to Sections 2.11, 2.16 or 8.05 not involving any transfer.

  
    - 24 -

    
      
 

  

  (iv) Notwithstanding anything to the contrary in this Indenture or the Notes, a Note may not be
    transferred or exchanged in part unless the portion to be so transferred or exchanged is in an Authorized Denomination.

   

  (v) The Trustee will have no obligation or duty to monitor, determine or inquire as to compliance with
    any transfer restrictions imposed under this Indenture or applicable law with respect to any Security, other than to require the delivery of such certificates or other documentation or evidence as expressly required by this Indenture and to examine the
    same to determine substantial compliance as to form with the requirements of this Indenture.

   

  (vi) Each Note issued upon transfer of, or in exchange for, another Note will bear each legend, if any,
    required by Section 2.09.

   

  (vii) Upon satisfaction of the requirements of this Indenture to effect a transfer or exchange of any
    Note, the Company will cause such transfer or exchange to be effected as soon as reasonably practicable after the date of such satisfaction.

   

  (B)          Transfers and Exchanges of Global Notes.

   

  (i) Subject to the other clauses of this paragraph (B), no Global Note may be transferred or exchanged
    in whole except (x) by the Depositary to a nominee of the Depositary; (y) by a nominee of the Depositary to the Depositary or to another nominee of the Depositary; or (z) by the Depositary or any such nominee to a successor Depositary or a nominee of
    such successor Depositary.

   

  (ii) Transfer and Exchange of Beneficial Interests in the Global Notes. The transfer and
    exchange of beneficial interests in the Global Notes will be effected through the Depositary, in accordance with the provisions of this Indenture and the Applicable Procedures. Beneficial interests in the Restricted Global Notes will be subject to
    restrictions on transfer comparable to those set forth herein to the extent required by the Securities Act. Transfers of beneficial interests in the Global Notes also will require compliance with either subparagraph (1) or (2) below, as applicable, and
    if applicable either subparagraph (3) or (4) below:

   

  (1)          Transfer of Beneficial Interests in the Same Global Note. Beneficial interests in any
    Restricted Global Note may be transferred to Persons who take delivery thereof in the form of a beneficial interest in the same Restricted Global Note in accordance with the transfer restrictions set forth in the Private Placement Legend. Beneficial
    interests in any Unrestricted Global Note may be transferred to Persons who take delivery thereof in the form of a beneficial interest in an Unrestricted Global Note. No written orders or instructions shall be required to be delivered to the Registrar
    to effect the transfers described in this subsection (1).

   

  (2)          All Other Transfers and Exchanges of Beneficial Interests in

  
    - 25 -

    
      
 

  

  Global Notes. In connection with all transfers and exchanges of beneficial interests that are not
    subject to subsection (1) above, the transferor of such beneficial interest must deliver to the Registrar a written order, through a Participant or an Indirect Participant in the applicable Global Note given to the Depositary in accordance with the
    Applicable Procedures, instructing the Depositary to credit or cause to be credited a beneficial interest in the applicable Global Note in an amount equal to the beneficial interest to be transferred or exchanged and containing information regarding
    the Participant account to be credited with such increase.

   

  (3)           Transfer of Beneficial Interests from one Restricted Global Note to Another Restricted
      Global Note. A beneficial interest in any Restricted Global Note may be transferred to a Person who takes delivery thereof in the form of a beneficial interest in another Restricted Global Note if the transfer complies with the requirements of
    subsection (2) above and the Registrar receives the following:

   

  (A)  if the transferee will take delivery in the form of a beneficial interest in the 144A Global Note, a
    certificate from the holder certifying that the exchange or transfer is being effected pursuant to and in accordance with Rule 144A under the Securities Act, and that the beneficial interest is being transferred to a Person that the Transferor
    reasonably believes is purchasing the beneficial interest for its own account, or for one or more accounts with respect to which such Person exercises sole investment discretion, and such Person and each such account is a “qualified institutional
    buyer” within the meaning of Rule 144A in a transaction meeting the requirements of Rule 144A, and such Transfer is in compliance with any applicable blue sky securities laws of any state of the United States; and

   

  (B) if the transferee will take delivery in the form of a beneficial interest in the IAI Global Note, a
    certificate from the holder certifying that the exchange or transfer is being effected in compliance with the transfer restrictions applicable to beneficial interests in the Restricted Global Note and pursuant to and in accordance with the Securities
    Act and any applicable blue sky securities laws of any state of the United States, and such exchange or transfer is being effected to an Institutional Accredited Investor and pursuant to an exemption from the registration requirements of the Securities
    Act, and the Transferor hereby further certifies that it has not engaged in any general solicitation within the meaning of Regulation D under the Securities Act and the Transfer complies with the transfer restrictions applicable to beneficial interests
    in a Restricted Global Note.

   

  (4)           Transfer and Exchange of Beneficial Interests in a Restricted Global Note for Beneficial
      Interests in an Unrestricted Global Note. A beneficial interest in any Restricted Global Note may be exchanged by any holder thereof for a beneficial interest in an Unrestricted Global Note or transferred to a Person who takes delivery thereof
    in the form of a beneficial interest in an Unrestricted Global Note if the exchange or transfer complies with the requirements of subsection (2) above and: (x) such exchange or transfer is effected pursuant to an effective Registration Statement under
    the Securities Act, or (y) the Registrar receives (A) a certificate from such holder certifying that the exchange or transfer has been effected in compliance with any transfer

  
    - 26 -

    
      
 

  

  restrictions applicable under the Securities Act, that the restrictions on transfer contained in the Private
    Placement Legend are not required in order to maintain compliance with the Securities Act and that the beneficial interest in the Unrestricted Global Note is being acquired in compliance with any applicable blue sky securities laws of any state of the
    United States, and (B) if the Registrar so requests, an Opinion of Counsel in form reasonably acceptable to the Registrar to the effect that such exchange or transfer is in compliance with the Securities Act.

   

  (iii) No Global Note (or any portion thereof) may be transferred to, or exchanged for, a Physical Note; provided,

      however, that a Global Note will be exchanged, pursuant to customary procedures, for one or more Physical Notes if:

   

  (1)            (x) the Depositary notifies the Company or the Trustee that the Depositary is unwilling or unable to continue as
    depositary for such Global Note or (y) the Depositary ceases to be a “clearing agency” registered under Section 17A of the Exchange Act and, in each case, the Company fails to appoint a successor Depositary within ninety (90) days of such notice or
    cessation;

   

  (2)            an Event of Default has occurred and is continuing and the Company, the Trustee or the Registrar has received a
    written request from the Depositary, or from a holder of a beneficial interest in such Global Note, to exchange such Global Note or beneficial interest, as applicable, for one or more Physical Notes; or

   

  (3)           the Company, in its sole discretion, permits the exchange of any beneficial interest in such Global Note for one or more
    Physical Notes at the request of the owner of such beneficial interest.

   

  (iv) Upon satisfaction of the requirements of this Indenture to effect a transfer or exchange of any Global Note (or any portion
    thereof):

   

  (1)           the Trustee will reflect any resulting decrease of the principal amount of such Global Note by notation on the “Schedule
    of Exchanges of Interests in the Global Note” forming part of such Global Note (and, if such notation results in such Global Note having a principal amount of zero, the Company may (but is not required to) instruct the Trustee to cancel such Global
    Note pursuant to Section 2.14);

   

  (2)           if required to effect such transfer or exchange, then the Trustee will reflect any resulting increase of the principal
    amount of any other Global Note by notation on the “Schedule of Exchanges of Interests in the Global Note” forming part of such other Global Note;

   

  (3)           if required to effect such transfer or exchange, then the Company will issue, execute and deliver, and the Trustee will
    authenticate, in each case in accordance with Section 2.02, a new Global Note bearing each legend, if any, required by Section 2.09; and

   

  (4)           if such Global Note (or such portion thereof), or any beneficial

  
    - 27 -

    
      
 

  

  interest therein, is to be exchanged for one or more Physical Notes, then the Company will issue, execute
    and deliver, and the Trustee will authenticate, in each case in accordance with Section 2.02, one or more Physical Notes that are in Authorized Denominations (not to exceed, in the aggregate, the
    principal amount of such Global Note to be so exchanged), are registered in such name(s) as the Depositary specifies (or as otherwise determined pursuant to customary procedures) and bear each legend, if any, required by Section 2.09.

   

  (v) Each transfer or exchange of a beneficial interest in any Global Note will be made in accordance
    with the Depositary Procedures.

   

  (C)          Transfers and Exchanges of Physical Notes.

   

  (i) Subject to this Section 2.10, a Holder of a
    Physical Note may (x) transfer such Physical Note (or any portion thereof in an Authorized Denomination) to one or more other Person(s); (y) exchange such Physical Note (or any portion thereof in an Authorized Denomination) for one or more other
    Physical Notes in Authorized Denominations having an aggregate. principal amount equal to the aggregate principal amount of the Physical Note (or portion thereof) to be so exchanged: and (z) if then permitted by the Depositary Procedures, transfer such
    Physical Note (or any portion thereof in an Authorized Denomination) in exchange for a beneficial interest in one or more Global Notes; provided, however, that, to effect any such transfer or exchange, such Holder must:

   

  (1)           surrender such Physical Note to be transferred or exchanged to the office of the Registrar, together with any
    endorsements or transfer instruments reasonably required by the Company, the Trustee or the Registrar; and

   

  (2)           deliver such certificates, documentation or evidence as may be required pursuant to Section 2.10(D).

   

  (ii) Upon the satisfaction of the requirements of this Indenture to effect a transfer or exchange of
    any Physical Note (such Physical Note being referred to as the “old Physical Note” for purposes of this Section 2.10(C)(ii)) of a Holder (or any portion of such old Physical Note in an Authorized
    Denomination):

   

  (1)            such old Physical Note will be promptly cancelled pursuant to Section 2.14;

   

  (2)            if such old Physical Note is to be transferred or exchanged only in part, then the Company will issue, execute and
    deliver, and the Trustee will authenticate, in each case in accordance with Section 2.02, one or more Physical Notes that (x) are in Authorized Denominations and have an aggregate principal amount
    equal to the principal amount of such old Physical Note not to be transferred or exchanged; (y) are registered in the name of such Holder; and (z) bear each legend, if any, required by Section 2.09;

  
    - 28 -

    
      
 

  

  (3)      in the case of a transfer:

   

  (a)           to the Depositary or a nominee thereof that will hold its interest in such old Physical Note (or such portion thereof)
    to be so transferred in the form of one or more Global Notes, the Trustee will reflect an increase of the principal amount of one or more existing Global Notes by notation on the “Schedule of Exchanges of Interests in the Global Note” forming part of
    such Global Note(s), which increase(s) are in Authorized Denominations and aggregate to the principal amount to be so transferred, and which Global Note(s) bear each legend, if any, required by Section 2.09;
    provided, however, that if such transfer cannot be so effected by notation on one or more existing Global Notes (whether because no Global Notes bearing each legend, if any, required by Section 2.09 then exist, because any such
    increase will result in any Global Note having an aggregate principal amount exceeding the maximum aggregate principal amount permitted by the Depositary or otherwise), then the Company will issue, execute and deliver, and the Trustee will
    authenticate, in each case in accordance with Section 2.02, one or more Global Notes that (x) are in Authorized Denominations and have an aggregate principal amount equal to the principal amount to be
    so transferred; and (y) bear each legend, if any, required by Section 2.09; and

   

  (b)           to a transferee that will hold its interest in such old Physical Note (or such portion thereof) to be so transferred
    in the form of one or more Physical Notes, the Company will issue, execute and deliver, and the Trustee will authenticate, in each case in accordance with Section 2.02, one or more Physical Notes that
    (x) are in Authorized Denominations and have an aggregate principal amount equal to the principal amount to be so transferred; (y) are registered in the name of such transferee; and (z) bear each legend, if any, required by Section 2.09; and

   

  (4)       in the case of an exchange, the Company will issue, execute and deliver, and the Trustee will authenticate, in each case in
    accordance with Section 2.02, one or more Physical Notes that (x) are in Authorized Denominations and have an aggregate principal amount equal to the principal amount to be so exchanged; (y) are
    registered in the name of the Person to whom such old Physical Note was registered; and (z) bear each legend, if any, required by Section 2.09.

  
    - 29 -

    
      
 

  

  (D)           Requirement of Affiliates to Deliver Documentation and Other Evidence. If a Holder
    of any Note that is an Affiliate requests to register the transfer of such Note to the name of another Person, then the Company, the Guarantors, the Trustee and the Registrar may refuse to effect such identification, removal or transfer, as applicable,
    unless there is delivered to the Company, the Guarantors, the Trustee and the Registrar such certificates or other documentation or evidence as the Company, the Guarantors, the Trustee and the Registrar may reasonably require to determine that such
    transfer complies with the Securities Act and other applicable securities laws.

   

  (E)           Transfers of Notes Subject to Redemption, Repurchase or Conversion. Notwithstanding
    anything to the contrary in this Indenture or the Notes, the Company, the Guarantors, the Trustee and the Registrar will not be required to register the transfer of or exchange any Note that (i) has been surrendered for conversion, except to the extent
    that any portion of such Note is not subject to conversion; (ii) is subject to a Fundamental Change Repurchase Notice validly delivered, and not withdrawn, pursuant to Section 4.02(F), except to the
    extent that any portion of such Note is not subject to such notice or the Company fails to pay the applicable Fundamental Change Repurchase Price when due or (iii) has been selected for Redemption pursuant to a Redemption Notice, except to the extent
    that any portion of such Note is not subject to Redemption or the Company fails to pay the applicable Redemption Price when due.

   

  (F)           Neither the Trustee nor any Agent shall have any responsibility for any actions taken or not
    taken by the Depositary.

   

   Section 2.11. Exchange and Cancellation

        of Notes to Be Converted, Redeemed or Repurchased.

   

  (A)          Partial Conversions, Redemptions and Repurchases of Physical Notes. If only a portion
    of a Physical Note of a Holder is to be converted pursuant to Article 5 or repurchased pursuant to a Repurchase Upon Fundamental Change or Redemption, then, as soon as reasonably practicable after such Physical Note is surrendered for such
    conversion, Redemption or repurchase, the Company will cause such Physical Note to be exchanged, pursuant and subject to Section 2.10(C), for (i) one or more Physical Notes that are in Authorized
    Denominations and have an aggregate principal amount equal to the principal amount of such Physical Note that is not to be so converted, redeemed or repurchased, as applicable, and deliver such Physical Note(s) to such Holder; and (ii) a Physical Note
    having a principal amount equal to the principal amount to be so converted, redeemed or repurchased, as applicable, which Physical Note will be converted, redeemed or repurchased, as applicable, pursuant to the terms of this Indenture; provided,
      however, that the Physical Note referred to in this clause (ii) need not be issued at any time after which such principal amount subject to such conversion, Redemption or repurchase, as applicable, is deemed to cease to be outstanding pursuant
    to Section 2.17.

   

  (B)           Cancellation of Converted, Redeemed and Repurchased Notes.

   

  (i) Physical Notes. If a Physical Note (or any portion thereof that has not theretofore been
    exchanged pursuant to Section 2.11(A)) of a Holder is to be converted pursuant to Article 5 or repurchased pursuant to a Repurchase

  
    - 30 -

    
      
 

  

  Upon Fundamental Change or Redemption, then, promptly after the later of the time such Physical Note (or
    such portion) is deemed to cease to be outstanding pursuant to Section 2.17 and the time such Physical Note is surrendered for such conversion or repurchase, as applicable, (1) such Physical Note will be cancelled pursuant to Section 2.14;
    and (2) in the case of a partial conversion, Redemption or repurchase, the Company will issue, execute and deliver to such Holder, and the Trustee will authenticate, in each case in accordance with Section 2.02,
    one or more Physical Notes that (x) are in Authorized Denominations and have an aggregate principal amount equal to the principal amount of such Physical Note that is not to be so converted, redeemed or repurchased; (y) are registered in the name of
    such Holder; and (z) bear each legend, if any, required by Section 2.09.

   

  (ii) Global Notes. If a Global Note (or any portion thereof) is to be converted pursuant to Article

      5 or repurchased pursuant to a Repurchase Upon Fundamental Change or Redemption, then, promptly after the time such Note (or such portion) is deemed to cease to be outstanding pursuant to Section 2.17, the Trustee will reflect a decrease
    of the principal amount of such Global Note in an amount equal to the principal amount of such Global Note to be so converted, redeemed or repurchased, as applicable, by notation on the “Schedule of Exchanges of Interests in the Global Note” forming
    part of such Global Note (and, if the principal amount of such Global Note is zero following such notation, cancel such Global Note pursuant to Section 2.14).

   

  Section 2.12. Replacement Notes.

   

  If a Holder of any Note claims that such Note has been mutilated, lost, destroyed or wrongfully taken,
    then the Company will issue, execute and deliver, and the Trustee will authenticate, in each case in accordance with Section 2.02, a replacement Note upon surrender to the Trustee of such mutilated Note, or upon delivery to the Trustee of
    evidence of such loss, destruction or wrongful taking reasonably satisfactory to the Trustee and the Company. In the case of a lost, destroyed or wrongfully taken Note, the Company and the Trustee may require the Holder thereof to provide such security
    or indemnity that is reasonably satisfactory to the Company and the Trustee to protect the Company and the Trustee from any loss that any of them may suffer if such Note is replaced.

   

  Every replacement Note issued pursuant to this Section 2.12 will be an additional obligation of
    the Company and will be entitled to all of the benefits of this Indenture equally and ratably with all other Notes issued under this Indenture.

   

  Section 2.13. Registered Holders; Certain Rights with Respect
      to Global Notes.

   

  Only the Holder of a Note will have rights under this Indenture as the owner of such Note. Without
    limiting the generality of the foregoing, Depositary Participants will have no rights as such under this Indenture with respect to any Global Note held on their behalf by the Depositary or its nominee, or by the Trustee as its custodian, and the
    Company, the Guarantors,

  
    - 31 -

    
      
 

  

  the Trustee and the Note Agents, and their respective agents, may treat the Depositary as the absolute owner
    of such Global Note for all purposes whatsoever; provided, however, that (A) the Holder of any Global Note may grant proxies and otherwise authorize any Person, including Depositary Participants and Persons that hold interests in Notes through
    Depositary Participants, to take any action that such Holder is entitled to take with respect to such Global Note under this Indenture or the Notes; and (B) the Company and the Trustee, and their respective agents, may give effect to any written
    certification, proxy or other authorization furnished by the Depositary.

   

  Section 2.14. Cancellation.

   

  Without limiting the generality of Section 3.08, the Company may at any time deliver Notes to the
    Trustee for cancellation. The Registrar, the Paying Agent and the Conversion Agent will forward to the Trustee each Note duly surrendered to them for transfer, exchange, payment or conversion. The Trustee will promptly cancel all Notes so surrendered
    to it in accordance with its customary procedures. Without limiting the generality of Section 2.03(B), the Company may not originally issue new Notes to replace Notes that it has paid or that have been cancelled
    upon transfer, exchange, payment or conversion.

   

  Section 2.15. Notes Held by the Company.

   

  Without limiting the generality of Section 3.08, in determining
    whether the Holders of the required aggregate principal amount of Notes have concurred in any direction, waiver or consent, Notes owned by the Company will be deemed not to be outstanding; provided, however, that, for purposes of determining
    whether the Trustee is protected in relying on any such direction, waiver or consent, only Notes that the Trustee knows are so owned will be so disregarded.

   

  Section 2.16. TEMPORARY NOTES.

   

  Until definitive Notes are ready for delivery, the Company may issue, execute and deliver, and the Trustee
    will authenticate, in each case in accordance with Section 2.02, temporary Notes. Temporary Notes will be substantially in the form of definitive Notes but may have variations that the Company considers appropriate for temporary Notes. The
    Company will promptly prepare, issue, execute and deliver, and the Trustee will authenticate, in each case in accordance with Section 2.02, definitive Notes in exchange for temporary Notes. Until so exchanged, each temporary Note will in all
    respects be entitled to the same benefits under this Indenture as definitive Notes.

   

  Section 2.17. Outstanding Notes.

   

  (A)          Generally. The Notes that are outstanding at any time will be deemed to be those
    Notes that, at such time, have been duly executed and authenticated, excluding those Notes (or portions thereof) that have theretofore been (i) cancelled by the Trustee or delivered to the Trustee for cancellation in accordance with Section 2.14;
    (ii) assigned a principal amount of zero by notation on the “Schedule of Exchanges of Interests in the Global Note” forming part of any a Global Note representing such Note; (iii) paid in full in accordance with this Indenture; or (iv) deemed to cease
    to be outstanding to the extent provided in, and subject to, clause (B), (C) or

  
    - 32 -

    
      
 

  

  (D) of this Section 2.17.

   

  (B)           Replaced Notes. If a Note is replaced pursuant to Section 2.12, then such Note will cease to be outstanding at the time of its replacement, unless the Trustee and the Company receive proof reasonably satisfactory to them that such Note is held by a “bona fide purchaser”

    under applicable law.

   

  (C)           Maturing Notes and Notes Called for Redemption or Subject to Repurchase. If, on a
    Redemption Date, a Fundamental Change Repurchase Date or the Maturity Date, the Paying Agent holds money sufficient to pay the aggregate Redemption Price, Fundamental Change Repurchase Price or principal amount, respectively, together, in each case,
    with the aggregate interest, in each case due on such date, then (unless there occurs a Default in the payment of any such amount) (i) the Notes (or portions thereof) to be redeemed or repurchased, or that mature, on such date will be deemed, as of
    such date, to cease to be outstanding, except to the extent provided in Sections 4.02(D), 4.03(F) or 5.02(D); and (ii) the rights of the Holders of
    such Notes (or such portions thereof), as such, will terminate with respect to such Notes (or such portions thereof), other than the right to receive the Redemption Price, Fundamental Change Repurchase Price or principal amount, as applicable, of, and
    accrued and unpaid interest on, such Notes (or such portions thereof), in each case as provided in this Indenture.

   

  (D)           Notes to Be Converted. At the Close of Business on the Conversion Date for any Note
    (or any portion thereof) to be converted, such Note (or such portion) will (unless there occurs a Default in the delivery of the Conversion Consideration or interest due, pursuant to Section 5.03(B) or Section 5.02(D), upon such conversion) be deemed to cease to be outstanding, except to the extent provided in Section 5.02(D).

   

  (E)           Cessation of Accrual of Interest. Except as provided in Sections 4.02(D), 4.03(F) or 5.02(D), interest will cease to accrue on each Note from, and including, the date that such Note is deemed, pursuant to this Section 2.17, to cease to be outstanding, unless there occurs a default in the payment or delivery of any cash or other property due on such Note.

   

  Section 2.18. Repurchases by the Company.

   

  Without limiting the generality of Section 2.14, the
    Company may, from time to time, repurchase Notes in open market purchases, in negotiated transactions or otherwise without delivering prior notice to Holders; provided that no Default or Event of Default will have occurred and be continuing at such
    time.

   

  Section 2.19. CUSIP and ISIN Numbers.

   

  The Company may use one or more CUSIP or ISIN numbers to identify any of the Notes, and, if so, the
    Company and the Trustee will use such CUSIP or ISIN number(s) in notices to Holders; provided, however, that (i) the Trustee makes no representation as to the correctness or accuracy of any such CUSIP or ISIN number; and (ii) the effectiveness
    of any such notice will not be affected by any defect in, or omission of, any such CUSIP or ISIN number. The Company will promptly notify the Trustee of any change in the CUSIP or ISIN number(s) identifying any Notes.

  
    - 33 -

    
      
 

  

  Article 3. COVENANTS

   

  Section 3.01. Payment on Notes.

   

  (A)          Generally. The Company will pay or cause to be paid all the principal of, the
    Fundamental Change Repurchase Price and Redemption Price for, interest on, and other amounts due with respect to, the Notes on the dates and in the manner set forth in this Indenture.

   

  (B)          Deposit of Funds. Before 10:00 A.M., New York City time, on each Redemption Date,
    Fundamental Change Repurchase Date or Interest Payment Date, and on the Maturity Date or any other date on which any cash amount is due on the Notes, the Company will deposit, or will cause there to be deposited, with the Paying Agent cash, in funds
    immediately available on such date, sufficient to pay the cash amount due on the applicable Notes on such date. The Paying Agent will return to the Company, as soon as practicable, any money not required for such purpose.

   

  Section 3.02. Reports.

   

  (A)          Generally. The Company will send to the Trustee (i) copies of all reports that the
    Company is required to file with the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act within fifteen (15) calendar days after the date that the Company is required to file the same (after giving effect to all applicable grace periods under
    the Exchange Act); provided, however, that the Company need not send to the Trustee any material for which the Company has received, or is seeking in good faith and has not been denied, confidential treatment by the SEC and (ii) customary
    quarterly financial reports within forty-five (45) calendar days of the end of each fiscal quarter. Any report that the Company files with the SEC through the EDGAR system or the RNS system in the United Kingdom (or any successor thereto) or posts on
    its website will be deemed to be sent to the Trustee at the time such report is so filed via the EDGAR system or RNS system (or such successor) or posted on its website. Upon the request of any Holder, the Trustee will provide to such Holder a copy of
    any report that the Company has sent the Trustee pursuant to this Section 3.02(A), other than a report that is deemed to be sent to the Trustee pursuant to the preceding sentence.

   

  (B)           Trustee’s Disclaimer. The Trustee need not determine whether the Company has filed
    any material via the EDGAR system (or such successor). The sending or filing of reports to the Trustee pursuant to Section 3.02(A) is for informational purposes only and will not be deemed to constitute actual or constructive notice to the
    Trustee of any information contained, or determinable from information contained, therein, including the Company’s compliance with any of its covenants under this Indenture (as to which the Trustee is entitled to conclusively rely on an Officer’s
    Certificate).

   

  Section 3.03. Additional Interest.

   

  (A)          Accrual of Additional Interest. If, at any time on or after the Last Original Issue
    Date of any Note, such Note is not Freely Tradable, then Additional Interest will accrue on such Note for each day during such period on which such failure is continuing or such Note is not Freely Tradable. For the avoidance of doubt, any Note bearing
    the Private Placement Legend is

  

  

   

  
    - 34 -

    
      
 

  

  deemed held by an Affiliate of the Company and no Additional Interest will accrue on the such Note.

   

  (B)           Amount and Payment of Additional Interest. Any Additional Interest that accrues on a
    Note pursuant to Section 3.03(A) will be payable on the same dates and in the same manner as the Stated Interest on such Note and will accrue at a rate per annum equal to one half of one percent (0.50%) of the principal amount thereof. For the
    avoidance of doubt, any Additional Interest that accrues on a Note will be in addition to the Stated Interest that accrues on such Note and in addition to any Special Interest that accrues on such Note.

   

  (C)           Notice of Accrual of Additional Interest; Trustee’s Disclaimer. The Company will
    send notice to the Holder of each Note, and to the Trustee, of the commencement and termination of any period in which Additional Interest accrues on such Note. In addition, if Additional Interest accrues on any Note, then, no later than five (5)
    Business Days before each date on which such Additional Interest is to be paid, the Company will deliver an Officer’s Certificate to the Trustee and the Paying Agent stating (i) that the Company is obligated to pay Additional Interest on such Note on
    such date of payment; and (ii) the amount of such Additional Interest that is payable on such date of payment. The Trustee will have no duty to determine whether any Additional Interest is payable or the amount thereof.

   

  Section 3.04. Additional Amounts.

   

  (A)          Requirement to Pay Additional Amounts. All payments and deliveries made by, or on
    behalf of, the Company under or with respect to the Notes (including payment of the principal of, or the Redemption Price or Fundamental Change Repurchase Price for, or any interest on, or the delivery of any consideration due upon conversion of, any
    Note) will be made without withholding or deduction for, or on account of, any present or future Taxes, unless such withholding or deduction is required by law or regulation or by governmental policy having the force of law. If any Taxes levied by or
    on behalf of any jurisdiction (or any political subdivision or taxing authority thereof or therein) in which the Company or any Successor Corporation is, for tax purposes, organized or resident or doing business or through which payment is made or
    deemed to be made (each such jurisdiction, subdivision or authority, as applicable, a “Relevant Taxing Jurisdiction”) are required to be withheld or deducted
    from any payments or deliveries made under or with respect to the Notes, then, subject to Section 4.03(C)(ii), the Company or such Successor Corporation, as applicable, will pay to the holder of each
    note such additional amounts (the “Additional Amounts”) as may be necessary to ensure that the net amount received by the beneficial owner of such Note after
    such withholding or deduction (and after withholding or deducting any Taxes on the Additional Amounts) will equal the amounts that would have been received by such beneficial owner had no such withholding or deduction been required; provided,
      however, that such obligation to pay Additional Amounts will not apply to:

   

  (i) any Tax that would not
    have been imposed but for:

   

  (1)          the existence of any present or former connection between the Holder or beneficial owner of
    such Note and the Relevant Taxing Jurisdiction (other than merely holding or being a beneficial owner of such Note or the receipt or enforcement of payments thereunder), including such Holder or beneficial owner being or having been a

  
    - 35 -

    
      
 

  

  national, domiciliary or resident, or treated as a resident, of, or being or having been physically present or engaged in a trade or business,
    or having had a permanent establishment, in, such Relevant Taxing Jurisdiction;

   

  (2)          in cases where presentation of such Note is required to receive such payment or delivery, the presentation of such Note after a
    period of thirty (30) days after the later of (x) the date on which such payment or delivery became due and payable or deliverable, as applicable, pursuant to the terms of this Indenture and (y) the date such payment or delivery was made or duly
    provided for, except, in each case, to the extent that such Holder or beneficial owner would have been entitled to Additional Amounts if it presented such Note for payment or delivery, as applicable, at the end of such thirty (30) day period; or

   

  (3)          the failure of such Holder or beneficial owner to comply with a timely request from the Company or the Successor
    Corporation, addressed to such Holder or beneficial owner, to (x) provide certification, information, documentation or other evidence concerning such Holder’s or beneficial owner’s nationality, residence, identity or connection with such Relevant
    Taxing Jurisdiction; or (y) make any declaration or satisfy any other reporting requirement prescribed by applicable law as a basis to reduce or eliminate the amount of Tax required to be deducted or withheld with respect to payments or deliveries made
    under or with respect to the Notes, in each case if and to the extent that such Holder or beneficial owner is legally entitled to comply with such request; provided, however, that compliance with any of the foregoing (other than the provision
    of customary certification forms issued by the US Internal Revenue Service or with respect to U.S. withholding taxes) shall not be required if in the Holder’s or beneficial owner’s reasonable judgment such compliance would subject such Holder or
    beneficial owner to any material unreimbursed cost or expense or would materially prejudice its legal or commercial position;

   

  (ii) any estate,
    inheritance, gift, sale, transfer, personal property or similar Tax;

   

  (iii) any tax that is
    payable other than by withholding or deduction from payments under or with respect to the Notes;

   

  (iv) any withholding or
    deduction required by (x) sections 1471 through 1474 of the Internal Revenue Code and any current or future U.S. Treasury Regulations or rulings promulgated thereunder (“FATCA”); (y) any inter-governmental agreement between the United States and
    any other non-U.S. jurisdiction to implement FATCA or any law enacted by such other jurisdiction to give effect to such agreement; or (z) any agreement with the U.S. Internal Revenue Service pursuant to Section 1471(b)(1) of the Internal Revenue Code;

   

  (v) any taxes imposed on or
    with respect to any payment by the Company to such Holder if such Holder is a fiduciary, partnership or person other than the sole beneficial owner of such payment, to the extent that such payment would be required, under the laws of such Relevant
    Taxing Jurisdiction, to be included for tax purposes in the income of a beneficiary or settlor with respect to such fiduciary, a partner or member of such partnership, or a beneficial owner, who would not have been entitled to such additional amounts
    had such beneficiary, settlor, partner, member or beneficial owner been the Holder thereof;

  

  

  
    - 36 -

    
      
 

  

  

  

   

  (vi) withholding taxes
    imposed on amounts payable with respect to the Notes pursuant to a law or regulation in effect on the date on which a beneficial owner acquires any Notes; or

   

  (vii) any combination of
    items referred to in the preceding clauses (i) through (vi), inclusive, above.

   

  (B)           Indemnification for Other Taxes. The Company will pay and indemnify each Holder for
    any present or future stamp, issue, registration, transfer; court, documentary, excise or property Taxes (“Other Taxes”) levied by any Relevant Taxing
    Jurisdiction in connection with the execution, delivery, registration, issuance or enforcement of any of the Notes (other than on or in connection with a transfer of a note that occurs after the initial sales thereof) or the receipt of any payments or
    deliveries with respect to the Notes; provided, however, that, with respect to any such taxes attributable to the receipt of any payments or deliveries with respect to the Notes, Other Taxes will not include those excluded under any
    combination of clauses (i), (ii), (iv), (v) and (vi) of Section 3.04(A).

   

  (C)           For the avoidance of doubt, if any Note is called for a Tax Redemption and the Redemption
    Date is after a Regular Record Date and on or before the next Interest Payment Date, then the Company’s obligation to pay Additional Amounts will apply to the interest payment due on such Note on such Interest Payment Date unless such Note is the
    subject to a Tax Redemption Opt-Out Election Notice.

   

  (D)           Tax Receipts. If the Company is required to make any deduction or withholding from
    any payments with respect to the Notes, then the (i) Company will deliver to the Trustee official tax receipts (or, if, after expending reasonable efforts, the Company is unable to obtain such receipts, other evidence of payments) evidencing the
    remittance to the relevant tax authorities of the amounts so withheld or deducted; and (ii) the Trustee or the Company will provide a copy of such receipts or evidence, as applicable, upon request from any Holder or beneficial owner of any Notes for
    whom such deduction or withholding is required to be made.

   

  (E)           Interpretation of Indenture and Notes. All references in this Indenture or the Notes
    to any payment on, or delivery with respect to, the Notes (including payment of the principal of, or the Redemption Price or Fundamental Change Repurchase Price for, or any interest on, or the delivery of any Conversion Consideration due upon
    conversion of, any Note) will, to the extent that Additional Amounts are payable in respect thereof, be deemed to include the payment of such Additional Amounts.

   

  (F)           Survival of Obligations. The obligations set forth in this Section 3.04 will

    survive any transfer of Notes by a Holder (or, in the case of a Global Note, a holder of a beneficial

   

  
    - 37 -

    
      
 

  

  interest therein).

   

  Section 3.05. Compliance and Default Certificates.

   

  (A)          Annual Compliance Certificate. Within ninety (90) days after December 31, 2019 and
    each fiscal year of the Company ending thereafter, the Company and the Guarantors will deliver an Officer’s Certificate to the Trustee stating (i) that the signatory thereto has supervised a review of the activities of the Company and the Guarantors
    during such fiscal year with a view towards determining whether any Default or Event of Default has occurred; and (ii) whether, to such signatory’s knowledge, a Default or Event of Default has occurred or is continuing (and, if so, describing all such
    Defaults or Events of Default and what action the Company or Guarantors is taking or proposes to take with respect thereto).

   

  (B)           Default Certificate. If a Default or Event of Default occurs, then the Company will
    promptly deliver an Officer’s Certificate to the Trustee describing the same and what action the Company is taking or proposes to take with respect thereto.

   

  Section 3.06. Stay, Extension and Usury Laws.

   

  To the extent that it may lawfully do so, the Company (A) agrees that it will not at any time insist upon,
    plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law (wherever or whenever enacted or in force) that may affect the covenants or the performance of this Indenture; and (B) expressly waives all
    benefits or advantages of any such law and agrees that it will not, by resort to any such law, hinder, delay or impede the execution of any power granted to the Trustee by this Indenture, but will suffer and permit the execution of every such power as
    though no such law has been enacted.

   

  Section 3.07. Corporate Existence.

   

  Subject to Article 6, the Company will cause to
    preserve and keep in full force and effect:

   

  (A)          its corporate existence in accordance with the organizational documents of the Company; and

   

  (B)           the material rights (charter and statutory), licenses and franchises of the Company and its
    Subsidiaries;

   

  provided, however, that the Company need not preserve or keep in full force and effect any such license or franchise if the Board of
    Directors determines that (x) the preservation thereof is no longer desirable in the conduct of the business of the Company and its Subsidiaries, taken as a whole; and (y) the loss thereof is not, individually or in the aggregate, materially adverse to
    the Holders.

   

  Section 3.08. Restriction on Acquisition of Notes by the
      Company.

   

  The Company will promptly deliver to the Trustee for cancellation all Notes that the Company or any of its
    Subsidiaries have purchased or otherwise acquired.

  

  

   

  
    - 38 -

    
      
 

  

  Section 3.09. Further Instruments and Acts.

   

  At the Trustee’s request, the Company will execute and deliver such further instruments and do such
    further acts as may be reasonably necessary or proper to more effectively carry out the purposes of this Indenture.

   

  Section 3.10. Listing.

   

  The Parent shall use commercially reasonable efforts to list the Ordinary Shares or ADRs representing
    Ordinary Shares on Nasdaq and maintain such listing for so long as any Notes are outstanding.

   

  If the Company lists ADRs on Nasdaq, then the Company may by notice to the Trustee and the holders elect,
    subject to the terms of the ADR facility, to have future conversion of Notes settled in ADRs. For so long as such election is in effect, references to Ordinary Shares will be deemed to refer to ADRs and appropriate adjustment will be made to the
    settlement and trading provisions of the Notes to account for any deposit ratio between ADRs and Ordinary Shares; provided, that if ADRs cannot be issued to a converting holder under the terms of the ADR facility as then in place, then the settlement
    and the trading provisions will be deemed to refer to Ordinary Shares with respect to such conversion.

   

  Section 3.11. Restricted Payments.

   

  So long as any Notes remain outstanding, the Company and the Guarantors shall not, and shall not permit
    any of their Subsidiaries to declare or make, directly or indirectly, any Restricted Payment:

   

  (A)          unless, at the time of such Restricted Payment:

   

  (i) no Default shall have occurred and be continuing or would occur as a consequence thereof;

   

  (ii) immediately after giving effect to such transaction on a pro forma basis, the Parent or
    such Subsidiary, as applicable, could incur $1.00 of additional Indebtedness under Section 3.13(F); and

   

  (iii) such Restricted Payment, together with the aggregate amount of all other Restricted Payments made
    by the Parent or such Subsidiary after the Issue Date, excluding Restricted Payments permitted by Section 3.11(B), is less than the amount equal to the Cumulative Credit.

   

  (B)           The provisions of Section 3.11(A) will not
    prohibit:

   

  (i) Customary tax distributions and overhead payments;

   

  (ii) Cashless exchange of Indebtedness;

  
    - 39 -

    
      
 

  

  (iii) Restricted Payments in the amount of five million dollars ($5,000,000) for repurchases of
    Ordinary Shares; provided no Default or Event of Default will have occurred and be continuing at the time of such Restricted Payment;

   

  (iv) to the extent constituting a Restricted Payment, the payment of fees of non-insider directors not
    to exceed an annual amount of [***] and the reimbursement of reasonable expenses;

   

  (v) (i) direct or indirect Restricted Payments to the Company and other Subsidiaries of the Company
    that are Guarantors from other Subsidiaries of the Borrower and (ii) in the case of Subsidiaries that are not Guarantors, direct or indirect Restricted Payments to other Subsidiaries that are not Guarantors;

   

  (vi) (i) Restricted Payments to the Parent to be used for (A) customary director indemnification and
    compensation payments to the Parent’s director nominees serving on the board of directors of Parent, Company or on the board of directors of any Subsidiary and (B) payment of income Taxes to the extent such income Taxes are attributable to the income
    of its direct or indirect Subsidiaries, and (ii) so long as no Event of Default has occurred and is continuing, Restricted Payments to the Parent and to Amryt Pharmaceuticals DAC to be used for financial and other reporting and similar customary
    administrative costs and expenses attributable and fairly allocable to the Company and the Guarantors (including audit and professional fees and other ordinary course operating and administrative expenses incurred by the Parent in its capacity as the
    ultimate holding company of the Company and the other Guarantors);

   

  (vii)  the Parent may declare and make dividend payments or other distributions payable solely in the
    common stock or other common Equity Interests of such Person (other than Disqualified Equity Interests); and

   

  (viii) transactions consisting of intercompany services among the Parent and its wholly-owned
    Subsidiaries in the ordinary course of business on an arm’s length basis, charged on a cost plus a maximum of 10% basis.

   

  Section 3.12. Dispositions.

   

  So long as any Notes remain outstanding, the Company and the Guarantors shall not, and shall not permit
    any of their Subsidiaries to declare or make, directly or indirectly, any Disposition or enter into any agreement to make any Disposition, except:

   

  (A)          Dispositions of obsolete, worn out or surplus property, whether now owned or hereafter
    acquired, in the ordinary course of business and Dispositions of property no longer used or useful in the conduct of the business of the Parent and its Subsidiaries, in each case to the extent constituting immaterial property;

   

  (B)           Dispositions in the ordinary course of business of Cash Equivalents;

  
    - 40 -

    
      
 

  

  (C)           sales of inventory in the ordinary course of business;

   

  (D)           Dispositions (other than of material Intellectual Property or of assets relating to
    metreleptin) for fair market value (as determined by the Company in good faith); provided that (i) the amount of Dispositions does not exceed $250,000 individually or $2,500,000 in the aggregate for all Dispositions while any Notes are
    outstanding, (ii) immediately prior to and immediately after giving effect to such Disposition, no Default or Event of Default shall have occurred and be continuing or would result therefrom and (iii) no less than one hundred percent (100%) of the
    consideration received for any such Disposition is received in cash;

   

  (E)           the leasing, as lessor, of real or personal property not presently used or useful in such
    Person’s business and is otherwise in the ordinary course of business;

   

  (F)           Dispositions of equipment or other assets, to the extent that such equipment is exchanged
    for credit against the purchase price of similar replacement equipment or assets or the proceeds of such Dispositions are reasonably promptly applied to the purchase price of similar replacement equipment, all in the ordinary course of business;

   

  (G)           Dispositions constituting an Intellectual Property that is not material to the conduct of
    the business of the Parent, the Guarantors and their Subsidiaries;

   

  (H)           Dispositions otherwise permitted by Section 3.13 and Dispositions from any
    Subsidiary that is not a Loan Party to any other Subsidiary that is not a Loan Party;

   

  (I)            the licensing of AP101 and AP103 assets outside of the United States and European
    territories;

   

  (J)            Dispositions consisting of licenses of AP102 assets; and

   

  (K)           non-ordinary course Disposition of assets subject only to the receipt of fair market value
    (as determined by the Company in good faith), at least seventy five percent (75%) of the proceeds consisting of cash or Cash Equivalents, and Net Cash Proceeds being applied to repay secured Indebtedness, reinvested within twelve (12) months (or
    committed to be reinvested into a clinical development program approved by the Parent Board within twelve (12) months) or offered to repurchase the Notes at a purchase price (without premium or penalty) equal to 100% of the principal amount of such
    Notes plus accrued and unpaid interest on such Notes, if any, to, but excluding, such date of repurchase, which will be a Business Day of the Company’s choosing no later than the end of such twelve (12) month period.

   

  Section 3.13. Indebtedness.

   

  So long as any Notes remain outstanding, the Company and the Guarantors shall not, and shall not permit
    any of their Subsidiaries to, directly or indirectly, create, incur, assume or suffer to exist any Indebtedness, except the following, without duplication:

   

  (A)          Indebtedness outstanding on the Issue Date (including the Notes);

   

  (B)          Indebtedness incurred in connection with the Plan (including the Senior Secured

  
    - 41 -

    
      
 

  

  Credit Facility, and which shall further permit the principal amount of indebtedness under the Senior
    Secured Credit Facility to be increased to one hundred million dollars ($100,000,000) prior to any refinancing of the Senior Secured Credit Facility);

   

  (C)        additional Capital Leases incurred after the Issue Date and purchase money Indebtedness in an
    aggregate amount not to exceed $750,000 in the aggregate at any time outstanding, and any Refinancing Indebtedness in respect of such Indebtedness; provided that any such Indebtedness (i) in the case of additional Capital Leases or purchase
    money Indebtedness, shall be secured only by the asset subject to such additional Capital Leases or acquired asset in connection with the incurrence of such Indebtedness, as the case may be, and (ii) in the case of purchase money Indebtedness, shall
    constitute not less than 75% of the aggregate consideration paid with respect to such asset;

   

  (D)          other unsecured Indebtedness in an aggregate principal amount not to exceed $250,000 at any
    time outstanding;

   

  (E)    Indebtedness subordinated to the Notes so long as such
    Indebtedness has a maturity date one year past the Maturity Date and an interest rate lower than the Notes (the “Junior Indebtedness”);

   

  (F)       Indebtedness

    that is pari passu in right of payment to the Notes (including secured Indebtedness) if net pharmaceutical product revenue for the twelve (12) months prior to the incurrence of such Indebtedness, on a pro forma basis, exceeds 1:00 to 1:00 of
    all funded Indebtedness (excluding the Junior Indebtedness);

   

  (G)   Indebtedness in respect of performance of bids, trade contracts,
    governmental contracts and leases (other than Indebtedness for borrowed money), statutory obligations, surety, stay, indemnity, customs and appeal bonds, performance bonds and other obligations of a like nature (including those to secure health, safety
    and environmental obligations), and, in each case, letters of credit in respect thereof, incurred in the ordinary course of business;

   

  (H)   non-recourse Indebtedness incurred by the Company or the
    Guarantors or any of their Subsidiaries to finance the payment of insurance premiums of such Person;

   

  (I)         Indebtedness owed to any Person providing worker’s compensation, unemployment insurance and
    other social security legislation, health, disability or other employee benefits or property, casualty or liability insurance to the Company or the Guarantors or any of their Subsidiaries incurred in connection with such Person providing such benefits
    or insurance pursuant to customary reimbursement or indemnification obligations to such Person;

   

  (J)      reimbursement obligations owed to banks and financial institutions with respect to credit card services in an aggregate amount at any one time not exceeding
    $400,000;

   

  (K)   Indebtedness consisting of accounts payable incurred in the
    ordinary course of business past due for more than 120 days after its stated due date (except for accounts payable contested in good faith) which do not in the aggregate exceed $750,000;

   

  (L)           Indebtedness of the Company and the Guarantors under the Deed Poll

  
    - 42 -

    
      
 

  

  Constituting Loan Notes in an aggregate principal amount not to exceed $85,000,000 at any time outstanding;

   

  (M)          finance leases with respect to AP101 and AP103 equipment in an amount not to exceed
    $5,000,000 in the aggregate at any time outstanding; provided that such Indebtedness shall be secured only by the equipment financed thereunder;

   

  (N)           Indebtedness under that certain Finance Contract dated as of December 1, 2016 between Amryt
    Pharmaceuticals DAC and European Investment Bank, as the same may be amended, restated, supplemented or otherwise modified from time to time, from the period from the Issue Date up through one (1) Business Day following the Issue Date which
    Indebtedness shall be paid in full no later than one (1) Business Day following the Issue Date; and

   

  (O)           The refinancing of any Indebtedness that was permitted under this Indenture when it was
    incurred, only to the extent such principal amount of such refinancing is not more than the principal amount of such Indebtedness being refinanced, plus any customary fees and reasonable expenses.

   

  Article 4. REPURCHASE AND REDEMPTION

   

  Section 4.01. No Sinking Fund.

   

  No sinking fund is required to be provided for the Notes.

   

  Section 4.02. Right of Holders to Require the Company to
        Repurchase Notes upon a Fundamental Change.

   

  (A)          Right of Holders to Require the Company to Repurchase Notes Upon a Fundamental Change. Subject

    to the other terms of this Section 4.02, if a Fundamental Change occurs, then each Holder will have the right (the “Fundamental Change Repurchase Right”) to require the Company to repurchase such Holder’s Notes (or any portion thereof in an Authorized Denomination) on the Fundamental Change Repurchase Date for such Fundamental Change for a cash purchase
    price equal to the Fundamental Change Repurchase Price.

   

  (B)           Repurchase Prohibited in Certain Circumstances. If the principal amount of the Notes
    has been accelerated and such acceleration has not been rescinded on or before the Fundamental Change Repurchase Date for a Repurchase Upon Fundamental Change (including as a result of the payment of the related Fundamental Change Repurchase Price, and
    any related interest pursuant to the proviso to Section 4.02(D), on such Fundamental Change Repurchase Date), then (i) the Company shall not repurchase any Notes pursuant to this Section 4.02; and (ii) the Company will cause any Notes theretofore surrendered for such Repurchase upon Fundamental Change to be returned to the Holders thereof (or, if applicable with respect to Global Notes, cancel
    any instructions for book-entry transfer to the Company, the Trustee or the Paying Agent of the applicable beneficial interest in such Notes in accordance with the Depositary Procedures).

   

  (C)           Fundamental Change Repurchase Date. The Fundamental Change Repurchase Date for any
    Fundamental Change will be a Business Day of the Company’s choosing that is no

  
    - 43 -

    
      
 

  

  more than thirty five (35), nor less than twenty (20), Business Days after the date the Company sends the
    related Fundamental Change Notice pursuant to Section 4.02(E).

   

  (D)           Fundamental Change Repurchase Price. The Fundamental Change Repurchase Price for any
    Note to be repurchased upon a Repurchase Upon Fundamental Change following a Fundamental Change is an amount in cash equal to 100% of the principal amount of such Note plus accrued and unpaid interest on such Note, if any, to, but excluding, the
    Fundamental Change Repurchase Date for such Fundamental Change; provided, however, that if such Fundamental Change Repurchase Date is after a Regular Record Date and on or before the next Interest Payment Date, then (i) the Holder of such Note
    at the Close of Business on such Regular Record Date will be entitled, notwithstanding such Repurchase Upon Fundamental Change, to receive, on or, at the Company’s election, before such Interest Payment Date, the unpaid interest that would have accrued
    on such Note to, but excluding, such Interest Payment Date (assuming, solely for these purposes, that such Note remained outstanding through such Interest Payment Date, if such Fundamental Change Repurchase Date is before such Interest Payment Date);
    and (ii) the Fundamental Change Repurchase Price will not include accrued and unpaid interest on such Note to, but excluding, such Fundamental Change Repurchase Date. For the avoidance of doubt, if an Interest Payment Date is not a Business Day within
    the meaning of Section 2.05(C) and such Fundamental Change Repurchase Date occurs on the Business Day immediately after such Interest Payment Date, then (x) accrued and unpaid interest on Notes to, but excluding, such Interest Payment Date
    will be paid, in accordance with Section 2.05(C), on the next Business Day to Holders at of the Close of Business on the immediately preceding Regular Record Date; and (y) the Fundamental Change
    Repurchase Price will include interest on Notes to be repurchased from, and including, such Interest Payment Date.

   

  (E)           Fundamental Change Notice. On or before the twentieth (20th) calendar day after the
    occurrence of a Fundamental Change, the Company will send to each Holder, the Trustee and the Paying Agent a notice of such Fundamental Change (a “Fundamental Change Notice”).

   

  Such Fundamental Change Notice must state:

   

  (i) briefly, the events causing such Fundamental Change;

   

  (ii) the effective date of such Fundamental Change;

   

  (iii) the procedures that a Holder must follow to require the Company to repurchase its Notes pursuant
    to this Section 4.02, including the deadline for exercising the Fundamental Change Repurchase Right and the procedures for submitting and withdrawing a Fundamental Change Repurchase Notice;

   

  (iv) the Fundamental Change Repurchase Date for such Fundamental Change;

   

  (v) the Fundamental Change Repurchase Price per $1,000 principal amount of Notes for such Fundamental
    Change (and, if such Fundamental Change Repurchase Date is after a Regular Record Date and on or before the next Interest Payment Date, the amount, manner and timing of the interest payment payable pursuant to the proviso to Section 4.02(D));

  
    - 44 -

    
      
 

  

  (vi) the name and address of the Paying Agent and the Conversion Agent;

   

  (vii) the Conversion Rate in effect on the date of such Fundamental Change Notice and a description and quantification of any
    adjustments to the Conversion Rate that may result from such Fundamental Change (including pursuant to Section 5.07);

   

  (viii) that Notes for which a Fundamental Change Repurchase Notice has been duly tendered and not duly withdrawn must be delivered to
    the Paying Agent for the Holder thereof to be entitled to receive the Fundamental Change Repurchase Price;

   

  (ix) that Notes (or any portion thereof) that are subject to a Fundamental Change Repurchase Notice that has been duly tendered may
    be converted only if such Fundamental Change Repurchase Notice is withdrawn in accordance with this Indenture; and

   

  (x) the CUSIP and IS1N numbers, if any, of the Notes.

   

  Neither the failure to deliver a Fundamental Change Notice nor any defect in a Fundamental Change Notice will limit the Fundamental
    Change Repurchase Right of any Holder or otherwise affect the validity of any proceedings relating to any Repurchase Upon Fundamental Change.

   

  (F)           Procedures to Exercise the Fundamental Change Repurchase Right.

   

  (i) Delivery of Fundamental Change Repurchase Notice and Notes to Be Repurchased. To exercise its Fundamental Change
    Repurchase Right for a Note following a Fundamental Change, the Holder thereof must deliver to the Paying Agent:

   

  (1)           before the Close of Business on the second Business Day immediately before the related Fundamental Change Repurchase
    Date (or such later time as may be required by law), a duly completed, written Fundamental Change Repurchase Notice with respect to such Note; and

   

  (2)           such Note, duly endorsed for transfer (if such Note is a Physical Note) or by book-entry transfer (if such Note is a
    Global Note).

   

  The Paying Agent will promptly deliver to the Company a copy of each Fundamental Change Repurchase Notice that it receives.

   

  (ii) Contents of Fundamental Change Repurchase Notices. Each Fundamental Change Repurchase Notice with respect to a Note
    must state:

   

  (1)           if such Note is a Physical Note, the certificate number of such Note;

  
    - 45 -

    
      
 

  

   

  
    
      (2)          the
          principal amount of such Note to be repurchased, which must be an Authorized Denomination; and

       

      (3)          that
          such Holder is exercising its Fundamental Change Repurchase Right with respect to such principal amount of such Note;

    

    
       

      provided, however, that if such Note is a Global Note, then such Fundamental Change
        Repurchase Notice must comply with the Depositary Procedures (and any such Fundamental Change Repurchase Notice delivered in compliance with the Depositary Procedures will be deemed to satisfy the requirements of this Section 4.02(F)).

    

    
       

      (iii) Withdrawal of Fundamental Change Repurchase Notice. A Holder that
        has delivered a Fundamental Change Repurchase Notice with respect to a Note may withdraw such Fundamental Change Repurchase Notice by delivering a written notice of withdrawal to the Paying Agent at any time before the Close of Business on the
        second Business Day immediately before the related Fundamental Change Repurchase Date. Such withdrawal notice must state:

    

    
       

      (1)          if such
          Note is a Physical Note, the certificate number of such Note;

       

      (2)          the
          principal amount of such Note to be withdrawn, which must be an Authorized Denomination; and

       

      (3)          the
          principal amount of such Note, if any, that remains subject to such Fundamental Change Repurchase Notice, which must be an Authorized Denomination;

    

    
       

      provided, however, that if such Note is a Global Note, then such withdrawal notice must
        comply with the Depositary Procedures (and any such withdrawal notice delivered in compliance with the Depositary Procedures will be deemed to satisfy the requirements of this Section 4.02(F)).

       

      Upon receipt of any such withdrawal notice with respect to a Note (or any portion thereof), the Paying Agent will (x) promptly deliver
        a copy of such withdrawal notice to the Company; and (y) if such Note is surrendered to the Paying Agent, cause such Note (or such portion thereof in accordance with Section 2.11,
        treating such Note as having been then surrendered for partial repurchase in the amount set forth in such withdrawal notice as remaining subject to repurchase) to be returned to the Holder thereof (or, if applicable with respect to any
        Global Note, cancel any instructions for book-entry transfer to the Company, the Trustee or the Paying Agent of the applicable beneficial interest in such Note in accordance with the Depositary Procedures).

    

    
       

      (G)           Payment of the Fundamental Change Repurchase Price. Without limiting the Company’s obligation to deposit the Fundamental Change Repurchase Price within the time proscribed by Section 3.01(B), the Company will cause the Fundamental Change Repurchase

    

    
       

      
        - 46 -

        
          
 

      

      Price for a Note (or portion thereof) to be repurchased pursuant to a Repurchase Upon Fundamental Change to be paid to the Holder thereof on or before the
        later of (i) the applicable Fundamental Change Repurchase Date; and (ii) the date (x) such Note is delivered to the Paying Agent (in the case of a Physical Note) or (y) the Depositary Procedures relating to the repurchase, and the delivery to the
        Paying Agent, of such Holder’s beneficial interest in such Note to be repurchased are complied with (in the case of a Global Note). For the avoidance of doubt, interest payable pursuant to the proviso to Section
          4.02(D) on any Note to be repurchased pursuant to a Repurchase Upon Fundamental Change must be paid pursuant to such proviso regardless of whether such Note is delivered or such Depositary Procedures are complied with pursuant to the
        first sentence of this Section 4.02(G).

    

    
       

      (H)          Compliance with Applicable Securities Laws. To the extent applicable, the Company will comply with all federal and state securities laws in connection with a Repurchase Upon Fundamental Change (including complying with Rules
          13e-4 and 14e-l under the Exchange Act and filing any required Schedule TO, to the extent applicable) so as to permit effecting such Repurchase Upon Fundamental Change in the manner set forth in this Indenture.

       

      (I)            Repurchase in Part, Subject to the terms of this Section 4.02, Notes may be repurchased pursuant to a Repurchase Upon Fundamental Change in
          part, but only in Authorized Denominations. Provisions of this Section 4.02 applying to the repurchase of a Note in whole will equally apply to the repurchase of a permitted portion of a Note.

    

    
       

      Section 4.03. Right of the Company to Redeem the Notes.

    

    
       

      (A)          No Right to Redeem Before October 1, 2022. The Company may not redeem the Notes at its option at any time before October 1, 2022, except pursuant to a Tax Redemption.

       

      (B)           Right to Redeem the Notes on or After October 1, 2022. Subject to the terms of this Section 4.03, the Company has the right, at its election,
          to redeem all, or any portion in an Authorized Denomination, of the Notes, at any time and from time to time, on a Redemption Date on or after October 1, 2022 and on or before the twentieth (20th) Scheduled Trading Day immediately before the
          Maturity Date, for a cash purchase price equal to the Redemption Price, but only if the Daily VWAP per Ordinary Share exceeds one hundred and fifty percent (150%) of the Conversion Price on (i) each of at least twenty (20) VWAP Trading Days
          (whether or not consecutive) during the thirty (30) consecutive VWAP Trading Days ending on, and including, the VWAP Trading Day immediately before the Redemption Notice Date for such Redemption; and (ii) the VWAP Trading Day immediately before
          such Redemption Notice Date.

    

    
       

      (C)           Right to
          Redeem the Notes After a Change in Tax Law.

    

    
       

      (i) Generally. Subject to the terms of this Section 4.03, and without limiting the Company’s right to redeem any Notes pursuant to Section 4.03(B), the

        Company has the right, at its election, to redeem all, but not less than all, of the Notes, at any time, on a Redemption Date before the Maturity Date, for a cash purchase price equal to the Redemption Price, but only if (i) the Company has (or, on
        the next Interest Payment Date, would) become obligated to pay any Additional Amounts to Holders as a result of any Change

    

    
       

      
        - 47 -

        
          
 

      

      in Tax Law; (ii) the Company cannot avoid such obligation by taking reasonable measures available to the Company; and (iii) the Company
        delivers to the Trustee (1) an Opinion of Counsel from outside legal counsel of recognized standing in the Relevant Taxing Jurisdiction attesting to clause (i) above; and (2) an Officer’s Certificate attesting to clauses (i) and (ii) above.

    

    
       

      (ii) Tax Redemption Opt-Out Election. If the Company calls the Notes for
        a Tax Redemption, then, notwithstanding anything to the contrary in this Section 4.03 or in Section 3.04, each Holder will
        have the right to elect (a “Tax Redemption Opt-Out Election”) not to have such Holder’s Notes (or any portion thereof in
        an Authorized Denomination) redeemed pursuant to such Tax Redemption, in which case, from and after the Redemption Date for such Tax Redemption (or, if the Company fails to pay the Redemption Price due on such Redemption Date in full, from and
        after such time as the Company pays such Redemption Price in full), the Company will no longer have any obligation to pay any Additional Amounts with respect to such Notes solely as a result of such Change in Tax Law, and all future payments with
        respect to such Notes (other than any Conversion Consideration prior to the corresponding Redemption Date) will be subject to the deduction or withholding of such Relevant Taxing Jurisdiction’s taxes required by law to be deducted or withheld as a
        result of such Change in Tax Law (it being understood, for the avoidance of doubt, that if such Holder converts such Notes prior to the corresponding Redemption Date, then the Company will be obligated to pay Additional Amounts, if any, and subject
        to the limitations on the payment of such Additional Amounts set forth in Section 3.04, with respect to such conversion).

    

    
       

      (1)          Tax Redemption Opt-Out Election Notice. To make a Tax Redemption Opt-Out Election with respect to any Note (or any portion thereof in an Authorized Denomination), the Holder of such Note must deliver a notice
          (a “Tax Redemption Opt-Out Election Notice”) to the Paying Agent before the Close of Business on the second Business Day
          immediately before the related Redemption Date, which notice must state: (x) if such Note is a Physical Note, the certificate number of such Note; (y) the principal amount of such Note as to which the Tax Redemption Opt-Out Election will apply,
          which must be an Authorized Denomination; and (z) that such Holder is making a Tax Redemption Opt-Out Election with respect to such Note (or such portion thereof); provided, however, that if such Note is
          a Global Note, then such notice must comply with the Depositary Procedures (and any such notice delivered in compliance with the Depositary Procedures will be deemed to satisfy the requirements of this Section
            4.03(C)(ii)(1)).

       

      (2)          Withdrawal of Tax Redemption Opt-Out Election Notice. A Holder that has delivered a Tax Redemption Opt-Out Election Notice with respect to any Note (or any portion thereof in an Authorized Denomination) may
          withdraw such Tax Redemption Opt-Out Election Notice by delivering a withdrawal notice to the Paying Agent at any time before the Close of Business on the second Business Day immediately before the related Redemption Date, which withdrawal notice
          must state: (x) if such Note

    

    
       

      
        - 48 -

        
          
 

      

      is a Physical Note, the certificate number of such Note; (y) the principal amount of such Note as to which the Tax Redemption Opt-Out
        Election is being withdrawn, which must be an Authorized Denomination; and (z) that such Holder is withdrawing the Tax Redemption Opt-Out Election with respect to such Note (or such portion thereof); provided,
          however, that if such Note is a Global Note, then such withdrawal notice must comply with the Depositary Procedures (and any such withdrawal notice delivered in compliance with the Depositary Procedures will be deemed to satisfy the
        requirements of this Section 4.03(C)(ii)(2)).

    

    
       

      (D)          Redemption Prohibited in Certain Circumstances. If the principal amount of the Notes has been accelerated and such acceleration has not been rescinded on or before the Redemption Date (including as a result of the payment of
          the related Redemption Price, and any related interest pursuant to the proviso to Section 4.03(F), on such Redemption Date), then (i) the Company may not call for
          Redemption or otherwise redeem any Notes pursuant to this Section 4.03; and (ii) the Company will cause any Notes theretofore surrendered for such Redemption to
          be returned to the Holders thereof (or, if applicable with respect to Global Notes, cancel any instructions for book-entry transfer to the Company, the Trustee or the Paying Agent of the applicable beneficial interests in such Notes in accordance
          with the Depositary Procedures).

       

      (E)          Redemption Date. The Redemption Date for any Redemption will be a Business Day of the Company’s choosing that is no more than forty-five (45), nor less than twenty-five (25), Scheduled Trading Days after the Redemption Notice
          Date for such Redemption.

       

      (F)          Redemption Price. The Redemption Price for any Note called for Redemption is an amount in cash equal to the principal amount of such Note plus accrued and unpaid interest on such Note to, but excluding, the Redemption Date for
          such Redemption; provided, however, that if such Redemption Date is after a Regular Record Date and on or before the next Interest Payment Date, then (i) the Holder of such Note at the Close of Business
          on such Regular Record Date will be entitled, notwithstanding such Redemption, to receive, on or, at the Company’s election, before such Interest Payment Date, the unpaid interest that would have accrued on such Note to, but excluding, such
          Interest Payment Date (assuming, solely for these purposes, that such Note remained outstanding through such Interest Payment Date, if such Redemption Date is before such Interest Payment Date); and (ii) the Redemption Price will not include
          accrued and unpaid interest on such Note to, but excluding, such Redemption Date. For the avoidance of doubt, if an Interest Payment Date is not a Business Day within the meaning of Section 2.05(C) and
          such Redemption Date occurs on the Business Day immediately after such Interest Payment Date, then (x) accrued and unpaid interest on Notes to, but excluding, such Interest Payment Date will be paid, in accordance with Section 2.05(C), on the next Business Day to Holders at of the Close of Business on the immediately preceding Regular Record Date; and (y) the Redemption Price will include interest on
          Notes to be redeemed from, and including, such Interest Payment Date.

       

      (G)          Redemption Notice. To call any Notes for Redemption, the Company must (x) send to each Holder of such Notes, the Trustee and the Paying Agent a written notice of such Redemption (a “Redemption Notice”) and (y) substantially contemporaneously therewith, issue a press release through such national newswire service as the Company then
          uses (or publish the

    

    
       

      
        - 49 -

        
          
 

      

      same through such other widely disseminated public medium as the Company then uses, including its website) containing the information set forth in the
        Redemption Notice.

    

    
       

      Such Redemption Notice must state:

    

    
       

      (i) that the Notes have been called for Redemption, briefly describing the Company’s Redemption right under this
        Indenture;

    

    
       

      (ii) the Redemption Date for such Redemption;

    

    
       

      (iii) the Redemption Price per $1,000 principal amount of Notes for such Redemption (and, if the Redemption Date is
        after a Regular Record Date and on or before the next Interest Payment Date, the amount, manner and timing of the interest payment payable pursuant to the proviso to Section 4.03(F));

       

      (iv) the name and address of the Paying Agent and the Conversion Agent;

       

      (v) that Notes called for Redemption may be converted at any time before the Close of Business on the second
        Business Day immediately before the Redemption Date (or, if the Company fails to pay the Redemption Price due on such Redemption Date in full, at any time until such time as the Company pays such Redemption Price in full);

       

      (vi) the Conversion Rate in effect on the Redemption Notice Date for such Redemption and a description and
        quantification of any adjustments to the Conversion Rate that may result from such Redemption (including pursuant to Section 5.07);

    

    
       

      (vii) the Settlement
          Method that will apply to all conversions of Notes with a Conversion Date that occurs on or after such Redemption Notice Date and before such Redemption Date; and

       

      (viii) the CUSIP and
          ISIN numbers, if any, of the Notes.

    

    
       

      On or before the Redemption Notice Date, the Company will send a copy of such Redemption Notice to the Trustee and the Paying Agent.

       

      (H) Special Requirement for Notice of Tax Redemption. A Redemption Notice relating to a Tax
        Redemption must be sent pursuant to Section 4.03(G) no earlier than one hundred and eighty (180) calendar days before the earliest date on which the Company would have been required to make the related
        payment or withholding (assuming a payment in respect of the Notes were then due), and the obligation to pay Additional Amounts must be in effect as of the date the Company sends such Redemption Notice and must be expected to remain in effect at
        the time of the next payment or delivery in respect of the Notes.

    

    
      

      

      
        - 50 -

        
          
 

      

       

      (I)            If less than all Notes then
          outstanding are called for Redemption, then:

    

    
       

      (i) the Notes to be redeemed will be selected by the Company as follows: (1) in the case of Global Notes, in
        accordance with the Depositary Procedures; and (2) in the case of Physical Notes, pro rata, by lot or by such other method the Company considers fair and appropriate; and

       

      (ii) if only a portion of a Note is subject to Redemption and such Note is converted in part, then the converted
        portion of such Note will be deemed to be from the portion of such Note that was subject to Redemption.

    

    
       

      (J)           Payment of the Redemption Price. Without limiting the Company’s obligation to deposit the Redemption Price by the time proscribed by Section 3.01(B), the

          Company will cause the Redemption Price for a Note (or portion thereof) subject to Redemption to be paid to the Holder thereof on or before the later of (i) the applicable Redemption Date; and (ii) the date (x) such Note is delivered to the
          Paying Agent (in the case of a Physical Note) or (y) the Depositary Procedures relating to the repurchase, and the delivery to the Paying Agent, of such Holder’s beneficial interest in such Note to be repurchased are complied with (in the case of
          a Global Note). For the avoidance of doubt, interest payable pursuant to the proviso to Section 4.03(F) on any Note (or portion thereof) subject to Redemption must be paid pursuant to such proviso.

    

    
       

      Article 5. CONVERSION

    

    
       

      Section 5.01. Right to Convert.

    

    
       

      (A)          Generally. Subject to the provisions of this Article 5, each Holder may, at its option, convert such Holder’s Notes into Conversion
          Consideration.

       

      (B)          Conversions in Part. Subject to the terms of this Indenture, Notes may be converted in part, but only in Authorized Denominations. Provisions of this Article 5 applying to the
          conversion of a Note in whole will equally apply to conversions of a permitted portion of a Note.

    

    
       

      (C)          When
          Notes May Be Converted.

    

    
       

      (i) Generally. A Holder may convert its Notes at any time until the Close
        of Business on the second (2nd) Scheduled Trading Day immediately before the Maturity Date, unless such Notes have been previously redeemed or repurchased by the Company in accordance with this Indenture.

       

      (ii) Limitations and Closed Periods. Notwithstanding anything to the
        contrary in this Indenture or the Notes:

    

    
       

      (1)          Notes
          may be surrendered for conversion only after the Open of Business and before the Close of Business on a day that is a Business Day;

       

      (2)          in no
          event may any Note be converted after the Close of Business

    

    
       

      
        - 51 -

        
          
 

      

      on the second (2nd) Scheduled Trading Day immediately before the Maturity Date;

    

    
       

      (3)          if the
          Company calls any Note for Redemption pursuant to Section 4.03, then the Holder of such Note may not convert such Note after the Close of Business on the second
          Business Day immediately before the applicable Redemption Date, except to the extent the Company fails to pay the Redemption Price for such Note in accordance with this Indenture; and

       

      (4)          if a
          Fundamental Change Repurchase Notice is validly delivered pursuant to Section 4.02(F) with respect to any Note, then such Note may not be converted, except to the extent (a) such Note is not subject to
          such notice; (b) such notice is validly withdrawn in accordance with Section 4.02(F); or (c) the Company fails to pay the Fundamental Change Repurchase Price for
          such Note in accordance with this Indenture.

    

    
       

      Section 5.02. Conversion Procedures.

    

    
       

      
        		(A)	
                Generally.

              

      

    

    
       

      (i) Global Notes. To convert a beneficial interest in a Global Note, the
        owner of such beneficial interest must (1) comply with the Depositary Procedures for converting such beneficial interest (at which time such conversion will become irrevocable); and (2) pay any amounts due pursuant to Section 5.02(D) or Section 5.02(E).

       

      (ii) Physical Notes. To convert all or a portion of a Physical Note, the
        Holder of such Note must (1) complete, manually sign and deliver to the Conversion Agent the conversion notice attached to such Physical Note or a facsimile of such conversion notice; (2) deliver such Physical Note to the Conversion Agent (at which
        time such conversion will become irrevocable); (3) furnish any endorsements and transfer documents that the Company or the Conversion Agent may require; and (4) pay any amounts due pursuant to Section 5.02(D) or

        Section 5.02(E).

    

    
       

      (B)          Effect of Converting a Note. At the Close of Business on the Conversion Date for a Note (or any portion thereof), such Note (or such portion thereof) will be deemed to cease to be outstanding (and, for the avoidance of doubt,
          no Person will be deemed to be a Holder of such Note (or such portion thereof) as of the Close of Business on such Conversion Date), except to the extent provided in Section 5.02(D).

       

      (C)          Holder of Record of Conversion Shares. The Person in whose name any Ordinary Share is issuable upon conversion of any Note will be deemed to become the holder of record of such share as of the Close of Business on (i) the
          Conversion Date for such conversion, in the case of Physical Settlement; or (ii) the last VWAP Trading Day of the Observation Period for such conversion, in the case of Combination Settlement.

       

      (D)          Interest Payable upon Conversion. If the Conversion Date of a Note is after a Regular Record Date and before the next Interest Payment Date, then (i) the Holder of such Note

    

    
       

      
        - 52 -

        
          
 

      

      at the Close of Business on such Regular Record Date will be entitled, notwithstanding such conversion, to receive, on or, at the Company’s election,
        before such Interest Payment Date, the unpaid interest that would have accrued on such Note to, but excluding, such Interest Payment Date (assuming, solely for these purposes, that such Note remained outstanding through such Interest Payment Date).

    

    
       

      (E)          Taxes and Duties. If a Holder converts a Note, the Company will pay any documentary, stamp or similar issue or transfer tax or duty due on the issue of any Ordinary Shares upon such conversion; provided, however, that if any tax or duty is due because such Holder requested such shares to be registered in a name other than such Holder’s name, then such Holder will pay such tax or duty and, until having received a sum
          sufficient to pay such tax or duty, the Conversion Agent may refuse to deliver any such shares to be issued in a name other than that of such Holder.

       

      (F)          Conversion Agent to Notify Company of Conversions. If any Note is submitted for conversion to the Conversion Agent or the Conversion Agent receives any notice of conversion with respect to a Note, then the Conversion Agent will
          promptly notify the Company and the Trustee of such occurrence, together with any other information reasonably requested by the Company, and will cooperate with the Company to determine the Conversion Date for such Note.

    

    
       

      Section 5.03. Settlement upon Conversion.

    

    
       

      (A)          Upon the conversion of any
          Note, the Company will settle such conversion by paying or delivering, as applicable and as provided in this Article 5, either (x) Ordinary Shares, together, if
          applicable, with cash in lieu of fractional shares as provided in Section 5.03(B)(i)(1) (a “Physical Settlement”); (y) solely cash as provided in Section 5.03(B)(i)(2) (a “Cash Settlement”); or (z) a combination of cash and Ordinary Shares, together, if applicable, with cash in lieu of fractional
          shares as provided in Section 5.03(B)(i)(3) (a “Combination Settlement”).

       

      The Company will have the right to elect the Settlement Method applicable to any conversion of a Note; provided, however, that:

    

    
       

      (i) subject to clause (iii) below, all conversions of Notes with a
        Conversion Date that occurs on or after October 1, 2024 will be settled using the same Settlement Method, and the Company will send notice of such Settlement Method to Holders and the Conversion Agent no later than the Open of Business on October
        1, 2024;

       

      (ii) subject to clause (iii) below, if the Company elects a Settlement
        Method with respect to the conversion of any Note whose Conversion Date occurs before October 1, 2024, then the Company will send notice of such Settlement Method to the Holder of such Note and the Conversion Agent no later than the Close of
        Business on the Business Day immediately after such Conversion Date;

    

    
       

      (iii) if any Notes are called for Redemption, then (1) the Company will

    

    
       

      
        - 53 -

        
          
 

      

      specify, in the related Redemption Notice sent pursuant to Section 4.03(G), the Settlement Method that will apply to all conversions of Notes with a Conversion Date that occurs on or after the related Redemption Notice Date and before the related Redemption Date; and (2) if such Redemption
        Date occurs on or after October 1, 2024, then such Settlement Method must be the same Settlement Method that, pursuant to clause (i) above, applies to all conversions of Notes with a Conversion Date that
        occurs on or after October 1, 2024;

    

    
       

      (iv) the Company will use the same Settlement Method for all conversions of Notes with a Conversion Date that occurs
        on the same day (and, for the avoidance of doubt, the Company will not be obligated to use the same Settlement Method with respect to conversions of Notes whose Conversion Dates occur on different days, except as provided in clause (i) or (iii) above);

       

      (v) if the Company does not timely elect a Settlement Method with respect to the conversion of a Note, then the
        Company will be deemed to have elected the Default Settlement Method (and, for the avoidance of doubt, the failure to timely make such election will not constitute a Default or Event of Default);

       

      (vi) if the Company timely elects Combination Settlement with respect to the conversion of a Note but does not
        timely notify the Holder of such Note of the applicable Specified Dollar Amount, then the Specified Dollar Amount for such conversion will be deemed to be $1,000 per $1,000 principal amount of Notes (and, for the avoidance of doubt, the failure to
        timely send such notification will not constitute a Default or Event of Default); and

    

    
       

      (vii) the Settlement
          Method will be subject to Sections 5.09(A)(2).

    

    
       

      
        		(B)	
                Conversion Consideration.

              

      

    

    
       

      (i) Generally. Subject to Section
          5.03(B)(ii) and Section 5.03(B)(iii), the type and amount of consideration (the “Conversion

          Consideration”) due in respect of each $1,000 principal amount of a Note to be converted will be as follows:

    

    
       

      (1)          if
          Physical Settlement applies to such conversion, a number of Ordinary Shares equal to the Conversion Rate in effect on the Conversion Date for such conversion;

       

      (2)          if Cash
          Settlement applies to such conversion, cash in an amount equal to the sum of the Daily Conversion Values for each VWAP Trading Day in the Observation Period for such conversion; or

    

    
       

      (3)          if
          Combination Settlement applies to such conversion,

    

    
       

      
        - 54 -

        
          
 

      

    

    consideration consisting of (a) a number of Ordinary Shares equal to the sum of the Daily Share Amounts for
      each VWAP Trading Day in the Observation Period for such conversion; and (b) an amount of cash equal to the sum of the Daily Cash Amounts for each VWAP Trading Day in such Observation Period.

    
       

      (ii) Cash in Lieu of Fractional Shares. If Physical Settlement or
        Combination Settlement applies to the conversion of any Note and the number of Ordinary Shares deliverable pursuant to Section 5.03(B)(i) upon such conversion is not a whole number, then such number will be
        rounded down to the nearest whole number and the Company will deliver, in addition to the other consideration due upon such conversion, cash in lieu of the related fractional share in an amount equal to the product of (1) such fraction and (2) (x)
        the Daily VWAP on the Conversion Date for such conversion (or, if such Conversion Date is not a VWAP Trading Day, the immediately preceding VWAP Trading Day), in the case of Physical Settlement; or (y) the Daily VWAP on the last VWAP Trading Day of
        the Observation Period for such conversion, in the case of Combination Settlement.

       

      (iii) Conversion of Multiple Notes by a Single Holder. If a Holder
        converts more than one (1) Note on a single Conversion Date, then the Conversion Consideration due in respect of such conversion will (in the case of any Global Note, to the extent permitted by, and practicable under, the Depositary Procedures) be
        computed based on the total principal amount of Notes converted on such Conversion Date by such Holder.

       

      (iv) Notice of Calculation of Conversion Consideration. If Cash Settlement
        or Combination Settlement applies to the conversion of any Note, then the Company will determine the Conversion Consideration due thereupon promptly following the last VWAP Trading Day of the applicable Observation Period and will promptly
        thereafter send notice to the Trustee and the Conversion Agent of the same and the calculation thereof in reasonable detail. Neither the Trustee nor the Conversion Agent will have any duty to make any such determination.

    

    
       

      (C)          Delivery of the Conversion Consideration. Except as set forth in Sections 5.05(A), 5.05(C) and 5.09, the Company will pay or deliver, as applicable, the Conversion Consideration due upon the conversion of any Note to the Holder as follows: (i) if Cash Settlement or Combination Settlement applies
          to such conversion, on or before the second (2nd) Business Day immediately after the last VWAP Trading Day of the Observation Period for such conversion; and (ii) if Physical Settlement applies to such conversion, on or before the second (2nd)
          Business Day immediately after the Conversion Date for such conversion.

       

      (D)          Settlement of Accrued Interest Notwithstanding Conversion. If a Holder converts a Note, then the Company will pay accrued and unpaid interest, if any, to, but excluding, the applicable Conversion Date to such converting Holder,
          except as set forth in Section 5.02(D).

    

    
      

      

      
        - 55 -

        
          
 

      

    

    Section 5.04. Reserve and Status of Ordinary Shares
        Issued upon Conversion.

    
       

      (A)          Share Reserve. At all times when any Notes are outstanding, Parent will reserve, out of its authorized, unreserved and not outstanding Ordinary Shares, a number of Ordinary Shares sufficient to permit the conversion of all
          then-outstanding Notes, assuming (x) Physical Settlement will apply to such conversion; and (y) the Conversion Rate is increased by the maximum amount pursuant to which the Conversion Rate may be increased pursuant to Section 5.07.

       

      (B)          Status of Conversion Shares; Listing. Each Conversion Share, if any, delivered upon conversion of any Note will be a newly issued or treasury share and will be duly and validly issued, fully paid, non-assessable, free from
          preemptive rights and free of any lien or adverse claim (except to the extent of any lien or adverse claim created by the action or inaction of the Holder of such Note or the Person to whom such Conversion Share will be delivered). If the
          Ordinary Shares are then listed on any securities exchange, or quoted on any inter-dealer quotation system, then the Company will use commercially reasonable efforts to cause each Conversion Share, when delivered upon conversion of any Note, to
          be admitted for listing on such exchange or quotation on such system.

    

    
       

      Section 5.05. Adjustments to the Conversion Rate.

    

    
       

      (A)          Events Requiring an Adjustment to the Conversion Rate. The Conversion Rate will be adjusted from time to time as follows:

    

    
       

      (i) Share Dividends, Splits and Combinations. If Parent issues solely
        Ordinary Shares as a dividend or distribution on all or substantially all Ordinary Shares, or if Parent effects a share split or a share combination of the Ordinary Shares (in each case excluding an issuance solely pursuant to an Ordinary Share
        Change Event, as to which Section 5.09 will apply), then the Conversion Rate will be adjusted based on the following formula:

    

    
       

      

    

    
       

      where:

    

    
       

      
        	 	CR0   =	
                the Conversion Rate in effect immediately before the Open of Business on the Ex-Dividend Date for such dividend or distribution, or immediately before the Open of
                  Business on the effective date of such share split or share combination, as applicable;

              

      

       

      
        	 	CR1     =	
                the Conversion Rate in effect immediately after the Open of Business on such Ex-Dividend Date or the Open of Business on such effective date, as applicable;

              

      

       

      
        	 	OS0      =	
                the number of Ordinary Shares outstanding immediately before the Open

              

      

    

    
       

      
        - 56 -

        
          
 

      

    

    of Business on such Ex-Dividend Date or effective date, as applicable, without giving effect to such
      dividend, distribution, share split or share combination; and

    
       

      
        		OS1     =	
                the number of Ordinary Shares outstanding immediately after giving effect to such dividend, distribution, share split or share combination.

              

      

    

    
       

      If any dividend, distribution, share split or share combination of the type described in this Section
          5.05(A)(i) is declared or announced, but not so paid or made, then the Conversion Rate will be readjusted, effective as of the date the Parent Board determines not to pay such dividend or distribution or to effect such share split or
        share combination, to the Conversion Rate that would then be in effect had such dividend, distribution, share split or share combination not been declared or announced.

    

    
       

      (ii) Rights, Options and Warrants. If Parent distributes, to all or
        substantially all holders of Ordinary Shares, rights, options or warrants (other than rights issued or otherwise distributed pursuant to a shareholder rights plan, as to which the provisions set forth in Sections
          5.05(A)(iii)(1) and 5.05(E) will apply) entitling such holders, for a period of not more than sixty (60) calendar days after the record date of such distribution, to subscribe for or purchase
        Ordinary Shares at a price per share (translated, if necessary, to U.S. dollars at the Prevailing Exchange Rate on the Trading Day immediately before the date such distribution is announced) that is less than the average of the Last Reported Sale
        Prices per Ordinary Share for the ten (10) consecutive Trading Days ending on, and including, the Trading Day immediately before the date such distribution is announced, then the Conversion Rate will be increased based on the following formula:

    

    
       

      

    

    
       

      where:

    

    
       

      
        		CR0    =	
                the Conversion Rate in effect immediately before the Open of Business on the Ex-Dividend Date for such distribution;

              

      

       

      
        		CR1    =	
                the Conversion Rate in effect immediately after the Open of Business on such Ex-Dividend Date;

              

      

       

      
        		OS     =	
                the number of Ordinary Shares outstanding immediately before the Open of Business on such Ex-Dividend Date;

              

      

       

      
        		X       =	
                the total number of Ordinary Shares issuable pursuant to such rights, options or warrants; and

              

      

       

      
        		Y       =	
                a number of Ordinary Shares obtained by dividing (x) the aggregate price

              

      

    

    
       

      
        - 57 -

        
          
 

      

    

    payable to exercise such rights, options or warrants by (y) the average of the Last Reported Sale Prices per
      Ordinary Share for the ten (10) consecutive Trading Days ending on, and including, the Trading Day immediately before the date such distribution is announced.

    
       

      To the extent that Ordinary Shares are not delivered after the expiration of such rights, options or warrants (including as a result of
        such rights, options or warrants not being exercised), the Conversion Rate will be readjusted to the Conversion Rate that would then be in effect had the increase to the Conversion Rate for such distribution been made on the basis of delivery of
        only the number of Ordinary Shares actually delivered upon exercise of such rights, option or warrants. To the extent such rights, options or warrants are not so distributed, the Conversion Rate will be readjusted to the Conversion Rate that would
        then be in effect had the Ex-Dividend Date for the distribution of such rights, options or warrants not occurred.

       

      For purposes of this Section 5.05(A)(ii), in
        determining whether any rights, options or warrants entitle holders of Ordinary Shares to subscribe for or purchase Ordinary Shares at a price per share that is less than the average of the Last Reported Sale Prices per Ordinary Share for the ten
        (10) consecutive Trading Days ending on, and including, the Trading Day immediately before the date the distribution of such rights, options or warrants is announced, and in determining the aggregate price payable to exercise such rights, options
        or warrants, there will be taken into account any consideration the Parent receives for such rights, options or warrants and any amount payable on exercise thereof, with the value of such consideration, if not cash, to be determined by the Parent
        Board.

    

    
       

      (iii) Spin-Offs and Other Distributed Property.

    

    
       

      (1)           Distributions Other than Spin-Offs. If Parent distributes shares of its Capital Stock, evidences of its indebtedness or other assets or property of the Company, or rights, options or warrants to acquire
          Capital Stock of Parent or other securities, to all or substantially all holders of the Ordinary Shares, excluding:

    

    
       

      (v)          dividends,

          distributions, rights, options or warrants for which an adjustment to the Conversion Rate is required pursuant to Section 5.05(A)(i) or 5.05(A)(ii);

       

      (w)         dividends

          or distributions paid exclusively in cash for which an adjustment to the Conversion Rate is required pursuant to Section 5.05(A)(iv);

       

      (x)           rights

          issued or otherwise distributed pursuant to a shareholder rights plan, except to the extent provided in Section 5.05(E);

       

      (y)          Spin-Offs

          for which an adjustment to the Conversion Rate is required pursuant to Section 5.05(A)(iii)(2); and

    

    
       

      (z)           a
          distribution solely pursuant to an Ordinary Share Change

    

    
       

      
        - 58 -

        
          
 

      

      Event, as to which Section 5.09 will apply,

    

    
       

      then the Conversion Rate will be increased based on the following formula:

    

    
       

      

    

    
       

      where:

    

    
       

      
        		CR0    =	
                the Conversion Rate in effect immediately before the Open of Business on the Ex-Dividend Date for such distribution;

              

      

       

      
        		CR1    =	
                the Conversion Rate in effect immediately after the Open of Business on such Ex-Dividend Date;

              

      

       

      
        		SP      =	
                the average of the Last Reported Sale Prices per Ordinary Share for the ten (10) consecutive; Trading Days ending on, and including, the Trading Day immediately before such Ex-Dividend Date; and

              

      

       

      
        		FMV  =	
                the fair market value (as determined by the Parent Board and expressed in U.S. dollars, translated, if necessary, at the Prevailing Exchange Rate on such Ex-Dividend Date), as of such Ex-Dividend Date, of the shares of Capital Stock,
                  evidences of indebtedness, assets, property, rights, options or warrants distributed per Ordinary Share pursuant to such distribution;

              

      

    

    
       

      provided, however, that if FMV is equal to or
        greater than SP, then, in lieu of the foregoing adjustment to the Conversion Rate, each Holder will receive, for each $1,000 principal amount of Notes held by such Holder on the record date for such
        distribution, at the same time and on the same terms as holders of Ordinary Shares, the amount and kind of shares of Capital Stock, evidences of indebtedness, assets, property, rights, options or warrants that such Holder would have received if
        such Holder had owned, on such record date, a number of Ordinary Shares equal to the Conversion Rate in effect on such record date.

       

      To the extent such distribution is not so paid or made, the Conversion Rate will be readjusted to the Conversion Rate that would then
        be in effect had the adjustment been made on the basis of only the distribution, if any, actually made or paid.

    

    
       

      (2)            Spin-Offs. If Parent distributes or dividends shares of
        Capital Stock of any class or series, or similar equity interest, of or relating to an Affiliate, a Subsidiary or other business unit of Parent to all or substantially all holders of the Ordinary Shares (other than solely pursuant to an Ordinary
        Share Change Event, as to which Section 5.09 will apply), and such Capital Stock or equity interest is listed or quoted (or will be listed or quoted upon the consummation of the transaction) on a U.S.

    

    
       

      
        - 59 -

        
          
 

      

    

    national securities exchange or a reasonably comparable non-U.S. equivalent (as determined by the Parent
      Board) (a “Spin-Off), then the Conversion Rate will be increased based on the following formula:

    
       

      

    

    
       

      where:

    

     

    
      
        		CR0     =	
                the Conversion Rate in effect immediately before the Open of Business on the Ex-Dividend Date for such Spin-Off;

              

      

       

      
        		CR1    =	
                the Conversion Rate in effect immediately after the Open of Business on such Ex-Dividend Date;

              

      

       

      
        		FMV  =	
                the product of (x) the average of the Last Reported Sale Prices per-share or unit of the Capital Stock or equity interests distributed in such Spin-Off over the
                  ten (10) consecutive Trading Day period (the “Spin-Off Valuation Period”) beginning on, and including, such Ex-Dividend Date (such average to be determined as if references to Ordinary Shares in
                  the definitions of Last Reported Sale Price, Trading Day and Market Disruption Event were instead references to such Capital Stock or equity interests); and (y) the number of shares or units of such Capital Stock or equity interests
                  distributed per Ordinary Share in such Spin-Off; and

              

      

       

      
        		SP      =	
                the average of the Last Reported Sale Prices per Ordinary Share for each Trading Day in the Spin-Off Valuation Period.

              

      

    

    
       

      The adjustment to the Conversion Rate pursuant to this Section 5.05(A)(iii)(2) will be
        calculated as of the Close of Business on the last Trading Day of the Spin-Off Valuation Period but will be given effect immediately after the Open of Business on the Ex-Dividend Date for the Spin-Off, with retroactive effect. If a Note is
        converted and the Conversion Date (in the case of Physical Settlement) or any VWAP Trading Day of the applicable Observation Period (in the case of Cash Settlement or Combination Settlement) occurs during the Spin-Off Valuation Period, then,
        notwithstanding anything to the contrary in this Indenture or the Notes, the Company will, if necessary, delay the settlement of such conversion until the second (2nd) Business Day after the last day of the Spin-Off Valuation Period.

       

      To the extent any dividend or distribution of the type set forth in this Section
          5.05(A)(iii)(2) is declared but not made or paid, the Conversion Rate will be readjusted, effective as of the date the Parent Board determines not to make such distribution, to the Conversion Rate that would then be in effect had the
        adjustment been made on the basis of only the dividend or distribution, if any,

    

    
       

      
        - 60 -

        
          
 

      

      actually made or paid.

    

    
       

      (iv) Cash Dividends or Distributions. If any cash dividend or distribution
        is made to all or substantially all holders of Ordinary Shares, then the Conversion Rate will be increased based on the following formula:

    

    
       

      

    

    
       

      where:

    

     

    
      
        		CR0    =	
                the Conversion Rate in effect immediately before the Open of Business on the Ex-Dividend Date for such dividend or distribution;

              

      

       

      
        		CR1   =	
                the Conversion Rate in effect immediately after the Open of Business on such Ex-Dividend Date;

              

      

       

      
        		SP     =	
                the Last Reported Sale Price per Ordinary Share on the Trading Day immediately before such Ex-Dividend Date; and

              

      

       

      
        		D       =	
                the cash amount distributed per Ordinary Share in such dividend or distribution (translated, if necessary, to U.S. dollars at the Prevailing Exchange Rate on the Trading Day immediately before such Ex-Dividend Date);

              

      

    

    
       

      provided, however, that if D is equal to or
        greater than SP, then, in lieu of the foregoing adjustment to the Conversion Rate, each Holder will receive, for each $1,000 principal amount of Notes held by such Holder on the record date for such
        dividend or distribution, at the same time and on the same terms as holders of Ordinary Shares, the amount of cash that such Holder would have received if such Holder had owned, on such record date, a number of Ordinary Shares equal to the
        Conversion Rate in effect on such record date.

       

      To the extent such dividend or distribution is declared but not made or paid, the Conversion Rate will be readjusted to the Conversion
        Rate that would then be in effect had the adjustment been made on the basis of only the dividend or distribution, if any, actually made or paid.

    

    
       

      (v) Tender Offers or Exchange Offers. If Parent or any of its
        Subsidiaries makes a payment in respect of a tender offer or exchange offer for Ordinary Shares (other than solely pursuant to an odd-lot tender offer pursuant to Rule 13e-4(h)(5) under the Exchange Act), and the value (expressed in U.S. dollars,
        translated, if necessary, at the Prevailing Exchange Rate on the Expiration Date, and determined as of the Expiration Time by the Parent Board) of the cash and other consideration paid per Ordinary Share in such tender or exchange offer exceeds the
        Last Reported Sale Price per

    

    
       

      
        - 61 -

        
          
 

      

    

    Ordinary Share on the Trading Day immediately after the last date (the “Expiration

        Date”) on which tenders or exchanges may be made pursuant to such tender or exchange offer (as it may be amended), then the Conversion Rate will be increased based on the following formula:

    
       

      

    

    
       

      where:

    

     

    
      
        		CR0    =	
                the Conversion Rate in effect immediately before the time (the “Expiration Time”) such tender or exchange offer expires;

              

      

       

      
        		CR1    =	
                the Conversion Rate in effect immediately after the Expiration Time;

              

      

       

      
        		AC     =	
                the aggregate value (determined as of the Expiration Time by the Parent Board) of all cash and other consideration paid for Ordinary Shares purchased in such tender or exchange offer;

              

      

       

      
        		OS0    =	
                the number of Ordinary Shares outstanding immediately before the Expiration Time (before giving effect to the purchase of all Ordinary Shares accepted for purchase or exchange in such tender or exchange offer);

              

      

       

      
        		OS1    =	
                the number of Ordinary Shares outstanding immediately after the Expiration Time (after giving effect to the purchase or exchange of all Ordinary Shares accepted for purchase or exchange in such tender or exchange offer); and

              

      

       

      
        		SP     =	
                the average of the Last Reported Sale Prices per Ordinary Share over the ten (10) consecutive Trading Day period (the “Tender/Exchange Offer Valuation; Period”) beginning on, and including, the Trading Day immediately after the Expiration Date;

              

      

    

    
       

      provided, however, that the Conversion Rate will in no event be adjusted down pursuant to
        this Section 5.05(A)(v), except to the extent provided in the immediately following paragraph. The adjustment to the Conversion Rate pursuant to this Section 5.05(A)(v) will be calculated as of the Close of Business on the last Trading Day of the Tender/Exchange Offer Valuation Period but will be given effect immediately after the Expiration Time, with
        retroactive effect. If a Note is converted and the Conversion Date (in the case of Physical Settlement) or any VWAP Trading Day of the applicable Observation Period (in the case of Cash Settlement or Combination Settlement) occurs on the Expiration
        Date or during the Tender/Exchange Offer Valuation Period, then, notwithstanding anything to the contrary in this Indenture or the Notes, the Company will, if necessary, delay the settlement of such conversion until the second (2nd) Business Day
        after the last day of the Tender/Exchange Offer Valuation Period.

       

      
        - 62 -

        
          
 

      

      To the extent such tender or exchange offer is announced but not consummated (including as a result of Parent being precluded from
        consummating such tender or exchange offer under applicable law), or any purchases or exchanges of Ordinary Shares in such tender or exchange offer are rescinded, the Conversion Rate will be readjusted to the Conversion Rate that would then be in
        effect had the adjustment been made on the basis of only the purchases or exchanges of Ordinary Shares, if any, actually made, and not rescinded, in such tender or exchange offer.

    

    
       

      (B)          No
          Adjustments in Certain Cases.

    

    
       

      (i) Where Holders Participate in the Transaction or Event Without Conversion. Notwithstanding

        anything to the contrary in Section 5.05(A), the Company will not be obligated to adjust the Conversion Rate on account of a transaction or other event otherwise
        requiring an adjustment pursuant to Section 5.05(A) (other than a share split or combination of the type set forth in Section 5.05(A)(i) or a tender or exchange
        Offer of the type set forth in Section 5.05(A)(v)) if each Holder participates, at the same time and on the same terms as holders of Ordinary Shares, and solely by
        virtue of being a Holder of Notes, in such transaction or event without having to convert such Holder’s Notes and as if such Holder held a number of Ordinary Shares equal to the product of (i) the Conversion Rate in effect on the related record
        date; and (ii) the aggregate principal amount (expressed in thousands) of Notes held by such Holder on such date.

       

      (ii) Certain Events. The Company will not be required to adjust the
        Conversion Rate except as provided in Section 5.05 or Section 5.07. Without limiting the foregoing, the Company will not
        be obligated to adjust the Conversion Rate on account of:

    

    
       

      (1)          except
          as otherwise provided in Section 5.05, the sale of Ordinary Shares by Parent, the Company or otherwise for a purchase price that is less than the market price per
          Ordinary Share or less than the Conversion Price;

       

      (2)          the
          issuance of any Ordinary Shares by Parent, the Company or otherwise pursuant to any present or future plan providing for the reinvestment of dividends or interest payable on Parent’s securities and the investment of additional optional amounts in
          Ordinary Shares under any such plan;

       

      (3)          the
          issuance of any Ordinary Shares or options or rights to purchase Ordinary Shares by Parent, the Company or otherwise pursuant to any present or future employee, director or consultant benefit plan or program of, or assumed by, Parent or any of
          its Subsidiaries;

       

      (4)          the
          issuance of any Ordinary Shares by Parent, the Company or otherwise pursuant to any option, warrant, right, contingent value right or exercisable, convertible or exchangeable security of Parent or its Subsidiaries outstanding as of the

    

    
       

      
        - 63 -

        
          
 

      

    

    Issue Date (other than an adjustment pursuant to Section 5.05(A)(iii)(1) in connection with the separation of rights under Parent’s shareholder rights plan existing as of the Issue Date);

    
       

      (5)          solely a
          change in the par value of the Ordinary Shares;

       

      (6)          accrued
          and unpaid interest on the Notes; or

       

      (7)          the
          transactions contemplated by the Plan (including the establishment of a holding company above the Parent).

    

    
       

      (C)          Adjustments Not Yet Effective. Notwithstanding anything to the contrary in this Indenture or the Notes, if:

    

    
       

      (i) a Note is to be converted pursuant to Physical Settlement or Combination Settlement;

       

      (ii) the record date, effective date or Expiration Time for any event that requires an adjustment to the Conversion
        Rate pursuant to Section 5.05(A) has occurred on or before the Conversion Date for such conversion (in the case of Physical Settlement) or on or before any VWAP Trading Day in the Observation Period for
        such conversion (in the case of Combination Settlement), but an adjustment to the Conversion Rate for such event has not yet become effective as of such Conversion Date or VWAP Trading Day, as applicable;

       

      (iii) the Conversion Consideration due upon such conversion (in the case of Physical Settlement) or due in respect
        of such VWAP Trading Day (in the case of Combination Settlement) includes any whole Ordinary Shares; and

       

      (iv) such shares are not entitled to participate in such event (because they were not held on the related record
        date or otherwise),

    

    
       

      then, solely for purposes of such conversion, the Company will, without duplication, give effect to such adjustment on such Conversion Date (in the case
        of Physical Settlement) or such VWAP Trading Day (in the case of Combination Settlement). In such case, if the date on which the Company is otherwise required to deliver the consideration due upon such conversion is before the first date on which
        the amount of such adjustment can be determined, then the Company will delay the settlement of such conversion until the second (2nd) Business Day after such first date.

    

    
       

      (D)          Conversion Rate Adjustments where Converting Holders Participate in the Relevant Transaction or Event. Notwithstanding anything to the contrary in this Indenture or the Notes, if:

    

    
       

      (i) a Conversion Rate adjustment for any dividend or distribution becomes effective on any Ex-Dividend Date pursuant
        to Section 5.05(A);

    

    
       

      (ii) a Note is to be converted pursuant to Physical Settlement or

    

    
       

      
        - 64 -

        
          
 

      

    

    Combination Settlement;

    
       

      (iii) the Conversion Date for such conversion (in the case of Physical Settlement) or any VWAP Trading Day in the
        Observation Period for such conversion (in the case of Combination Settlement) occurs on or after such Ex-Dividend Date and on or before the related record date;

       

      (iv) the Conversion Consideration due upon such conversion (in the case of Physical Settlement) or due with respect
        to such VWAP Trading Day (in the case of Combination Settlement) includes any whole Ordinary Shares based on a Conversion Rate that is adjusted for such dividend or distribution; and

       

      (v) such shares would be entitled to participate in such dividend or distribution (including pursuant to Section 5.02(C)),

    

    
       

      then (x) in the case of Physical Settlement, such Conversion Rate adjustment will not be given effect for such conversion, and the Ordinary Shares
        issuable upon such conversion based on such unadjusted Conversion Rate will be entitled to participate in such dividend or distribution; and (y) in the case of Combination Settlement, the Conversion Rate adjustment relating to such Ex-Dividend Date
        will be made for such conversion in respect of such VWAP Trading Day, but the Ordinary Shares issuable with respect to such VWAP Trading Day based on such adjusted Conversion Rate will not be entitled to participate in such dividend or
        distribution.

    

    
       

      (E)          Shareholder Rights Plans. If any Ordinary Shares are to be issued upon conversion of any Note and, at the time of such conversion, the Company has in effect any shareholder rights plan, then the Holder of such Note will be
          entitled to receive, in addition to, and concurrently with the delivery of, the Conversion Consideration otherwise payable under this Indenture upon such conversion, the rights set forth in such shareholder rights plan, unless such rights have
          separated from the Ordinary Shares at such time, in which case, and only in such case, the Conversion Rate will be adjusted pursuant to Section 5.05(A)(iii)(1) on account of such separation as if, at the
          time of such separation, the Company had made a distribution of the type referred to in such Section to all holders of the Ordinary Shares, subject to readjustment in accordance with such Section if such rights expire, terminate or are redeemed.

       

      (F)          Limitation on Effecting Transactions Resulting in Certain Adjustments. The Company will not engage in or be a party to any transaction or event that would require the Conversion Rate to be adjusted pursuant to Section 5.05(A) or Section 5.07 to an amount that would result in the Conversion Price per Ordinary Share being less than the par value per Ordinary Share.

       

      (G)          Equitable Adjustments to Prices. Except as otherwise set forth in Section 5.05(C) or Section 5.05(D), whenever

          any provision of this Indenture requires the Company to calculate the average of the Last Reported Sale Prices, or any function thereof, over a period of multiple days (including to calculate the Share Price or an adjustment to the Conversion
          Rate), or to calculate Daily VWAPs over an Observation Period, the Company will make proportionate adjustments, if any, to such calculations to account for any adjustment to the Conversion Rate

    

    
       

      
        - 65 -

        
          
 

      

    

    pursuant to Section 5.05(A)(i) that becomes effective, or any event requiring such an
      adjustment to the Conversion Rate where the Ex-Dividend Date or effective date, as applicable, of such event occurs, at any time during such period or Observation Period, as applicable.

    
       

      (H)          Calculation of Number of Outstanding Ordinary Shares. For purposes of Section 5.05(A), the number of Ordinary Shares outstanding at any time
          will (i) include shares issuable in respect of scrip certificates issued in lieu of fractions of Ordinary Shares; (ii) include shares issuable pursuant to the zero cost warrants issuable pursuant to the Plan and (iii) exclude Ordinary Shares held
          in the Company’s treasury (unless the Company pays any dividend or makes any distribution on Ordinary Shares held in its treasury).

       

      (I)            Calculations. All calculations with respect to the Conversion Rate and adjustments thereto will be made to the nearest 1/10,000th of an Ordinary Share (with 5/100,000ths rounded upward).

       

      (J)           Notice of Conversion Rate Adjustments. Upon the effectiveness of any adjustment to the Conversion Rate pursuant to Section 5.05(A), the Company
          will promptly send notice to the Holders, the Trustee and the Conversion Agent containing (i) a brief description of the transaction or other event on account of which such adjustment was made; (ii) the Conversion Rate in effect immediately after
          such adjustment; and (iii) the effective time of such adjustment.

    

    
       

      Section 5.06. Voluntary Adjustments.

    

    
       

      (A)          Generally. To the extent permitted by law and applicable stock exchange rules, the Company, from time to time, may (but is not required to) increase the Conversion Rate by any amount if (i) the Board of Directors determines
          that such increase is either (x) in the best interest of the Company; or (y) advisable to avoid or diminish any income tax imposed on holders of Ordinary Shares or rights to purchase Ordinary Shares as a result of any dividend or distribution of
          Ordinary Shares (or rights to acquire Ordinary Shares) or any similar event; (ii) such increase is in effect for a period of at least twenty (20) Business Days; and (iii) such increase is irrevocable during such period.

       

      (B)          Notice of Voluntary Increases. If the Board of Directors determines to increase the Conversion Rate pursuant to Section 5.06(A), then, no later
          than the first Business Day of the related twenty (20) Business Day period referred to Section 5.06(A), the Company will send notice to each Holder of such
          increase, the amount thereof and the period during which such increase will be in effect.

    

    
       

      Section 5.07. Adjustments to the Conversion Rate in Connection with a
          Make-Whole Fundamental Change.

    

    
       

      (A)          Generally. If a Make-Whole Fundamental Change occurs and the Conversion Date for the conversion of a Note occurs during the related Make-Whole Fundamental Change Conversion Period, then, subject to this Section 5.07, the Conversion Rate applicable to such conversion will be increased by a number of shares (the “Additional Shares”) set forth in the table below corresponding (after interpolation as provided in, and subject to, the provisions below) to the Make-Whole
          Fundamental Change Effective Date and the Share Price of such

    

    
       

      
        - 66 -

        
          
 

      

    

    Make-Whole Fundamental Change:

     

    	 	
            Share Price

          
	
             Make-Whole

             Fundamental Change

             Effective Date

          	
            $2.15

          	
            $2.25

          	
            $2.59

          	
            $3.00

          	
            $3.50

          	
            $3.88

          	
            $4.50

          	
            $6.00

          	
            $7.50

          	
            $10.00

          
	
             10/1/19

          	
            121.4018

          	
            112.2628

          	
            86.4189

          	
            64.0178

          	
            45.5830

          	
            35.6131

          	
            23.9672

          	
            8.9946

          	
            2.6633

          	
            0.0000

          
	
             4/1/20

          	
            122.8119

          	
            113.4598

          	
            87.0650

          	
            64.2588

          	
            45.5751

          	
            35.5048

          	
            23.7883

          	
            8.8226

          	
            2.5589

          	
            0.0000

          
	
             4/1/21

          	
            124.4477

          	
            114.6413

          	
            87.1003

          	
            63.5532

          	
            44.4663

          	
            34.3045

          	
            22.6059

          	
            7.9912

          	
            2.0999

          	
            0.0000

          
	
             4/1/22

          	
            123.9865

          	
            113.6540

          	
            84.9064

          	
            60.6895

          	
            41.4452

          	
            31.3841

          	
            20.0418

          	
            6.4074

          	
            1.3159

          	
            0.0000

          
	
             4/1/23

          	
            119.4853

          	
            108.5144

          	
            78.4475

          	
            53.8290

          	
            34.9588

          	
            25.4501

          	
            15.1618

          	
            3.7706

          	
            0.3000

          	
            0.0000

          
	
             4/1/24

          	
            106.7106

          	
            94.7416

          	
            62.8992

          	
            38.5379

          	
            21.5864

          	
            13.9042

          	
            6.5287

          	
            0.3851

          	
            0.0000

          	
            0.0000

          
	
             4/1/25

          	
            77.3517

          	
            57.6944

          	
            0.0000

          	
            0.0000

          	
            0.0000

          	
            0.0000

          	
            0.0000

          	
            0.0000

          	
            0.0000

          	
            0.0000

          

    
       

      If such Make-Whole Fundamental Change Effective Date or Share Price is not set forth in the table above, then:

    

    
       

      (i) if such Share Price is between two Share Prices in the table above or the Make-Whole Fundamental Change
        Effective Date is between two dates in the table above, then the number of Additional Shares will be determined by a straight-line interpolation between the numbers of Additional Shares set forth for the higher and lower Share Prices in the table
        and the earlier and later dates in the table above, as applicable, based on a 365- or 366-day year, as applicable; and

       

      (ii) if the Share Price is greater than [***] (subject to adjustment in the same manner as the Share Prices set
        forth in the column headings of the table above are adjusted pursuant to Section 5.07(B)), or less than [***] (subject to adjustment, in the same manner), per
        share, then no Additional Shares will be added to the Conversion Rate.

    

    
       

      Notwithstanding anything to the contrary in this Indenture or the Notes, in no event will the Conversion Rate be increased to an amount
        that exceeds [***] Ordinary Shares per $1,000 principal amount of Notes, which amount is subject to adjustment in the same manner as, and at the same time and for the same events for which, the Conversion Rate is required to be adjusted pursuant to
        Section 5.05(A).

       

      For the avoidance of doubt, (x) the sending of a Redemption Notice will constitute a Make-Whole Fundamental Change only with respect to
        the Notes called for Redemption pursuant to such Redemption Notice, and not with respect to any other Notes; and (y) the Conversion Rate applicable to the Notes not so called for Redemption will not be subject to increase pursuant to this Section 5.07 on account of such Redemption Notice.

       

      The Share Prices in the table are expressed in U.S. dollars and, if expressed in a different currency as of any relevant Make-Whole
        Fundamental Change Effective Date, will be translated to U.S. dollars at the Prevailing Exchange Rate on such Make-Whole Fundamental Change Effective Date.

    

    
       

      
        - 67 -

        
          
 

      

    

    
      (B)          Adjustment of Share Prices and Additional Shares. The Share Prices in the first row (i.e., the column headers) of the table set forth in Section
            5.07(A) will be adjusted in the same manner as, and at the same time and for the same events for which, the Conversion Price is adjusted as a result of the operation of Section 5.05(A). The numbers of Additional Shares in the table set forth in Section 5.07(A) will be adjusted in the same manner as, and at the same time and for the same
          events for which, the Conversion Rate is adjusted pursuant to Section 5.07(A).

       

      (C)          Notice of the Occurrence of a Make-Whole Fundamental Change. If a Make-Whole Fundamental Change occurs, then, promptly and in no event later than the Business Day immediately after the Make-Whole Fundamental Change Effective
          Date of such Make-Whole Fundamental Change, the Company will notify the Holders of the occurrence of such Make-Whole Fundamental Change and of such Make-Whole Fundamental Change Effective Date, briefly stating the circumstances under which the
          Conversion Rate will be increased pursuant to this Section 5.07 in connection with such Make-Whole Fundamental Change.

       

      (D)          Settlement of Cash Make-Whole Fundamental Changes. For the avoidance of doubt, if holders of Ordinary Shares receive solely cash in a Make-Whole Fundamental Change, then, pursuant to Section
            5.09, conversions of Notes will thereafter be settled no later than the second (2nd) Business Day after the relevant Conversion Date.

    

    
       

      Section 5.08. Restriction on Conversions.

    

    
       

      (A)          Notwithstanding anything
          to the contrary in this Indenture or the Notes, no Ordinary Shares will be issued upon conversion of any Note, no Note will be convertible by the Holder thereof, and the Company will not effect any conversion of any Note, in each case to the
          extent, and only to the extent, that such issuance, convertibility or conversion would result in such Holder or a “person” or “group” (within the meaning of Section 13(d)(3) of the Exchange Act) beneficially owning in excess of 9.9% of the
          then-outstanding Ordinary Shares. For these purposes, beneficial ownership and calculations of percentage ownership will be determined in accordance with Rule 13d-3 under the Exchange Act. For the avoidance of doubt, the limitations on the
          convertibility of any Note pursuant to this Section 5.08(A) will not, in themselves, cause such Note to cease to be outstanding (and interest will continue to accrue on any portion of a Note that has been
          tendered for conversion and whose convertibility is suspended pursuant to this Section 5.08(A)), and such limitations will cease to apply if and when such Note’s
          convertibility and conversion will not violate this Section 5.08(A). Each Holder, by notice to the Company, may elect in connection with any conversion of Notes
          that the provisions of this Section 5.08(A) not apply to such Holder; provided, however, upon delivery of such a notice to the Company, the provisions of this Section 5.08(A) will continue to apply to such conversion until the sixty-first (61st) calendar day following such delivery. For the avoidance of doubt, nothing in this Section

            5.08(A) will affect the Company’s ability to elect any Settlement Method in accordance with this Indenture. Except to the extent the Company has received a notice as set forth in the preceding sentence, the Company and Trustee may
          conclusively rely on a Holder’s completion of the applicable procedures set forth in Section 5.02(A) as evidence that such conversion will not violate this Section
            5.08(A).

    

    
       

      
        - 68 -

        
          
 

      

      Section 5.09. Effect of Ordinary Share Change Event.

    

    
       

      
        		(A)	
                Generally. If there occurs any:

              

      

    

    
       

      (i) recapitalization, reclassification or change of the Ordinary Shares (other than (x) changes solely resulting
        from a subdivision or combination of the Ordinary Shares, (y) a change only in par value or from par value to no par value or no par value to par value and (z) share splits and share combinations that do not involve the issuance of any other series
        or class of securities);

       

      (ii) consolidation, merger, combination or binding or statutory share exchange involving the Company or the Parent;
        or

       

      (iii) sale, lease or other transfer of all or substantially all of the assets of the Parent and its Subsidiaries,
        taken as a whole, to any Person,

    

    
       

      and, as a result of which, the Ordinary Shares are converted into, or are exchanged for, or represent solely the right to receive, other securities, cash
        or other property, or any combination of the foregoing (such an event, an “Ordinary Share Change Event,” and such other
        securities, cash or property, the “Reference Property,” and the amount and kind of Reference Property that a holder of one
        (1) Ordinary Share would be entitled to receive on account of such Ordinary Share Change Event (without giving effect to any arrangement not to issue or deliver a fractional portion of any security or property), a “Reference Property Unit”), then, notwithstanding anything to the contrary in this Indenture or the Notes,

    

    
       

      (1)          from
          and after the effective time of such Ordinary Share Change Event, (I) the Conversion Consideration due upon conversion of any Note will be determined in the same manner as if each reference to any number of Ordinary Shares in this Article 5 (or in any related definitions) were instead a reference to the same number of Reference Property Units; (II) for purposes of Section 4.03, each reference to any number of Ordinary Shares in such Section (or in any related definitions) will instead be deemed to be a reference to the same number of Reference Property Units; and (III) for purposes of the
          definition of “Fundamental Change” and “Make-Whole Fundamental Change,” the terms “Ordinary Shares” and “common equity” will be deemed to mean the common equity (including depositary receipts representing common equity), if any, forming part of
          such Reference Property;

       

      (2)          if such
          Reference Property Unit consists entirely of cash, then the Company will be deemed to elect Physical Settlement in respect of all conversions whose Conversion Date occurs on or after the effective date of such Ordinary Share Change Event and will
          pay the cash due upon such conversions no later than the second (2nd) Business Day after the relevant Conversion Date; and

       

      (3)          for
          these purposes, the Daily VWAP or Last Reported Sale Price of any Reference Property Unit or portion thereof that does not consist of a class of securities will be the fair value of such Reference Property Unit or portion thereof, as applicable,
          determined in good faith by the Company (or, in the case of cash denominated in U.S.

    

    
       

      
        - 69 -

        
          
 

      

    

    dollars, the face amount thereof).

    
       

      If the Reference Property consists of more than a single type of consideration to be determined based in part upon any form of
        shareholder election, then the composition of the Reference Property Unit will be deemed to be the weighted average of the types and amounts of consideration actually received, per Ordinary Share, by the holders of Ordinary Shares. The Company will
        notify Holders of such weighted average as soon as practicable after such determination is made.

       

      At or before the effective time of such Ordinary Share Change Event, the Company and the resulting, surviving or transferee Person (if
        not the Company) of such Ordinary Share Change Event (the “Successor Person”) will execute and deliver to the Trustee a
        supplemental indenture pursuant to Section 8.01(F), which supplemental indenture will (x) provide for subsequent conversions of Notes in the manner set forth in
        this Section 5.09; (y) provide for subsequent adjustments to the Conversion Rate pursuant to Section 5.07(A) in a manner
        consistent with this Section 5.09; and (z) contain such other provisions as the Company reasonably determines are appropriate to preserve the economic interests of
        the Holders and to give effect to the provisions of this Section 5.09(A). If the Reference Property includes shares of stock or other securities or assets of a
        Person other than the Successor Person, then such other Person will also execute such supplemental indenture and such supplemental indenture will contain such additional provisions the Company reasonably determines are appropriate to preserve the
        economic interests of the Holders.

       

      (B)          Notice of Ordinary Share Change Events. The Company will provide notice of each Ordinary Share Change Event to Holders no later than the effective date of such Ordinary Share Change Event.

       

      (C)          Compliance Covenant. The Company will not become a party to any Ordinary Share Change Event unless its terms are consistent with this Section 5.09.

    

    
       

      Section 5.10. Responsibility of Trustee.

    

    
       

      (A)          The Trustee and any other
          Conversion Agent shall not at any time be under any duty or responsibility to any Holder to determine or calculate the Conversion Rate (or any adjustment thereto) or whether any facts exist that may require any adjustment (including any increase)
          of the Conversion Rate, or with respect to the nature or extent or calculation of any such adjustment when made, or with respect to the method employed, or herein or in any supplemental indenture provided to be employed, in making the same. The
          Trustee and any other Conversion Agent shall not be accountable with respect to the validity or value (or the kind or amount) of any Conversion Consideration; and the Trustee and any other Conversion Agent make no representations with respect
          thereto. Neither the Trustee nor any Conversion Agent shall be responsible or liable for any failure of the Company to make any cash payment to issue, transfer or deliver any Conversion Consideration upon the surrender of any Note for the purpose
          of conversion or to comply with any of the duties, responsibilities or covenants of the Company contained in this Article.

    

    
       

      
        - 70 -

        
          
 

      

      Article 6. SUCCESSORS

    

    
       

      Section 6.01. When the Company May Merge, Etc.

    

    
       

      (A)          Generally. Neither the Parent nor the Company will consolidate with or merge with or into, or (directly, or indirectly through one or more of its Subsidiaries) sell, lease or otherwise transfer, in one transaction or a series
          of transactions, all or substantially all of the assets of the Parent or the Company and their respective Subsidiaries, taken as a whole, to another Person (a “Business
            Combination Event”), unless:

    

    
       

      (i) the resulting, surviving or transferee Person either (x) is the Company or the Parent, as applicable, or (y) if
        not the Company or the Parent, as applicable, is a corporation (or equivalent entity) (the “Successor Corporation”) duly
        organized and existing under the laws of the United States of America, any State thereof or the District of Columbia, or, with respect to the Parent, the United Kingdom or Ireland that expressly assumes (by executing and delivering to the Trustee,
        at or before the effective time of such Business Combination Event, a supplemental indenture pursuant to Section 8.01(E)) all of the Company’s or the Parent’s
        obligations, as applicable, under this Indenture and the Notes (including, for the avoidance of doubt, the obligation to pay Additional Amounts pursuant to Section 3.04); and

       

      (ii) immediately after giving effect to such Business Combination Event, no Default or Event of Default will have
        occurred and be continuing.

    

    
       

      (B)          Delivery of Officer’s Certificate and Opinion of Counsel to the Trustee. Before the effective time of any Business Combination Event, the Company will deliver to the Trustee (x) an Officer’s Certificate stating that (i) such
          Business Combination Event (and, if applicable, the related supplemental indenture) complies with Section 6.01(A); and (ii) all conditions precedent to such
          Business Combination Event provided in this Indenture have been satisfied and (y) an Opinion of Counsel stating that all conditions precedent to such Business Combination Event provided in this Indenture have been satisfied.

    

    
       

      Section 6.02. Successor Corporation Substituted.

    

    
       

      At the effective time of any Business Combination Event that complies with Section 6.01, the Successor Corporation (if not the Company or the Parent, as applicable) will succeed to, and may exercise every right and power of, the Company or the Parent, as applicable, under this Indenture
        and the Notes with the same effect as if such Successor Corporation had been named as the Company or Parent, as applicable, in this Indenture and the Notes, and, except in the case of a lease, the predecessor Company or Parent, as applicable, will
        be discharged from its obligations under this Indenture and the Notes.

    

    
       

      
        - 71 -

        
          
 

      

      Article 7. DEFAULTS AND REMEDIES

    

    
       

      Section 7.01. Events of Default.

    

    
       

      (A)          Definition of Events of Default. “Event of Default” means the occurrence of any of the following:

    

    
       

      (i) a default in the payment when due (whether at maturity, upon Redemption or Repurchase Upon Fundamental Change or
        otherwise) of the principal of, or the Redemption Price or Fundamental Change Repurchase Price for, any Note;

       

      (ii) a default for thirty (30) days in the payment when due of interest on any Note;

       

      (iii) the Company’s failure to deliver, when required by this Indenture, a Fundamental Change Notice, or a notice
        pursuant to Section 4.02(E);

       

      (iv) a default in the Company’s obligation to convert a Note in accordance with Article

          5 upon the exercise of the conversion right with respect thereto, if such default is not cured within five (5) Business Days after its occurrence;

    

    
       

      (v) a default in the Company’s or Parent’s obligations under Article 6;

    

    
       

      (vi) a default in any of the Company’s obligations or agreements, or in any Guarantor’s obligations or agreements,
        under this Indenture or the Notes (other than a default set forth in clause (i), (ii), (iii),
          (iv) or (v) of this Section 7.01(A)) where such default is not cured or waived within sixty (60) days after
        notice to the Company and Parent by the Trustee, or to the Company, the Parent and the Trustee by Holders of at least twenty five percent (25%) of the aggregate principal amount of Notes then outstanding, which notice must specify such default,
        demand that it be remedied and state that such notice is a “Notice of Default”;

       

      (vii) a default by the Parent, the Company or any of the Parent’s Significant Subsidiaries with respect to any one
        or more mortgages, agreements or other instruments under which there is outstanding, or by which there is secured or evidenced, any indebtedness for money borrowed of at least twelve million dollars ($12,000,000) (or its foreign currency
        equivalent) in the aggregate of the Parent, the Company or any of the Parent’s Significant Subsidiaries, whether such indebtedness exists as of the Issue Date or is thereafter created, where such default:

    

    
       

      (1)          constitutes

          a failure to pay the principal of such indebtedness when due and payable at its stated maturity, upon required repurchase, upon declaration of acceleration or otherwise, in each case after the expiration of any applicable grace period; or

       

      
        - 72 -

        
          
 

      

      (2)          results
          in such indebtedness becoming or being declared due and payable before its stated maturity,

    

    
       

      in each case where such default is not cured or waived within sixty (60) days after notice to the Company by the Trustee or to the
        Company and the Trustee by Holders of at least twenty five percent (25%) of the aggregate principal amount of Notes then outstanding;

    

    
       

      (viii) one or more final judgments being rendered against the Parent, the Company or any of the Parent’s
        Significant Subsidiaries for the payment of at least twelve million dollars ($12,000,000) (or its foreign currency equivalent) in the aggregate (excluding any amounts covered by insurance), where such judgment is not discharged or stayed within
        sixty (60) days after (i) the date on which the right to appeal the same has expired, if no such appeal has commenced; or (ii) the date on which all rights to appeal have been extinguished;

    

     

    
       

      (ix) the Company, the Parent or any of the Parent’s Significant Subsidiaries, pursuant to or within the meaning of
        any Bankruptcy Law, either:

    

    
       

      (1)          commences
          a voluntary case or proceeding;

    

    
       

      (2)          consents

          to the entry of an order for relief against it in an involuntary case or proceeding;

       

      (3)          consents

          to the appointment of a custodian of it or for any substantial part of its properly;

    

    
       

      (4)          makes a
          general assignment for the benefit of its creditors;

    

    
       

      (5)          takes
          any comparable action under any foreign Bankruptcy Law; or

    

    
       

      (6)          generally
          is not paying its debts as they become due; or

    

    
      

      

      (x) a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that either:

    

    
       

      (1)          is for
          relief against the Company, the Parent or any of the Parent’s Significant Subsidiaries in an involuntary case or proceeding;

       

      (2)          appoints

          a custodian of the Company, the Parent or any of the Parent’s Significant Subsidiaries, or for any substantial part of the property of the Company, the Parent or any of the Parent’s Significant Subsidiaries;

       

      (3)          orders
          the winding up or liquidation of the Company, the Parent or any of the Parent’s Significant Subsidiaries; or

    

    
       

      
        - 73 -

        
          
 

      

      (4)          grants any
          similar relief under any foreign Bankruptcy Law,

    

    
       

      and, in each case under this Section 7.01(A)(x), such

        order or decree remains unstayed and in effect for at least sixty (60) days. For the avoidance of doubt, no transactions or actions taken pursuant to and in accordance with the Plan shall constitute an Event of Default under clause (ix) or (x) of this Section 7.01(A)).

    

    
       

      (B)          Cause Irrelevant. Each of the events set forth in Section 7.01(A) will constitute an Event of Default regardless of the cause thereof or whether voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order of any court or any order, rule or
        regulation of any administrative or governmental body.

    

    
       

      Section 7.02. Acceleration.

    

    
       

      (A)          Automatic Acceleration in Certain Circumstances. If an Event of Default set forth in Section 7.01(A)(ix) or 7.01(A)(x) occurs with respect to
          the Company or any Guarantor (and not solely with respect to a Significant Subsidiary of the Company or any Guarantor), then the principal amount of, and all accrued and unpaid interest on, all of the Notes then outstanding will immediately
          become due and payable without any further action or notice by any Person.

       

      (B)          Optional Acceleration. Subject to Section 7.03, if an Event of Default (other than an Event of Default to which Section 7.02(A) applies) occurs
          and is continuing, then the Trustee, by notice to the Company, or Holders of at least twenty five percent (25%) of the aggregate principal amount of Notes then outstanding, by notice to the Company and the Trustee, may declare the principal
          amount of, and all accrued and unpaid interest on, all of the Notes then outstanding to become due and payable immediately.

       

      (C)          Rescission of Acceleration. Notwithstanding anything to the contrary in this Indenture or the Notes, the Holders of a majority in aggregate principal amount of the Notes then outstanding, by notice to the Company and the
          Trustee, may, on behalf of all Holders, rescind any acceleration of the Notes and its consequences if (i) such rescission would not conflict with any judgment or decree of a court of competent jurisdiction; and (ii) all existing Events of Default
          (except the non-payment of principal of, or interest on, the Notes that has become due solely because of such acceleration) have been cured or waived. No such rescission will affect any subsequent Event of Default or impair any right consequent
          thereto.

    

    
       

      Section 7.03. Sole Remedy for a Failure to Report.

    

    
       

      (A)          Generally. Notwithstanding anything to the contrary in this Indenture or the Notes, the Company may elect that the sole remedy for any Event of Default (a “Reporting

            Event of Default”) pursuant to Section 7.01(A)(vi) arising from the Company’s failure to comply with Section 3.02 will,

          for each of the first one hundred eighty (180) calendar days on which a Reporting Event of Default has occurred and is continuing, consist exclusively of the accrual of Special Interest on the Notes. If the Company has made such an election, then
          (i) the Notes will be subject to acceleration pursuant to Section 7.02 on account of the relevant Reporting Event of Default from, and including, the one hundred eighty-first (181st) calendar day on which
          a Reporting Event of Default has occurred and is continuing or if the Company

    

    
       

      
        - 74 -

        
          
 

      

    

    fails to pay any accrued and unpaid Special Interest when due; and (ii) Special Interest will cease to accrue on any Notes from,
      and including, such one hundred eighty-first (181st) calendar day (it being understood that interest on any defaulted Special Interest will nonetheless accrue pursuant to Section 2.05(B)).

    
       

      (B)          Amount and Payment of Special Interest. Any Special Interest that accrues on a Note pursuant to Section 7.03(A) will be payable on the same dates and in the same manner as the Stated
          Interest on such Note and will accrue at a rate per annum equal to one quarter of one percent (0.25%) of the principal amount thereof for the first ninety (90) days on which Special Interest accrues and, thereafter, at a rate per annum equal to
          one half of one percent (0.50%) of the principal amount thereof. For the avoidance of doubt, any Special Interest that accrues on a Note will be in addition to the Stated Interest that accrues on such Note and in addition to any Additional
          Interest that accrues on such Note.

       

      (C)          Notice of Election. To make the election set forth in Section 7.03(A), the Company must send to the Holders, the Trustee and the Paying Agent,
          before the date on which each Reporting Event of Default first occurs, a notice that (i) briefly describes the report(s) that the Company failed to file or provide; (ii) states that the Company is electing that the sole remedy for such Reporting
          Event of Default consist of the accrual of Special Interest; and (iii) briefly describes the periods during which and rate at which Special Interest will accrue and the circumstances under which the Notes will be subject to acceleration on
          account of such Reporting Event of Default.

       

      (D)          Notice to Trustee and Paying Agent; Trustee’s Disclaimer. If Special Interest accrues on any Note, then, no later than five (5) Business Days before each date on which such Special Interest is to be paid, the Company will
          deliver an Officer’s Certificate to the Trustee and the Paying Agent stating (i) that the Company is obligated to pay Special Interest on such Note on such date of payment; and (ii) the amount of such Special Interest that is payable on such date
          of payment. The Trustee will have no duty to determine whether any Special Interest is payable or the amount thereof.

       

      (E)          No Effect on Other Events of Default. No election pursuant to this Section 7.03 with respect to a Reporting Event of Default will affect the rights of any Holder with respect to any
          other Event of Default, including with respect to any other Reporting Event of Default.

    

    
       

      Section 7.04. Other Remedies.

    

    
       

      (A)          Trustee May Pursue All Remedies. If an Event of Default occurs and is continuing, then the Trustee may pursue any available remedy to collect the payment of any amounts due with respect to the Notes or to enforce the
          performance of any provision of this Indenture or the Notes.

       

      (B)          Procedural Matters. The Trustee may maintain a proceeding even if it does not possess any of the Notes or does not produce any of them in such proceeding. A delay or omission by the Trustee or any Holder in exercising any right
          or remedy following an Event of Default will not impair the right or remedy or constitute a waiver of, or acquiescence in, such Event of Default. All remedies will be cumulative to the extent permitted by law.

    

    
       

      
        - 75 -

        
          
 

      

    

    Section 7.05. Waiver of Past Defaults.

    
       

      An Event of Default pursuant to clause (i), (ii), (iv) or (vi) of Section 7.01(A) (that, in the case of clause (vi) only,
        results from a Default under any covenant that cannot be amended without the consent of each affected Holder), and a Default that could lead to such an Event of Default, can be waived only with the consent of each affected Holder. Each other
        Default or Event of Default may be waived, on behalf of all Holders, by the Holders of a majority in aggregate principal amount of the Notes then outstanding. If an Event of Default is so waived, then it will cease to exist. If a Default is so
        waived, then it will be deemed to be cured and any Event of Default arising therefrom will be deemed not to occur. However, no such waiver will extend to any subsequent or other Default or Event of Default or impair any right arising therefrom.

    

    
       

      Section 7.06. Control by Majority.

    

    
       

      Holders of a majority in aggregate principal amount of the Notes then outstanding, determined in accordance with Section 2.15, may
        direct the time, method and place of conducting any proceeding for exercising any remedy available to the Trustee or exercising any trust or power conferred on it. However, the Trustee may refuse to follow any direction that conflicts with law,
        this Indenture or the Notes, or that, subject to Section 11.01, the Trustee determines may be unduly prejudicial to the rights of other Holders or may involve the
        Trustee in liability, unless the Trustee is offered security and indemnity satisfactory to the Trustee against any loss, liability or expense to the Trustee that may result from the Trustee’s following such direction.

    

    
       

      Section 7.07. Limitation on Suits.

    

    
       

      No Holder may pursue any remedy with respect to this Indenture or the Notes (except to enforce (x) its rights to receive the principal
        of, or the Redemption Price or Fundamental Change Repurchase Price for, or interest on, any Notes; or (y) the Company’s obligations to convert any Notes pursuant to Article 5), unless:

       

      (A)          such Holder has previously
          delivered to the Trustee notice that an Event of Default is continuing;

       

      (B)          Holders of at least twenty
          five percent (25%) in aggregate principal amount of the Notes then outstanding deliver a request to the Trustee to pursue such remedy;

       

      (C)          such Holder or Holders
          offer and, if requested, provide to the Trustee security and indemnity satisfactory to the Trustee against any loss, liability or expense to the Trustee that may result from the Trustee’s following such request;

       

      (D)          the Trustee does not
          comply with such request within sixty (60) calendar days after its receipt of such request and such offer of security or indemnity; and

       

      (E)          during such sixty (60)
          calendar day period, Holders of a majority in aggregate principal amount of the Notes then outstanding do not deliver to the Trustee a direction that is inconsistent with such request.

    

    
       

      
        - 76 -

        
          
 

      

    

    A Holder of a Note may not use this Indenture to prejudice the rights of another Holder or to obtain a
      preference or priority over another Holder. The Trustee will have no duty to determine whether any Holder’s use of this Indenture complies with the preceding sentence.

    
       

      Section 7.08. Absolute Right of Holders to Receive Payment and Conversion
          Consideration.

    

    
       

      Notwithstanding anything to the contrary in this Indenture or the Notes (but without limiting Section
          8.01), the right of each Holder of a Note to receive payment or delivery, as applicable, of the principal of, or the Redemption Price or Fundamental Change Repurchase Price for, or any interest on, or the Conversion Consideration due
        pursuant to Article 5 upon conversion of, such Note on or after the respective due dates therefor provided in this Indenture and the Notes, or to bring suit for the enforcement of any such payment or
        delivery on or after such respective due dates, will not be impaired or affected without the consent of such Holder.

    

    
       

      Section 7.09. Collection Suit by Trustee.

    

    
       

      The Trustee will have the right, upon the occurrence and continuance of an Event of Default pursuant to clause (i), (ii) or (iv) of Section 7.01(A), to recover judgment in its own name and as trustee of an express trust against the Company for the total unpaid or undelivered principal of, or Redemption Price or Fundamental Change Repurchase Price for, or interest
        on, or Conversion Consideration due pursuant to Article 5 upon conversion of, the Notes, as applicable, and, to the extent lawful, any Default Interest on any Defaulted Amounts, and such further amounts
        sufficient to cover the costs and expenses of collection, including compensation provided for in Section 11.06.

    

    
       

      Section 7.10. Trustee May File Proofs of Claim.

    

    
       

      The Trustee has the right to (A) file such proofs of claim and other papers or documents as may be necessary or advisable in order to
        have the claims of the Trustee and the Holders allowed in any judicial proceedings relative to the Company (or any other obligor upon the Notes) or its creditors or property and (B) unless prohibited by law or applicable regulations, collect,
        receive and distribute any money or other property payable or deliverable on any such claims. Each Holder authorizes any custodian in such proceeding to make such payments to the Trustee, and, if the Trustee consents to the making of such payments
        directly to the Holders, to pay to the Trustee any amount due to the Trustee for the reasonable compensation, expenses, disbursements and advances of the Trustee, and its agents and counsel, and any other amounts payable to the Trustee pursuant to
        Section 11.06. To the extent that the payment of any such compensation, expenses, disbursements, advances and other amounts out of the estate in such proceeding, is denied for any reason, payment of the same
        will be secured by a lien on, and will be paid out of, any and all distributions, dividends, money, securities and other properties that the Holders may be entitled to receive in such proceeding (whether in liquidation or under any plan of
        reorganization or arrangement or otherwise). Nothing in this Indenture will be deemed to authorize the Trustee to authorize, consent to, accept or adopt on behalf of any Holder any plan of reorganization, arrangement, adjustment or composition
        affecting the Notes or the rights of any Holder, or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding.

    

    
       

      
        - 77 -

        
          
 

      

    

    Section 7.11. Priorities.

    
       

      The Trustee will pay or deliver in the following order any money or other property that it collects pursuant to this Article 7:

    

    
       

      First:              to the Trustee and its agents and attorneys for amounts due under Section 11.06, including payment of all fees, compensation, expenses and
          liabilities incurred, and all advances made, by the Trustee and the costs and expenses of collection;

       

      Second:          to Holders for unpaid amounts or other property due on the Notes, including the principal of, or the Redemption Price or Fundamental Change Repurchase Price for, or any interest on, or any Conversion Consideration due upon
          conversion of, the Notes, ratably, and without preference or priority of any kind, according to such amounts or other property due and payable on all of the Notes; and

       

      Third:             to the Company or such other Person as a court of competent jurisdiction directs.

    

    
       

      The Trustee may fix a record date and payment date for any payment or delivery to the Holders pursuant to this Section 7.11, in which case the Trustee will instruct the Company to, and the Company will, deliver, at least fifteen (15) calendar days before such record date, to each
        Holder and the Trustee a notice stating such record date, such payment date and the amount of such payment or nature of such delivery, as applicable.

    

    
       

      Section 7.12. Undertaking for Costs.

    

    
       

      In any suit for the enforcement of any right or remedy under this Indenture or the Notes or in any suit against the Trustee for any
        action taken or omitted by it as Trustee, a court, in its discretion, may (A) require the filing by any litigant party in such suit of an undertaking to pay the costs of such suit, and (B) assess reasonable costs (including reasonable attorneys’
        fees) against any litigant party in such suit, having due regard to the merits and good faith of the claims or defenses made by such litigant party; provided, however, that this Section 7.12 does not apply to any suit by the Trustee, any suit by a Holder pursuant to Section 7.08 or any suit by one or more Holders of more than ten percent (10%) in aggregate
        principal amount of the Notes then outstanding.

    

    
       

      Article 8. AMENDMENTS, SUPPLEMENTS AND WAIVERS

    

    
       

      Section 8.01. Without the Consent of Holders.

    

    
       

      Notwithstanding anything to the contrary in Section 8.02, the

        Company, the Guarantors and the Trustee may amend or supplement this Indenture or the Notes without the consent of any Holder to:

       

      (A)          cure any ambiguity or
          correct any omission, defect or inconsistency in this Indenture or the Notes;

    

    
      

      

      
        - 78 -

        
          
 

      

    

    (B)          add

        additional guarantees with respect to the Company’s obligations under this Indenture or the Notes;

    
       

      (C)          secure the Notes or any
          Guarantees;

    

    
       

      (D)          add to the Company’s or
          Guarantor’s covenants or Events of Default for the benefit of the Holders or surrender any right or power conferred on the Company or any Guarantor;

       

      (E)          provide for the assumption
          of the Company’s or any Guarantor’s obligations under this Indenture and the Notes pursuant to, and in compliance with, Article 6 or Section 9.04, as applicable;

       

      (F)           enter into supplemental
          indentures pursuant to, and in accordance with, Section 5.09 in connection with an Ordinary Share Change Event;

       

      (G)          irrevocably elect or
          eliminate any Settlement Method or Specified Dollar Amount; provided, however, that no such election or elimination will affect any Settlement Method theretofore elected (or deemed to be elected) with
          respect to any Note pursuant to Section 5.03(A);

       

      (H)          evidence or provide for
          the acceptance of the appointment, under this Indenture, of a successor Trustee;

       

      (I)            provide for or confirm
          the issuance of additional Notes pursuant to Section 2.03(B);

       

      (J)         comply with any
          requirement of the SEC in connection with any qualification of this Indenture or any supplemental indenture under the Trust Indenture Act, as then in effect;

    

    
       

      (K)           to comply with the rules of
          the Depositary; or

    

    
       

      (L)          make any other change to
          this Indenture or the Notes that does not, individually or in the aggregate with all other such changes, adversely affect the rights of the Holders, as such, in any material respect.

    

    
       

      Section 8.02. With the Consent of Holders.

    

    
       

      (A)          Generally. Subject to Sections 7.05, 7.08 and 8.01 and the
          immediately following sentence, the Company, the Guarantors and the Trustee may, with the consent of the Holders of a majority in aggregate principal amount of the Notes then outstanding, amend or supplement this Indenture or the Notes or waive
          compliance with any provision of this Indenture or the Notes. Notwithstanding anything to the contrary in the foregoing sentence, but subject to subject to Section 8.01, without the consent of each
          affected Holder, no amendment or supplement to this Indenture or the Notes, or waiver of any provision of this Indenture or the Notes, may:

    

    
       

      (i) reduce the principal, or extend the stated maturity, of any Note;

    

    
       

      
        - 79 -

        
          
 

      

    

    
      (ii) reduce the Redemption Price or Fundamental Change Repurchase Price for any Note or change the times at which,
        or the circumstances under which, the Notes may or will be redeemed or repurchased by the Company;

       

      (iii) reduce the rate, or extend the time for the payment, of interest on any Note;

       

      (iv) make any change that adversely affects the conversion rights of any Note;

       

      (v) impair the rights of any Holder set forth in Section 7.08 (as such
        section is in effect on the Issue Date);

    

    
       

      (vi) change the ranking of the Notes or the Guarantees;

       

      (vii) modify or amend the terms and conditions of the obligations of the Guarantors, as guarantors of the Notes, in
        any manner that is adverse to the rights of the Holders, as such, other than (A) any elimination of a Guarantee in accordance with this Indenture or (B) to the extent changes are made to the terms and conditions of the Notes in accordance with this
        Indenture, changes made mutatis mutandis to the obligation of the Guarantors;

       

      (viii) make any Note payable in a currency, or at a place of payment, other than that stated in this Indenture or the
        Note;

    

    
       

      (ix) make any direct or indirect change to Section 3.04 in any manner that
        is materially adverse to the rights of the Holders;

       

      (x) reduce the amount of Notes whose Holders must consent to any amendment, supplement, waiver or other
        modification; or

       

      (xi) make any direct or indirect change to any amendment, supplement, waiver or modification provision of this
        Indenture or the Notes that requires the consent of each affected Holder.

    

    
       

      For the avoidance of doubt, pursuant to clauses (i), (ii),
        (iii) and (iv) of this Section 8.02(A), no amendment or supplement to this
        Indenture or the Notes, or waiver of any provision of this Indenture or the Notes, may reduce the amount or change the type of consideration due on any Note (whether on an Interest Payment Date, Redemption Date, Fundamental Change Repurchase Date
        or the Maturity Date or upon conversion, or otherwise), or the date(s) or time(s) such consideration is payable or deliverable, as applicable, without the consent of each affected Holder.

       

      (B)          Holders Need Not Approve the Particular Form of any Amendment. A consent of any Holder pursuant to this Section 8.02 need approve only the substance, and not necessarily the particular
          form, of the proposed amendment, supplement or waiver.

    

    
       

      
        - 80 -

        
          
 

      

    

    Section 8.03. Notice of Amendments, Supplements and
        Waivers.

    
       

      Promptly after any amendment, supplement or waiver pursuant to Section 8.01 or 8.02 becomes effective, the Company will send to the Holders and the Trustee notice that (A) describes the substance of such amendment, supplement or waiver in reasonable detail and (B) states the effective date
        thereof. The failure to send, or the existence of any defect in, such notice will not impair or affect the validity of such amendment, supplement or waiver.

    

    
       

      Section 8.04. Revocation, Effect and Solicitation of Consents; Special Record
          Dates; Etc.

    

    
       

      (A)          Revocation and Effect of Consents. The consent of a Holder of a Note to an amendment, supplement or waiver will bind (and constitute the consent of) each subsequent Holder of any Note to the extent the same evidences any
          portion of the same indebtedness as the consenting Holder’s Note, subject to the right of any Holder of a Note to revoke (if not prohibited pursuant to Section 8.04(B))
          any such consent with respect to such Note by delivering notice of revocation to the Trustee before the time such amendment, supplement or waiver becomes effective.

       

      (B)          Special Record Dates. The Company may, but is not required to, fix a record date for the purpose of determining the Holders entitled to consent or take any other action in connection with any amendment, supplement or waiver
          pursuant to this Article 8. If a record date is fixed, then, notwithstanding anything to the contrary in Section 8.04(A), only Persons who are Holders as of such
          record date (or their duly designated proxies) will be entitled to give such consent, to revoke any consent previously given or to take any such action, regardless of whether such Persons continue to be Holders after such record date; provided, however, that no such consent will be valid or effective for more than one hundred and twenty (120) calendar days after such record date.

       

      (C)          Solicitation of Consents. For the avoidance of doubt, each reference in this Indenture or the Notes to the consent of a Holder will be deemed to include any such consent obtained in connection with a repurchase of, or tender or
          exchange offer for, any Notes.

       

      (D)          Effectiveness and Binding Effect. Each amendment, supplement or waiver pursuant to this Article 8 will become effective in accordance with its terms and, when it becomes effective with
          respect to any Note (or any portion thereof), will thereafter bind every Holder of such Note (or such portion).

    

    
       

      Section 8.05. Notations and Exchanges.

    

    
       

      If any amendment, supplement or waiver changes the terms of a Note, then the Trustee or the Company may, in its discretion, require the
        Holder of such Note to deliver such Note to the Trustee so that the Trustee may place an appropriate notation prepared by the Company on such Note and return such Note to such Holder. Alternatively, at its discretion, the Company may, in exchange
        for such Note, issue, execute and deliver, and the Trustee will authenticate, in each case in accordance with Section 2.02, a new Note that reflects the changed terms. The failure to make any appropriate
        notation or issue a new Note pursuant to this Section 8.05 will not impair

    

    
       

      
        - 81 -

        
          
 

      

      or affect the validity of such amendment, supplement or waiver.

    

    
       

      Section 8.06. Trustee to Execute Supplemental Indentures.

    

    
       

      Upon the written request of the Company, the Trustee will, and is hereby authorized to, execute and deliver any amendment or
        supplemental indenture authorized pursuant to this Article 8; provided, however, that the Trustee need not (but may, in
        its sole and absolute discretion) execute or deliver any such amendment or supplemental indenture that adversely affects the Trustee’s rights, duties, liabilities or immunities. In executing any amendment or supplemental indenture, the Trustee will
        be entitled to receive, and (subject to Sections 11.01 and 11.02) will be fully protected in relying on as conclusive
        evidence, an Officer’s Certificate and an Opinion of Counsel stating that (A) the execution and delivery of such amendment or supplemental indenture is authorized or permitted by this Indenture; and (B) in the case of the Opinion of Counsel, such
        amendment or supplemental indenture is valid, binding and enforceable against the Company in accordance with its terms.

    

    
       

      Article 9. GUARANTEES

    

    
       

      Section 9.01. Guarantees.

    

    
       

      (A)          Generally. By its execution of this Indenture (or any amended or supplemental indenture pursuant to Section 8.01(B)), each Guarantor
          acknowledges and agrees that it receives substantial benefits from the Company and that such Guarantor is providing its Guarantee for good and valuable consideration, including such substantial benefits. Subject to this Article 9, each of the Guarantors hereby, jointly and severally, fully and unconditionally guarantees, to (x) each Holder of a Note authenticated and delivered by the Trustee and (y) to
          the Trustee and its successors and assigns on behalf of such Holder that:

    

    
       

      (i) the principal of, any interest on, and any Conversion Consideration for, the Notes will be promptly paid in full
        when due, whether at maturity, by acceleration, on a Fundamental Change Repurchase Date, upon Redemption or otherwise, and interest on the overdue principal of, any interest on, or any Conversion Consideration for, the Notes, if lawful, and all
        other obligations of the Company to the Holders or the Trustee under this Indenture or the Notes (including the expense reimbursement and indemnification provisions of Section 11.06), will be promptly paid or delivered in full or performed, as
        applicable, in each case in accordance with this Indenture and the Notes; and

       

      (ii) in case of any extension of time of payment or renewal of any Notes or any of such other obligations, that the
        same will be promptly paid in full when due or performed in accordance with the terms of the extension or renewal, whether at stated maturity, by acceleration, on a Fundamental Change Repurchase Date, upon Redemption or otherwise,

    

    
       

      (collectively, the “Guaranteed Obligations”),
        in each case subject to Section 9.02.

    

    
       

      Upon the failure of any payment when due of any amount so guaranteed, and upon the

    

     

    
      - 82 -

      
        
 

    

    failure of any performance so guaranteed, for whatever reason, the Guarantors will be jointly and severally obligated to pay or
      perform, as applicable, the same immediately. Each Guarantor agrees that this is a guarantee of payment and not a guarantee of collection.

    
       

      (B)          Guarantee Is Unconditional; Waiver of Diligence, Presentment, Etc. Each Guarantor agrees that its Guarantee of the Guaranteed Obligations is unconditional, regardless of the validity or enforceability of this Indenture, the
          Notes or the obligations of the Company under this Indenture or the Notes, the absence of any action to enforce the same, any waiver or consent by any Holder with respect to any provisions of this Indenture or the Notes, the recovery of any
          judgment against the Company, any action to enforce the same or any other circumstance that might otherwise constitute a legal or equitable discharge or defense of a guarantor. Each Guarantor waives diligence, presentment, demand of payment,
          filing of claims with a court in the event of insolvency or bankruptcy of the Company, any right to require a proceeding first against the Company, protest, notice and all demands whatsoever, and covenants that this Guarantee will not be
          discharged except by complete performance of the obligations contained in this Indenture and the Notes.

       

      (C)          Reinstatement of Guarantee Upon Return of Payments. If any Holder or the Trustee is required by any court or otherwise to return, to the Company, the Guarantors or any custodian, trustee, liquidator or other similar official
          acting in relation to the Company or the Guarantors, any consideration paid or delivered by the Company or the Guarantors to such Holder or the Trustee, then each Guarantee, to the extent theretofore discharged, will be reinstated in full force
          and effect.

       

      (D)          Subrogation. Each Guarantor shall be subrogated to all rights of the Holders of the Notes against the Company in respect of any amounts paid by such Guarantor on account of such Notes pursuant to the provisions of its Guarantee
          or this Indenture; provided that each Guarantor agrees that any right of subrogation, reimbursement or contribution it may have in relation to the Holders or in respect of any Guaranteed Obligations will be subordinated to, and will not be
          enforceable until payment in full of, all Guaranteed Obligations. Each Guarantor further agrees that, as between the Guarantors, on the one hand, and the Holders and the Trustee, on the other hand, (i) the maturity of the Guaranteed Obligations
          may be accelerated as provided in Article 7, notwithstanding any stay, injunction or other prohibition preventing such acceleration in respect of the Guaranteed Obligations; and (ii) if any Guaranteed
          Obligations are accelerated pursuant to Article 7, then such Guaranteed Obligations will, whether or not due and payable, immediately become due and payable by the Guarantors.

    

    
       

      Section 9.02. Limitation on Guarantor Liability.

    

    
       

      Each Guarantor, and, by its acceptance of any Note, each Holder, confirms that each Guarantor and the Holders intend that the Guarantee
        of each Guarantor not constitute a fraudulent transfer or conveyance for purposes of Bankruptcy Law, the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or any similar federal or state law to the extent applicable to any
        Guarantee. Each of the Trustee, the Holders and each Guarantor irrevocably agrees that the obligations of each Guarantor under its Guarantee will be limited to the maximum amount that will, after giving effect to such maximum amount and all other
        contingent and fixed liabilities of such Guarantor that are relevant under such laws, and after

    

    
       

      
        - 83 -

        
          
 

      

    

    giving effect to any collections from, rights to receive contribution from or payments made by or on behalf of any other
      Guarantor in respect of the obligations of such other Guarantor under its Guarantee, result in the obligations of such Guarantor under its Guarantee not constituting a fraudulent transfer or conveyance.

    
       

      Section 9.03. Execution and Delivery of Guarantee.

    

    
       

      The execution by each Guarantor of this Indenture (or an amended or supplemental indenture pursuant to Section 8.01(B)) evidences the Guarantee of such Guarantor, and the delivery of any Note by the Trustee after its authentication constitutes due delivery of each Guarantee on behalf of each
        Guarantor. A Guarantee’s validity will not be affected by the failure of any officer of a Guarantor executing this Indenture or any such amended or supplemental indenture on such Guarantor’s behalf to hold, at the time any Note is authenticated,
        the same or any other office at such Guarantor, and each Guarantee will be valid and enforceable even if no notation, certificate or other instrument is set upon or attached to, or otherwise executed and delivered to the Holder of, any Note.

    

    
       

      Section 9.04. When Guarantors May Merge, Etc.

    

    
       

      (A)          Generally. No Guarantor will consolidate with or merge with or into, or sell, lease or otherwise transfer, in one transaction or a series of transactions, all or substantially all of the assets of such Guarantor and its
          Subsidiaries, taken as a whole, to another Person (other than the Company, another Guarantor or one or more of the Company’s Wholly Owned Subsidiaries) (a “Guarantor
            Business Combination Event”), unless (i) such transaction otherwise complies with Section 3.12, (ii) such
          Guarantor is an Immaterial Subsidiary or (iii) the resulting, surviving or transferee Person is such Guarantor or, if not such Guarantor, expressly assumes (by executing and delivering to the Trustee, at or before the effective time of such
          Guarantor Business Combination Event, a supplemental indenture pursuant to Section 8.01(E)) all of such Guarantor’s obligations under this Indenture and the
          Notes.

       

      (B)          Delivery of Officer’s Certificate and Opinion of Counsel to the Trustee. Before the effective time of any Guarantor Business Combination Event (unless such transaction otherwise complies with Section

            3.12), the Company will deliver to the Trustee an Officer’s Certificate and Opinion of Counsel, each stating that (i) such Guarantor Business Combination Event (and, if applicable, the related
          supplemental indenture) comply with Section 9.04(A); and (ii) all conditions precedent to such Guarantor Business Combination Event provided in this Indenture
          have been satisfied.

       

      (C)          Successor Corporation Substituted. At the effective time of any Guarantor Business Combination Event that complies with Section 9.04(A) and Section
            9.04(B) (unless such transaction otherwise complies with Section 3.12), the surviving Person (if not the applicable Guarantor) will succeed to, and may
          exercise every right and power of, such Guarantor under this Indenture and the Notes with the same effect as if such surviving Person had been named as a Guarantor in this Indenture and the Notes, and, except in the case of a lease, the
          predecessor Guarantor will be discharged from its obligations under this Indenture and the Notes.

    

     

    
      - 84 -

      
        
 

    

  

  
    
      Section 9.05. Future Guarantors.

    

    
       

      (A)          If, after the Issue Date,
          any entity becomes a Subsidiary of the Company or any Guarantor (including by acquisition or creation), then the Company will, as soon as reasonably practicable but no later than ten (10) Business Days after such entity became such a Subsidiary,
          cause such Subsidiary to execute an amended or supplemental indenture pursuant to Section 8.01(B) causing such Subsidiary to become a Guarantor under this Indenture, unless (x) such supplemental indenture
          would result in material adverse tax consequences to the Parent, the Company or their Subsidiary, (y) such supplemental indenture would conflict with applicable law or (z) such Subsidiary is an Immaterial Subsidiary or organized within France.

       

      (B)          The Company will, as soon
          as reasonably practicable after the Issue Date, cause each of the following Subsidiaries to execute an amended or supplemental indenture pursuant to Section 8.01(B) causing such Subsidiary to become a
          Guarantor under this Indenture, unless (x) such supplemental indenture would result in material adverse tax consequences to the Parent, the Company or their Subsidiary, (y) such supplemental indenture would conflict with applicable law or (z)
          such Subsidiary is an Immaterial Subsidiary:

    

    
       

      (i) Aegerion Brasil Comercio e Importacao de Medicamentos LTDA, a limited liability company organized in Brazil;

       

      (ii) Aegerion International Ltd., a limited company organized in Bermuda;

       

      (iii) Aegerion Pharmaceuticals (Canada) Ltd., a limited company organized in Canada;

       

      (iv) Aegerion Pharmaceuticals GmbH, a limited liability company organized in Germany;

       

      (v) Aegerion Pharmaceuticals K.K., a stock corporation organized in Japan;

       

      (vi) Aegerion Pharmaceuticals Ltd., a limited company organized in Bermuda;

       

      (vii) Aegerion Pharmaceuticals S.r.l., a limited liability company organized in Italy;

       

      (viii) Aegerion Pharmaceuticals SARL, a limited liability company organized in Switzerland;

       

      (ix) Aegerion Pharmaceuticals Spain, S.L., a limited liability company organized in Spain; and

       

      (x) Amryt Gmbh, a limited liability company organized in Germany.

    

    
      - 85 -

      
        
 

    

    
      Section 9.06. Application of Certain Provisions to the Guarantors.

    

    
       

      (A)          Officer’s Certificates and Opinions of Counsel. Upon any request or application by any Guarantor to the Trustee to take any action under this Indenture, the Trustee will be entitled to receive an Officer’s Certificate and an
          Opinion of Counsel pursuant to Section 12.02 with the same effect as if each reference to the Company in Section 12.02 or in the definitions of “Officer,”
          “Officer’s Certificate” or “Opinion of Counsel” were instead a reference to such Guarantor.

       

      (B)          Notices and Demands. Any notice or demand that this Indenture requires or permits to be given by the Trustee, or by any Holders, to the Company may instead be given to any Guarantor.

    

    
       

      Article 10. SATISFACTION AND DISCHARGE

         

    

    
      Section 10.01. Termination of Company’s Obligations.

    

    
       

      This Indenture will be discharged, and will cease to be of further effect as to all Notes issued under this Indenture, when:

       

      (A)          all Notes then outstanding
          (other than Notes replaced pursuant to Section 2.12) have (i) been delivered to the Trustee for cancellation; or (ii) become due and payable (whether on a
          Redemption Date, a Fundamental Change Repurchase Date, the Maturity Date, upon conversion or otherwise) for an amount of cash and/or Ordinary Shares (or, if applicable, Reference Property) and cash (in lieu of fractional Ordinary Shares or, if
          applicable, Reference Property Units) (solely to satisfy amounts due and owing as a result of conversions of the Notes), as applicable, that has been fixed;

       

      (B)          the Company has caused
          there to be irrevocably deposited with the Trustee, or with the Paying Agent (or, with respect to Conversion Consideration, the Conversion Agent), in each case for the benefit of the Holders, or has otherwise caused there to be delivered to the
          Holders, cash and/or Ordinary Shares (or, if applicable, Reference Property) and cash (in lieu of fractional Ordinary Shares or, if applicable, Reference Property Units) (solely to satisfy amounts due and owing as a result of conversions of the
          Notes) sufficient to satisfy all amounts or other property (including, if applicable, all related Additional Amounts) due on all Notes then outstanding (other than Notes replaced pursuant to Section 2.12);

    

    
       

      (C)          the Company has paid all
          other amounts payable by it under this Indenture; and

    

    
       

      (D)          the Company has delivered
          to the Trustee an Officer’s Certificate and an Opinion of Counsel, each stating that the conditions precedent to the discharge of this Indenture have been satisfied;

    

    
       

      provided, however, that Article 11 and Section 12.01 will survive such discharge and, until no Notes remain outstanding, Section 2.14 and the obligations of the Trustee, the Paying Agent and the Conversion Agent with respect to
        money or other property deposited with them will survive such discharge.

    

    
      - 86 -

      
        
 

    

    
      At the Company’s request, the Trustee will acknowledge the satisfaction and discharge of this Indenture.

    

    
       

      Section 10.02. Repayment to Company.

    

    
       

      Subject to applicable unclaimed property law, the Trustee, the Paying Agent and the Conversion Agent will promptly notify the Company
        if there exists (and, at the Company’s request, will promptly deliver to the Company) any cash, Conversion Consideration or other property held by any of them for payment or delivery on the Notes that remain unclaimed two (2) years after the date
        on which such payment or delivery was due. After such delivery to the Company, the Trustee, the Paying Agent and the Conversion Agent will have no further liability to any Holder with respect to such cash, Conversion Consideration or other
        property, and Holders entitled to the payment or delivery of such cash, Conversion Consideration or other property must look to the Company for payment as a general creditor of the Company.

    

    
       

      Section 10.03. Reinstatement.

    

    
       

      If the Trustee, the Paying Agent or the Conversion Agent is unable to apply any cash or other property deposited with it pursuant to Section 10.01 because of any legal proceeding or any order or judgment of any court or other governmental authority that enjoins, restrains or otherwise prohibits such application, then the discharge of this
        Indenture pursuant to Section 10.01 will be rescinded until such time as the Trustee, the Paying Agent or the Conversion Agent is permitted to apply such cash or other property pursuant to Section 10.01; provided, however, that if the Company pays or delivers any cash or other property due on the Notes to the
        Holders thereof, then the Company will be subrogated to the rights of such Holders to receive such cash or other property from the cash or other property, if any, held by the Trustee, the Paying Agent or the Conversion Agent, as applicable.

    

    
       

      Article 11. TRUSTEE 

       

        

      Section 11.01. Duties of the Trustee.

    

    
       

      (A)          If an Event of Default has
          occurred and is continuing, the Trustee will exercise such of the rights and powers vested in it by this Indenture, and use the same degree of care and skill in its exercise, as a prudent person would exercise or use under the circumstances in
          the conduct of such person’s own affairs.

    

    
       

      (B)          Except during the continuance
          of an Event of Default:

    

    
       

      (i) the duties of the Trustee will be determined solely by the express provisions of this Indenture, and the Trustee
        need perform only those duties that are specifically set forth in this Indenture and no others, and no implied covenants or obligations will be read into this Indenture against the Trustee; and

       

      (ii) in the absence of willful misconduct on its part, the Trustee may conclusively rely, as to the truth of the
        statements and the correctness of the

    

    
      - 87 -

      
        
 

    

    
      opinions expressed therein, upon Officer’s Certificates or Opinions of Counsel that are provided to the Trustee and conform to the
        requirements of this Indenture. However, the Trustee will examine the certificates and opinions to determine whether or not they conform to the requirements of this Indenture (but need not confirm or investigate the accuracy of mathematical
        calculations or other facts, statements, opinions or conclusions stated therein).

    

    
       

      (C)        The Trustee may not be
          relieved from liabilities for its negligence or willful misconduct, except that:

    

    
       

      (i) this paragraph will not limit the effect of Section 11.01(B) or Section 11.01(E);

       

      (ii) the Trustee will not be liable for any error of judgment made in good faith by a Responsible Officer, unless it
        is proved that the Trustee was negligent in ascertaining the pertinent facts; and

       

      (iii) the Trustee will not be liable with respect to any action it takes or omits to take in good faith in
        accordance with a direction received by it pursuant to Section 7.06.

    

    
       

      (D)        Each provision of this
          Indenture that in any way relates to the Trustee is subject to this Section 11.01, regardless of whether such provision so expressly provides.

       

      (E)        No provision of this
          Indenture will require the Trustee to expend or risk its own funds or incur any liability.

       

      (F)        The Trustee will not be
          liable for interest on any money received by it, except as the Trustee may agree in writing with the Company. Money held in trust by the Trustee need not be segregated from other funds, except to the extent required by law.

       

      (G)        The Trustee shall not be
          liable in respect of any payment (as to the correctness of amount, entitlement to receive or any other matters relating to payment) or notice effected by the Company or any Paying Agent or any records maintained by any co-Registrar with respect
          to the Notes.

       

      (H)        If any party fails to
          deliver a notice relating to an event the fact of which, pursuant to this Indenture, requires notice to be sent to the Trustee, the Trustee may conclusively rely on its failure to receive such notice as reason to act as if no such event occurred.

       

      (I)         In the absence of written
          investment direction from the Company, all cash received by the Trustee shall be placed in a non-interest bearing trust account, and in no event shall the Trustee be liable for the selection of investments or for investment losses incurred
          thereon or for losses incurred as a result of the liquidation of any such investment prior to its maturity date or the failure of the party directing such investments prior to its maturity date or the failure of the party directing such
          investment to provide timely written investment direction, and the Trustee shall have no obligation to invest or reinvest any amounts held hereunder in the absence of such written investment direction from the Company.

      
        - 88 -

        
          
 

      

      (J)           In the event that the
          Trustee is also acting as Custodian, Registrar, Paying Agent or Conversion Agent hereunder, the rights, privileges, immunities, benefits and protections afforded to the Trustee pursuant to this Article 11 shall also be afforded to such Custodian,
          Registrar, Paying Agent or Conversion Agent.

       

      (K)         The Trustee shall not be
          responsible for the application of any money by any Paying Agent other than the Trustee.

    

    
       

      Section 11.02. Rights of the Trustee.

    

    
       

      (A)         The Trustee may
          conclusively rely on any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other document that it believes to be genuine and signed or presented by the proper Person, and the Trustee
          need not investigate any fact or matter stated therein.

       

      (B)          Before the Trustee acts
          or refrains from acting, it may require an Officer’s Certificate, an Opinion of Counsel or both. The Trustee will not be liable for any action it takes or omits to take in good faith in reliance on such Officer’s Certificate or Opinion of
          Counsel. The Trustee may consult with counsel; and the advice of such counsel, or any Opinion of Counsel, will constitute full and complete authorization of the Trustee to take or omit to take any action in good faith in reliance thereon without
          liability.

       

      (C)         Any request, direction,
          order or demand of the Company mentioned herein shall be sufficiently evidenced by a Company Order (unless other evidence in respect thereof be herein specifically prescribed); and any board resolutions may be evidenced to the Trustee by a copy
          thereof certified by the Company’s Secretary, Assistant Secretary or other duly authorized Officer.

       

      (D)         The Trustee may act
          through its attorneys and agents and will not be responsible for the misconduct or negligence of any such attorney or agent appointed with due care.

       

      (E)          The Trustee will not be
          liable for any action it takes or omits to take in good faith and that it believes to be authorized or within the rights or powers vested in it by this Indenture. The rights, privileges, protections, immunities and benefits given to the Trustee,
          including, without limitation, its right to be indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder, and to each agent, custodian and other Person employed to act hereunder.

       

      (F)          Unless otherwise
          specifically provided in this Indenture, any demand, request, direction or notice from the Company or any Guarantor will be sufficient if signed by an Officer of the Company or Guarantor, as applicable. The Trustee may request that the Company or
          any Guarantor deliver a certificate setting forth the names of individuals and/or titles of officers authorized at such time to take specified actions pursuant to this Indenture, which certificate may be signed by any person authorized to sign an
          Officer’s Certificate, including any person specified as so authorized in any such certificate previously delivered and not superseded.

       

      (G)          The Trustee need not
          exercise any rights or powers vested in it by this Indenture at the request or direction of any Holder unless such Holder has offered the Trustee security or

    

    
      - 89 -

      
        
 

    

    
      indemnity satisfactory to the Trustee against any loss, liability or expense that it may incur in complying with such request or direction.

    

    
       

      (H)         Anything in this indenture
          notwithstanding, the Trustee will not be responsible or liable for any punitive, special, indirect or consequential loss or damage (including lost profits), even if the Trustee has been advised of the likelihood of such loss or damage and
          regardless of the form of action.

       

      (I)          The Trustee shall not be
          required to give any bond or surety in respect of the performance of its powers and duties hereunder.

       

      (J)          The Trustee shall be under
          no obligation to take or pursue any action that is not in accordance with applicable law.

       

      (K)         The Trustee may execute
          any of the trusts or powers hereunder or perform any duties hereunder either directly or by or through agents, custodians, nominees or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent,
          custodian, nominee or attorney appointed by it with due care hereunder.

       

      (L)         The permissive rights of
          the Trustee enumerated herein shall not be construed as duties.

    

    
       

      Section 11.03. Individual Rights of the Trustee.

    

    
       

      The Trustee, in its individual or any other capacity, may become the owner or pledgee of any Note and may otherwise deal with the
        Company or any of its Affiliates with the same rights that it would have if it were not Trustee; provided, however, that if the Trustee acquires a “conflicting interest” (within the meaning of Section
        310(b) of the Trust Indenture Act), then it must eliminate such conflict within ninety (90) days or resign as Trustee. Each Note Agent will have the same rights and duties as the trustee under this Section 11.03.

    

    
       

      Section 11.04. Trustee’s Disclaimer.

    

    
       

      The Trustee will not be (A) responsible for, and makes no representation as to, the validity or adequacy of this Indenture or the
        Notes; (B) accountable for the Company’s use of the proceeds from the Notes or any money paid to the Company or upon the Company’s direction under any provision of this Indenture; (C) responsible for the use or application of any money received by
        any Paying Agent other than the Trustee; (D) responsible for any statement or recital in this Indenture, the Notes or any other document relating to the sale of the Notes or this Indenture, other than the Trustee’s certificate of authentication;
        (E) responsible to make any calculation with respect to any matter under this Indenture; or (F) under any duty to monitor or investigate the Company’s compliance with or the breach of, or cause to be performed or observed, any representation,
        warranty, or covenant, or agreement of any Person, other than the Trustee, made in this Indenture. For the avoidance of doubt, neither the Trustee nor any Note Agent shall have any obligation to make any calculation (including determinations of the
        Last Reported Sale Price, the Daily Conversion Value, the Daily Cash Amount, the Daily Share Amount, the Daily VWAP, accrued interest on the Notes and the Conversion Rate) or to determine whether the Notes may be surrendered for conversion, or to
        notify the Company, any

    

    
      - 90 -

      
        
 

    

    
      Guarantor, the Depositary, or any Holders of the Notes if the Notes have become convertible.

    

    
       

      Section 11.05. Notice of Defaults.

    

    
       

      The Trustee shall not be deemed to have notice or be charged with knowledge of any Default or Event of Default unless a Responsible
        Officer receives written notice of such Default or Event of Default from the Company, the Guarantor or from Holders of Notes evidencing no less than twenty-five percent (25%) of the aggregate outstanding principal amount of Notes. If a Default or
        Event of Default occurs and is continuing and is known to the Trustee (as determined in accordance with the foregoing sentence), then the Trustee will send Holders a notice of such Default or Event of Default promptly (and in any event within ten
        (10) Business Days) after it becomes known to a Responsible Officer; provided, however, that, except in the case of a Default or Event of Default in the payment of the principal of, or interest on, any
        Note, the Trustee may withhold such notice if and for so long as it in good faith determines that withholding such notice is in the interests of the Holders.

    

    
       

      Section 11.06. Compensation and Indemnity.

    

    
       

      (A)          The Company will, from
          time to time, pay the Trustee reasonable compensation for its acceptance of this indenture and services under this Indenture. The Trustee’s compensation will not be limited by any law on compensation of a trustee of an express trust. In addition
          to the compensation for the Trustee’s services, the Company will reimburse the Trustee promptly upon request for all reasonable disbursements, advances and expenses incurred or made by it under this Indenture, including the reasonable
          compensation, disbursements and expenses of the Trustee’s agents and counsel.

       

      (B)          The Company and each
          Guarantor will, on a joint and several basis, indemnify the Trustee and any predecessor Trustee and their respective officers, directors, agents and employees and any authenticating agent and hold them harmless against any and all losses, claims,
          damages, liabilities or expenses, including fees and expenses of counsel, including taxes (other than taxes based upon, measured by or determined by the income of the Trustee) incurred by it arising out of or in connection with the acceptance or
          administration of its duties under this Indenture, the Notes and any other document or transaction entered into in connection herewith or therewith, including the costs and expenses of enforcing this Indenture against the Company or any Guarantor
          (including this Section 11.06) and defending itself against any claim (whether asserted by the Company, any Guarantor any Holder or any other Person) or liability
          in connection with the exercise or performance of any of its powers or duties under this Indenture, except to the extent any such loss, liability or expense may be attributable to its gross negligence or willful misconduct as determined in a
          final non-appealable judgment by a court of competent jurisdiction. The Trustee will promptly notify the Company of any claim for which it may seek indemnity, but the Trustee’s failure to so notify the Company will not relieve the Company or any
          Guarantor of its obligations under this Section 11.06(B). The Company and each Guarantor will defend such claim, and the Trustee will cooperate in such defense.
          The Trustee may retain separate counsel, and the Company and each Guarantor will, on a joint and several basis, pay the reasonable fees and expenses of such counsel. The Company need not pay for any settlement of any such claim made without its
          consent, which consent will not be unreasonably withheld.

      
        - 91 -

        
          
 

      

      (C)          The obligations of the
          Company and each Guarantor under this Section 11.06 will survive the resignation or removal of the Trustee, the satisfaction and discharge of this Indenture and the termination for any other reason of
          this Indenture. The Trustee’s right to receive payment of any amounts due under this Section 11.06 shall not be subordinate to any other liability or indebtedness of the Company.

       

      (D)          To secure the Company’s
          payment obligations in this Section 11.06 and the Guaranteed Obligations with respect to the Company’s obligations in this Section 11.06,
          the Trustee will have a lien prior to the Notes on all money or property held or collected by the Trustee, except that held in trust to pay principal of, or interest on, particular Notes, which lien will survive the discharge of this
          Indenture.

    

    
       

      (E)           If the Trustee incurs
          expenses or renders services after an Event of Default pursuant to clause (ix) or (x) of Section 7.01(A) occurs, then
          such expenses and the compensation for such services (including the fees and expenses of its agents and counsel) are intended to constitute expenses of administration under any Bankruptcy Law.

    

    
       

      (F)           Each Note Agent will
          have the same rights and duties as the Trustee under this Section 11.06.

    

    
       

      Section 11.07. Replacement of the Trustee.

    

    
       

      (A)          Notwithstanding anything
          to the contrary in this Section 11.07, a resignation or removal of the Trustee, and the appointment of a successor Trustee, will become effective only upon such
          successor Trustee’s acceptance of appointment as provided in this Section 11.07.

       

      (B)          The Trustee may resign at
          any time and be discharged from the trust created by this Indenture by so notifying the Company. The Holders of a majority in aggregate principal amount of the Notes then outstanding may remove the Trustee by so notifying the Trustee and the
          Company in writing. The Company may remove the Trustee if:

    

    
       

      (i) the Trustee fails to comply with Section 11.09;

       

      (ii) the Trustee is adjudged to be bankrupt or insolvent or an order for relief is entered with respect to the
        Trustee under any Bankruptcy Law;

       

      (iii) a custodian or public officer takes charge of the Trustee or its property; or

       

      (iv) the Trustee becomes incapable of acting.

    

    
       

      (C)          If the Trustee resigns or
          is removed, or if a vacancy exists in the office of Trustee for any reason, then by written instrument, one copy of which instrument shall be delivered to the resigning Trustee and one copy to the successor Trustee (i) the Company will promptly
          appoint a successor Trustee; and (ii) at any time within one (1) year after the successor Trustee takes office, the Holders of a majority in aggregate principal amount of the Notes then outstanding may appoint a successor Trustee to replace such
          successor Trustee appointed by the Company.

      
        - 92 -

        
          
 

      

      

      

      (D)          If a successor Trustee
          does not take office within sixty (60) days after the retiring Trustee resigns or is removed, then the retiring Trustee, the Company or the Holders of at least ten percent (10%) in aggregate principal amount of the Notes then outstanding may
          petition any court of competent jurisdiction for the appointment of a successor Trustee. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, appoint a successor Trustee.

       

      (E)          If the Trustee, after
          written request by a Holder of at least six (6) months, fails to comply with Section 11.09, then such Holder may petition any court of competent jurisdiction for the removal of the Trustee and the
          appointment of a successor Trustee.

       

      (F)          A successor Trustee will
          deliver a written acceptance of its appointment to the retiring Trustee and to the Company, upon which notice the resignation or removal of the retiring Trustee will become effective and the successor Trustee will have all the rights, powers and
          duties of the Trustee under this Indenture. The successor Trustee will send notice of its succession to Holders. The retiring Trustee will, upon payment of all amounts due to it under this Indenture, promptly transfer all property held by it as
          Trustee to the successor Trustee, which property will, for the avoidance of doubt, be subject to the lien provided for in Section 11.06(D).

       

      (G)          Notwithstanding
          replacement of the Trustee pursuant to this Section 11.07, the Company’s obligations under Section 11.06 shall continue for the benefit of the retiring Trustee.

       

      (H)          The Company shall execute
          such written instruments as are reasonably request in writing by any successor Trustee to confirm such successor Trustee’s rights and powers under this Indenture.

    

    
       

      Section 11.08. Successor Trustee by Merger, Etc.

    

    
       

      If the Trustee consolidates, merges or converts into, or transfers all or substantially all of its corporate trust business (including
        the administration of this Indenture) to, another Person, then such Person will become the successor Trustee without any further act.

    

    
       

      Section 11.09. Eligibility; Disqualification.

    

    
       

      There shall at all times be a U.S. Trustee hereunder which shall be a Person that is eligible pursuant to the Trust Indenture Act to
        act as such and has a combined capital and surplus of at least the minimum amount required by the Trust Indenture Act.

    

    
      - 93 -

      
        
 

    

    
      Article 12. MISCELLANEOUS

      

    

    
       

      Section 12.01. Notices.

    

    
       

      Any notice or communication by the Company or any Guarantor or the Trustee to the other will be deemed to have been duly given if in
        writing and delivered in person or by first class mail (registered or certified, return receipt requested), electronic transmission or other similar means of unsecured electronic communication or overnight air courier guaranteeing next day
        delivery, or to the other’s address, which initially is as follows:

       

      If to the Company or any Guarantor:

    

    
       

      Aegerion Pharmaceuticals, Inc.

    

    
      90 Harcourt Street

      Dublin 2, Ireland

      Attention: Chief Financial Officer

    

    
       

      with a copy to:

       

      Gibson, Dunn & Crutcher LLP

    

    
      200 Park Avenue, 47th Floor

      New York, NY 10166

      Attention: Andrew Fabens

    

    
       

      If to the Trustee:

    

    
       

      GLAS Trust Company LLC

    

    
      3 Second Street, Suite 206

      Jersey City, NJ 07311

      Facsimile: (212) 202-6246

      Attention: Administrator for Aegerion Pharmaceuticals, Inc.

    

    
       

      The Company, any Guarantor or the Trustee, by notice to the others, may designate additional or different addresses (including
        facsimile numbers and electronic addresses) for subsequent notices or communications.

       

      All notices and communications (other than those sent to Holders) will be deemed to have been duly given: (A) at the time delivered by
        hand, if personally delivered; (B) five (5) Business Days after being deposited in the mail, postage prepaid, if mailed; (C) when receipt acknowledged, if transmitted by electronic transmission or other similar means of unsecured electronic
        communication; and (D) the next Business Day after timely delivery to the courier, if sent by overnight air courier guaranteeing next day delivery.

       

      All notices or communications required to be made to a Holder pursuant to this Indenture must be made in writing and will be deemed to
        be duly sent or given in writing if mailed by first class mail, certified or registered, return receipt requested, or by overnight air courier guaranteeing next day delivery, to its address shown on the Register; provided,

          however, that a

    

    
      - 94 -

      
        
 

    

    
      notice or communication to a Holder of a Global Note may, but need not, instead be sent pursuant to the Depositary Procedures (in which case, such notice
        will be deemed to be duly sent or given in writing). The failure to send a notice or communication to a Holder, or any defect in such notice or communication, will not affect its sufficiency with respect to any other Holder.

    

    
       

      If the Trustee is then acting as the Depositary’s custodian for the Notes, then, at the reasonable request of the Company to the
        Trustee, the Trustee will cause any notice prepared by the Company to be sent to any Holder(s) pursuant to the Depositary Procedures, provided such request is evidenced in a Company Order delivered,
        together with the text of such notice, to the Trustee at least one (1) Business Day before the date such notice is to be so sent. The Trustee will not have any liability relating to the contents of any notice that it sends to any Holder pursuant to
        any such Company Order.

       

      If a notice or communication is mailed or sent in the manner provided above within the time prescribed, it will be deemed to have been
        duly given, whether or not the addressee receives it.

       

      Notwithstanding anything to the contrary in this Indenture or the Notes, whenever any provision of this Indenture requires a party to
        send notice to another party, no such notice need be sent if the sending party and the recipient arc the same Person acting in different capacities.

       

      The Trustee shall have the right, but shall not be required, to rely upon and comply with notices, instructions, directions or other
        communications sent by e-mail, facsimile and other similar unsecured electronic methods by persons believed by the Trustee to be authorized to give instructions and directions on behalf of the Company or the Guarantor. The Trustee shall have no
        duty or obligation to verify or confirm that the person who sent such instructions or directions is, in fact, a person authorized to give instructions or directions on behalf of the Company or the Guarantor; and the Trustee shall have no liability
        for any losses, liabilities, costs or expenses incurred or sustained by the Company or the Guarantor as a result of such reliance upon or compliance with such notices, instructions, directions or other communications. The Company and the Guarantor,
        as applicable, each agree to assume all risks arising out of the use of such electronic methods to submit notices, instructions, directions or other communications to the Trustee, including without limitation the risk of the Trustee acting on
        unauthorized instructions, and the risk of interception and misuse by third parties. The Company and the Guarantor shall use all reasonable endeavors to ensure that any such notices, instructions, directions or other communications transmitted to
        the Trustee pursuant to this Indenture are complete and correct. Any such notices, instructions, directions or other communications shall be conclusively deemed to be valid instructions from the Company or the Guarantor to the Trustee for the
        purposes of this Indenture.

      
        - 95 -

        
          
 

      

    

    
      Section 12.02. Delivery of Officer’s Certificate and Opinion of Counsel as to
          Conditions Precedent.

    

    
       

      Upon any request or application by the Company to the Trustee to take any action under this Indenture (other than the initial
        authentication of Notes under this Indenture), the Company will furnish to the Trustee:

       

      (A)          an Officer’s Certificate
          in form and substance reasonably satisfactory to the Trustee that complies with Section 12.03 and states that, in the opinion of the signatory thereto, all conditions precedent and covenants, if any,
          provided for in this Indenture relating to such action have been satisfied; and

       

      (B)          an Opinion of Counsel in
          form and substance reasonably satisfactory to the Trustee that complies with Section 12.03 and states that, in the opinion of such counsel, all such conditions precedent and covenants, if any, have been
          satisfied.

    

    
       

      Section 12.03. Statements Required in Officer’s Certificate and Opinion of
          Counsel.

    

    
       

      Each Officer’s Certificate (other than an Officer’s Certificate pursuant to Section 3.05) or
        Opinion of Counsel with respect to compliance with a covenant or condition provided for in this Indenture will include:

    

    
       

      (A)          a statement that the
          signatory thereto has read such covenant or condition;

    

    
       

      (B)          a brief statement as to
          the nature and scope of the examination or investigation upon which the statements or opinions contained therein are based;

       

      (C)          a statement that, in the
          opinion of such signatory, he, she or it has made such examination or investigation as is necessary to enable him, her or it to express an informed opinion as to whether or not such covenant or condition has been satisfied; and

       

      (D)          a statement as to whether,
          in the opinion of such signatory, such covenant or condition has been satisfied.

    

    
       

      Section 12.04. Rules by the Trustee, the Registrar and the Paying Agent.

    

    
       

      The Trustee may make reasonable rules for action by or at a meeting of Holders. The Registrar or Paying Agent may make reasonable rules
        and set reasonable requirements for its functions.

    

    
       

      Section 12.05. No Personal Liability of Directors, Officers, Employees and
          Shareholders.

    

    
       

      No past, present or future director, officer, employee, incorporator or shareholder of the Company or any Guarantor, as such, will have
        any liability for any obligations of the Company or any Guarantor under this Indenture, the Notes or the Guarantees or for any claim based on, in

    

    
      - 96 -

      
        
 

    

    
      respect of, or by reason of, such obligations or their creation. By accepting any Note, each Holder waives and releases all such liability. Such waiver
        and release are part of the consideration for the issuance of the Notes.

    

    
       

      Section 12.06. Governing Law; Waiver of Jury Trial.

    

    
       

      THIS INDENTURE, THE GUARANTEES AND THE NOTES, AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS INDENTURE, THE
        GUARANTEES OR THE NOTES, WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. EACH OF THE COMPANY, EACH GUARANTOR AND THE TRUSTEE IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL
        RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES, THE GUARANTEES OR THE TRANSACTIONS CONTEMPLATED BY THIS INDENTURE , THE NOTES OR THE GUARANTEES.

    

    
       

      Section 12.07. Submission to Jurisdiction.

    

    
       

      Any legal suit, action or proceeding arising out of or based upon this Indenture or the transactions contemplated by this Indenture may
        be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York, in each case located in the City of New York (collectively, the “Specified Courts”), and each party irrevocably submits to the non-exclusive jurisdiction of such courts in any such suit, action or proceeding. Service of
        any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party’s address set forth in Section 12.01 will be effective service of process
        for any such suit, action or proceeding brought in any such court. Each of the Company, each Guarantor, the Trustee and each Holder (by its acceptance of any Note) irrevocably and unconditionally waives any objection to the laying of venue of any
        suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waives and agrees not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum.

    

    
       

      Section 12.08. No Adverse Interpretation of Other Agreements.

    

    
       

      Neither this Indenture nor the Notes may be used to interpret any other indenture, note, loan or debt agreement of the Company or its
        Subsidiaries or of any other Person, and no such indenture, note, loan or debt agreement may be used to interpret this Indenture or the Notes.

    

    
       

      Section 12.09. Successors.

    

    
       

      All agreements of the Company in this Indenture and the Notes will bind its successors. All agreements of the Trustee in this Indenture
        will bind its successors.

    

    
       

      Section 12.10. Force Majeure.

    

    
       

      The Trustee and each Note Agent will not incur any liability for not performing, or any delay in performing, any act or fulfilling any
        duty, obligation or responsibility under this

    

    
      - 97 -

      
        
 

    

    
      Indenture or the Notes by reason of any occurrence beyond its control (including any act or provision of any present or future law or regulation or
        governmental authority, act of God or war, civil unrest, local or national disturbance or disaster, act of terrorism or unavailability of the Federal Reserve Bank wire or facsimile or other wire or communication facility).

    

    
       

      Section 12.11. U.S.A. PATRIOT Act.

    

    
       

      The Company acknowledges that, in accordance with Section 326 of the U.S.A. PATRIOT Act, the Trustee, like all financial institutions,
        in order to help fight the funding of terrorism and money laundering, is required to obtain, verify and record information that identifies each person or legal entity that establishes a relationship or opens an account with the Trustee. The Company
        agrees to provide the Trustee with such information as it may request to enable the Trustee to comply with the U.S.A. PATRIOT Act.

    

    
       

      Section 12.12. Calculations; Determinations.

    

    
       

      Unless otherwise provided in this Indenture, the Company will be responsible for making all calculations called for under this
        Indenture or the Notes, including determinations of the Last Reported Sale Price, the Daily Conversion Value, the Daily Cash Amount, the Daily Share Amount, the Daily VWAP, accrued interest on the Notes and the Conversion Rate and, in any event,
        neither the Trustee nor any Conversion Agent shall have any responsibility therefor.

       

      The Company will make all calculations in good faith, and, absent manifest error, its calculations will be final and binding on all
        Holders. The Company will provide a schedule of its calculations to the Trustee and the Conversion Agent, and each of the Trustee and the Conversion Agent may rely conclusively on the accuracy of the Company’s calculations without independent
        verification. The Trustee will promptly forward a copy of each such schedule to a Holder upon its written request therefor at the sole cost and expense of the Company.

    

    
       

      Section 12.13. Severability.

    

    
       

      If any provision of this Indenture or the Notes is invalid, illegal or unenforceable, then the validity, legality and enforceability of
        the remaining provisions of this Indenture or the Notes will not in any way be affected or impaired thereby.

    

    
       

      Section 12.14. Counterparts.

    

    
       

      The parties may sign any number of copies of this Indenture. Each signed copy will be an original, and all of them together represent
        the same agreement. Delivery of an executed counterpart of this Indenture by electronically in portable document format or in any other format will be effective as delivery of a manually executed counterpart for all purposes.

    

    
       

      Section 12.15. Table of Contents, Headings, Etc.

    

    
      

      

      The table of contents and the headings of the Articles and Sections of this Indenture have been inserted for convenience of reference
        only, are not to be considered a part of this Indenture and will in no way modify or restrict any of the terms or provisions of this Indenture.

    

    
      - 98 -

      
        
 

    

    
      Section 12.16. Withholding Taxes.

    

    
       

      Each Holder of a Note agrees, and each beneficial owner of an interest in a Global Note, by its acquisition of such interest, is deemed
        to agree, that if the Company or other applicable withholding agent pays withholding taxes or backup withholding on behalf of such Holder or beneficial owner as a result of an adjustment to the Conversion Rate, then the Company or such withholding
        agent, as applicable, may, at its option, set off such payments against payments of cash or the delivery of other Conversion Consideration on such Note, any payments on the Ordinary Shares or sales proceeds received by, or other funds or assets of,
        such Holder or the beneficial owner of such Note.

    

    
       

      Section 12.17. Trust Indenture Act Controls.

    

    
       

      If any provision of this Indenture limits, qualifies or conflicts with another provision that is required to be included in this
        Indenture by the Trust Indenture Act, then required provision of the Trust Indenture Act will control.

    

    
       

      [The Remainder of This Page Intentionally Left Blank; Signature Page Follows]

    

    
      - 99 -

      
        
 

    

    
      IN WITNESS WHEREOF, the parties to this Indenture have caused this Indenture to be duly executed
        as of the date first written above.

    

    	 	 	 
	 	
            Aegerion Pharmaceuticals, Inc.

          
	 	 	 
	 	
            By:

          	
            /s/ Joseph Wiley

          
	 	 	
            Name: Joseph Wiley

          
	 	 	
            Title: President and Director

          

    

    

    
      [Signature Page to Indenture]

    

    
      
        
 

    

    	 	 	 
	 	
            Amryt Pharma Holdings plc

          
	 	
            (to be renamed Amryt Pharma plc)

          
	 	 
	 	
            By:

          	
            /s/ Joe Wiley

          
	 	 	
            Name: Joe Wiley

          
	 	 	
            Title: Director

          

    
       

      [Signature Page to Indenture]

      
        
          
 

      

    

    	 	 	 
	 	
            Amryt Pharma plc

          
	 	
            (to be renamed Amryt Pharma Holding Limited)

          
	 	 	 
	 	
            By:

          	
            /s/ Joe Wiley

          
	 	 	
            Name: Joe Wiley

          
	 	 	
            Title: Director

          

    
       

      [Signature Page to Indenture]

      
        
          
 

      

    

    	 	 	 
	 	
            AEGERION PHARMACEUTICALS HOLDINGS, INC.

          
	 	 	 
	 	
            /s/ Ailish Hogan

          	 
	 	
            Ailish Hogan

          	 
	 	
            President and Director

          	 

    
       

      
        [Signature Page to Indenture]

      

      
        
          
 

      

    

    	 	 	 
	 	
            Aegerion Pharmaceuticals Limited

          
	 	 	 
	 	
            By:

          	
            /s/ John McEvoy

          
	 	 	
            Name: John McEvoy

          
	 	 	
            Title: Director

          

    
       

      [Signature Page to Indenture]

      
        
          
 

      

    

    	 	 	 
	 	
            Amryt Pharma (UK) Limited

          
	 	 	 
	 	
            By:

          	
            /s/ Joe Wiley

          
	 	 	
            Name: Joe Wiley

          
	 	 	
            Title: Director

          

    
       

      [Signature Page to Indenture]

      
        
          
 

      

    

    	 	 	 
	
            
              
                GIVEN under the common seal of Amryt Pharmaceuticals DAC  and DELIVERED as a DEED

              

            

          	 
	 	 
	 	
            By:

          	
            /s/ Joe Wiley

          
	 	 	
            Name: Joe Wiley

          
	 	 	
            Title:   Director

          
	 	 	 
	 	
            By:

          	
            /s/ Ailish Hogan

          
	 	 	
            Name: Ailish Hogan

          
	 	 	
            Title:   Director/Secretary

          

    
       

      [Signature Page to Indenture]

      
        
          
 

      

    

    	 	 	 
	
            
              GIVEN  under  the common  seal of Amryt Research Limited and DELIVERED as a DEED

            

          	 
	 	 
	 	
            By:

          	
            /s/ Joe Wiley

          
	 	 	
            Name: Joe Wiley

          
	 	 	
            Title:   Director

          
	 	 	 
	 	
            By:

          	
            /s/ Ailish Hogan

          
	 	 	
            Name: Ailish Hogan

          
	 	 	
            Title:   Director/Secretary

          

    
       

      [Signature Page to Indenture]

      
        
          
 

      

    

    	 	 	 
	
            
              GIVEN under the common seal of Amryt Genetics Limited
                and DELIVERED as a DEED

            

          	 
	 	 
	 	
            By:

          	
            /s/ Joe Wiley

          
	 	 	
            Name: Joe Wiley

          
	 	 	
            Title:   Director

          
	 	 	 
	 	
            By:

          	
            /s/ Ailish Hogan

          
	 	 	
            Name: Ailish Hogan

          
	 	 	
            Title:   Director/Secretary

          

    
       

      [Signature Page to Indenture]

      
        
          
 

      

    

    	 	 	 
	
            
              GIVEN under the common seal of Amryt Lipidology Limited and DELIVERED as a DEED

            

          	 
	 	 
	 	
            By:

          	
            /s/ Joe Wiley

          
	 	 	
            Name: Joe Wiley

          
	 	 	
            Title:   Director

          
	 	 	 
	 	
            By:

          	
            /s/ Ailish Hogan

          
	 	 	
            Name: Ailish Hogan

          
	 	 	
            Title:   Director/Secretary

          

    
       

      [Signature Page to Indenture]

      
        
          
 

      

    

    	 	 	 
	
            
              GIVEN under the common seal of Amryt Endocrinology Limited and DELIVERED as a DEED

            

          	 
	 	 
	 	
            By:

          	
            /s/ Joe Wiley

          
	 	 	
            Name: Joe Wiley

          
	 	 	
            Title:   Director

          
	 	 	 
	 	
            By:

          	
            /s/ Ailish Hogan

          
	 	 	
            Name: Ailish Hogan

          
	 	 	
            Title:   Director/Secretary

          

    
       

      [Signature Page to Indenture]

      
        
          
 

      

    

    	 	 	 
	 	
            GLAS Trust Company LLC

          
	 	 
	 	
            By:

          	
            /s/ Yana Kislenko

          
	 	
            Name: Yana Kislenko

          
	 	
            Title:    Vice President

          

    
       

      [Signature Page to Indenture]

    

    
      
        
 

    

    
    
      EXHIBIT A

    

    
      

      

       

      FORM OF NOTE

       

      [Insert Global Note Legend, if applicable]

       

      [Insert Private Placement Legend, if applicable]

       

      AEGERION PHARMACEUTICALS, INC.

       

      5.00% Convertible Senior Note due 2025

       

    

    	
            CUSIP No.:    [___]

          	
            Certificate No. [____]

          

    
      ISIN No.:        [___]

    

    
       

      Aegerion Pharmaceuticals, Inc., a Delaware corporation, for value received, promises to pay to Cede & Co., or its registered
        assigns, the principal sum of [     ] dollars ($[     ]) [(as revised by the attached Schedule of Exchanges of Interests in the Global Note)]* on April 1, 2025 and to pay interest thereon, as
        provided in the Indenture referred to below, until the principal and all accrued and unpaid interest are paid or duly provided for.

           

    

    	
            Interest Payment Dates:

          	
            April 1 and October 1 of each year, commencing on April 1, 2020.

          
	 	 
	
            Regular Record Dates:

          	
            March 16 and September 16.

          

    
       

      Additional provisions of this Note are set forth on the other side of this Note.

    

    
       

      [The Remainder of This Page Intentionally Left Blank; Signature Page Follows]

    

    
       

      
        
 

      *Insert bracketed language for Global Notes only.

      
        A-1

        
          
 

      

      IN WITNESS WHEREOF, Aegerion Pharmaceuticals, Inc. has caused this instrument to be duly executed
        as of the date set forth below.

    

    	 	 	 	 	 
	 	 	 	
            Aegerion Pharmaceuticals, Inc.

          
	 	 	 	 
	
            Date:

          	 	 	
            By:

          	 
	 	 	 	 	
            Name:

          
	 	 	 	 	
            Title:

          

    
      A-2

      
        
 

    

    
      TRUSTEE’S CERTIFICATE OF AUTHENTICATION

    

    
       

      GLAS Trust Company LLC, as Trustee, certifies that this is one of the Notes referred to in the within-mentioned Indenture.

    

    	 	 	 	 	 
	
            Date:

          	 	 	
            By:

          	 
	 	 	 	 	
            Authorized Signatory

          

    
      

         

      

      

      
        A-3

        
          
 

      

      AEGERION PHARMACEUTICALS, INC.

       

      5.00% Convertible Senior Note due 2025

    

    
       

      This Note is one of a duly authorized issue of notes of Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), designated as its 5.00% Convertible Senior Notes due 2025 (the “Notes”), all issued or to be issued pursuant to an indenture, dated as of September 24, 2019 (as the same may be amended from time to time, the “Indenture”), among the Company, the Guarantors and GLAS Trust Company LLC, as trustee. Capitalized terms used in this Note
        without definition have the respective meanings ascribed to them in the Indenture.

       

      The Indenture sets forth the rights and obligations of the Company, the Guarantors, the Trustee and the Holders and the terms of the
        Notes. Notwithstanding anything to the contrary in this Note, to the extent that any provision of this Note conflicts with the provisions of the Indenture, the provisions of the Indenture will control.

       

      1.          Interest. This Note will accrue interest at a rate and in the manner set forth in Section 2.05 of the Indenture. Stated Interest on this Note will begin to accrue from, and including,
          September 24, 2019.

       

      2.          Maturity. This Note will mature on April 1, 2025, unless earlier repurchased, redeemed or converted.

       

      3.          Guarantees. The Company’s obligations under the Indenture and the Notes are fully and unconditionally guaranteed by the Guarantors as provided in Article 9 of the Indenture.

       

      4.          Method of Payment. Cash amounts due on this Note will be paid in the manner set forth in Section 2.04 of the Indenture.

       

      5.          Persons Deemed Owners. The Holder of this Note will be treated as the owner of this Note for all purposes.

       

      6.          Denominations; Transfers and Exchanges. All Notes will be in registered form, without coupons, in principal amounts equal to any Authorized Denominations. Subject to the terms of the Indenture, the Holder of this Note may
          transfer or exchange this Note by presenting it to the Registrar and delivering any required documentation or other materials and any amounts required by the Indenture.

       

      7.          Right of Holders to Require the Company to Repurchase Notes upon a Fundamental Change. If a Fundamental Change occurs, then each Holder will have the right to require the Company to repurchase such Holder’s Notes (or any portion
          thereof in an Authorized Denomination) for cash in the manner, and subject to the terms, set forth in Section 4.02 of the Indenture.

       

      8.          Right of the Company to Redeem the Notes. The Company will have the right to redeem the Notes for cash in the manner, and subject to the terms, set forth in Section 4.03 of the Indenture.
         

      

    

    
      A-4

      
        
 

    

    
       

      9.           Conversion. The Holder of this Note may convert this Note into Conversion Consideration in the manner, and subject to the terms, set forth in Article 5 of the Indenture.

       

      10.         When the Company May Merge, Etc. Article 6 of the Indenture places limited restrictions on the Parent’s and the Company’s ability to be a party to a Business Combination Event.

       

      11.         Defaults and Remedies. If an Event of Default occurs, then the principal amount of, and all accrued and unpaid interest on, all of the Notes then outstanding may (and, in certain circumstances, will automatically) become due and
          payable in the manner, and subject to the terms, set forth in Article 7 of the Indenture.

       

      12.         Amendments, Supplements and Waivers. The Company, the Guarantors and the Trustee may amend or supplement the Indenture or the Notes or waive compliance with any provision of the Indenture or the Notes in the manner, and subject
          to the terms, set forth in Article 8 of the Indenture.

    

    
       

      13.         No Personal Liability of Directors, Officers, Employees and Shareholders. No past, present or future director, officer, employee, incorporator or shareholder of the Company or any Guarantor, as such, will have any liability for
          any obligations of the Company or any Guarantor under the Indenture, the Notes or the Guarantees or for any claim based on, in respect of, or by reason of, such obligations or their creation. By accepting any Note, each Holder waives and releases
          all such liability. Such waiver and release are part of the consideration for the issuance of the Notes.

    

    
       

      14.         Authentication. No Note will be valid until it is authenticated by the Trustee. A Note will be deemed to be duly authenticated only when an authorized signatory of the Trustee (or a duly appointed authenticating agent) manually
          signs the certificate of authentication of such Note.

       

      15.         Abbreviations. Customary abbreviations may be used in the name of a Holder or its assignee, such as TEN COM (tenants in common), TEN ENT (tenants by the entireties), JT TEN (joint tenants with right of survivorship and not as
          tenants in common), CUST (custodian), and U/G/M/A (Uniform Gift to Minors Act).

       

      16.         Governing Law. THIS NOTE, AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS NOTE, WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

       

        

      * * *

        

    

    
      A-5

      
        
 

    

    
      To request a copy of the Indenture, which the Company will provide to any Holder at no charge, please send a written request to the
        following address:

    

    
       

      Aegerion Pharmaceuticals, Inc.

    

    
      c/o Amryt Pharma pic

      90 Harcourt Street

      Dublin 2, Ireland

      Attention: Chief Financial Officer

    

    
      A-6

      
        
 

    

    
      SCHEDULE OF EXCHANGES OF INTERESTS IN THE GLOBAL NOTE*

       

      INITIAL PRINCIPAL AMOUNT OF THIS GLOBAL NOTE: $[____]

    

    
       

      The following exchanges, transfers or cancellations of this Global Note have been made:

       

      

    

    	
            Date

          	 	
            Amount of Increase

              (Decrease) in

              Principal Amount of

              this Global Note

          	 	
            Principal Amount of

              this Global Note

              After Such Increase

              (Decrease)

          	 	
            Signature of

              Authorized

              Signatory of Trustee

          
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 

    
       

      
        
 

      *Insert for Global Notes only.

    

    
      A-7

      
        
 

    

    
      CONVERSION NOTICE

       

      AEGERION PHARMACEUTICALS, INC.

       

      5.00% Convertible Senior Notes due 2025

    

    
       

      Subject to the terms of the Indenture, by executing and delivering this Conversion Notice, the undersigned Holder of the Note identified below directs the
        Company to convert (check one):

    

    
       

      
        		
                the entire principal amount of

              

      

       

      
        		
                $____________* aggregate principal amount of

              

      

    

    
       

      the Note identified by CUSIP No. ______________ and Certificate No. ______________.

    

    
       

      The undersigned acknowledges that if the Conversion Date of a Note to be converted is after a Regular Record Date and before the next Interest Payment
        Date, then such Note, when surrendered for conversion, must, in certain circumstances, be accompanied with an amount of cash equal to the interest that would have accrued on such Note to, but excluding, such Interest Payment Date.

      

    

    	 	 	 	 	 
	
            Date:

          	 	 	
             

            

          	 
	 	 	 	 	
            (Legal Name of Holder)

          
	 	 	 	 	 
	 	 	 	
            By:

          	 
	 	 	 	 	
            Name:

          
	 	 	 	 	
            Title:

          
	 	 	 	 	 
	 	 	 	
            Signature Guaranteed:

          
	 	 	 	 	 
	 	 	 	
            Participant in a Recognized Signature

              Guarantee Medallion Program

          
	 	 	 	 	 
	 	 	 	
            By:

          	 
	 	 	 	 	
            Authorized Signatory

          

     

    
      
 * Must be an Authorized Denomination.

    
      A-8

      
        
 

    

    
      FUNDAMENTAL CHANGE REPURCHASE NOTICE

       

      AEGERION PHARMACEUTICALS, INC.

       

      5.00% Convertible Senior Notes due 2025

    

    
       

      Subject to the terms of the Indenture, by executing and delivering this Fundamental Change Repurchase Notice, the undersigned Holder of the Note
        identified below is exercising its Fundamental Change Repurchase Right with respect to (check one):

    

    
       

      
        		
                the entire principal amount of

              

      

       

      
        		
                $____________* aggregate principal amount of

              

      

    

    
       

      the Note identified by CUSIP No. ______________ and Certificate No. ______________.

    

    
       

      The undersigned acknowledges that this Note, duly endorsed for transfer, must be delivered to the Paying Agent before the Fundamental Change Repurchase
        Price will be paid.

    

    	 	 	 	 	 
	
            Date:

          	 	 	
             

            

          	 
	 	 	 	 	
            (Legal Name of Holder)

          
	 	 	 	 	 
	 	 	 	
            By:

          	 
	 	 	 	 	
            Name:

          
	 	 	 	 	
            Title:

          
	 	 	 	 	 
	 	 	 	
            Signature Guaranteed:

          
	 	 	 	 	 
	 	 	 	
            Participant in a Recognized Signature

              Guarantee Medallion Program

          
	 	 	 	 	 
	 	 	 	
            By:

          	 
	 	 	 	 	
            Authorized Signatory

          

    
       

      
        
 

      * Must be an Authorized Denomination.

    

    
      A-9

      
        
 

    

    
      ASSIGNMENT FORM

       

      AEGERION PHARMACEUTICALS, INC.

       

      5.00% Convertible Senior Notes due 2025

    

    
       

      Subject to the terms of the Indenture, the undersigned Holder of the within Note assigns to:

    

    	 	 	 
	
            Name:

          	

          	 
	 	 	 
	
            Address:

          	 	 
	 	 	 
	 	 	 
	 	 	 
	
            Social security or

          	 	 
	
            tax identification

          	 	 
	
            number:

          	 	 

    
       

      the within Note and all rights thereunder irrevocably appoints:

       

      
        
 

      as agent to transfer the within Note on the books of the Company. The agent may substitute another to act for him/her.

    

    	 	 	 	 	 
	
            Date:

          	 	 	
             

            

          	 
	 	 	 	 	
            (Legal Name of Holder)

          
	 	 	 	 	 
	 	 	 	
            By:

          	 
	 	 	 	 	
            Name:

          
	 	 	 	 	
            Title:

          
	 	 	 	 	 
	 	 	 	
            Signature Guaranteed:

          
	 	 	 	 	 
	 	 	 	
            Participant in a Recognized Signature

              Guarantee Medallion Program

          
	 	 	 	 	 
	 	 	 	
            By:

          	 
	 	 	 	 	
            Authorized Signatory

          

    
      
        A-10

        
          
 

      

      TRANSFEREE ACKNOWLEDGEMENT

    

    
       

      The undersigned represents that it is purchasing the within Note for its own account, or for one or more accounts with respect to which the undersigned
        exercises sole investment discretion.

    

    	 	 	 	 
	
            Dated:

          	 	 
	 	 	 
	 	 	 
	
            (Name of Transferee)

          	 
	 	 
	
            By:

          	 	 	 
	 	
            Name:

          	 
	 	
            Title:

          	 

    
      A-11

      
        
 

    

    
    
       

      EXHIBIT B

    

    
       

      FORM OF GLOBAL NOTE LEGEND

    

    
       

      THIS IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE
        DEPOSITARY, WHICH MAY BE TREATED BY THE COMPANY, THE TRUSTEE AND ANY AGENT THEREOF AS THE OWNER AND HOLDER OF THIS NOTE FOR ALL PURPOSES.

       

      UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION
        OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT HEREON IS MADE TO CEDE & CO. OR TO SUCH OTHER
        ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

       

      TRANSFERS OF THIS GLOBAL NOTE WILL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF DTC, OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S
        NOMINEE, AND TRANSFERS OF PORTIONS OF THIS GLOBAL NOTE WILL BE LIMITED TO TRANSFERS MADE IN ACCORDANCE WITH THE RESTRICTIONS SET FORTH IN ARTICLE 2 OF THE INDENTURE HEREINAFTER REFERRED TO.

    

    
      B-1

      
        
 

    

    
       

      EXHIBIT C

    

    
       

      FORM OF PRIVATE PLACEMENT LEGEND

    

    
       

      THE NOTES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE
        OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (A) (1) TO A PERSON WHOM THE SELLER REASONABLY BELIEVES IS A QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT PURCHASING FOR ITS OWN ACCOUNT OR FOR THE
        ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A, (2) TO AN INSTITUTIONAL ACCREDITED INVESTOR IN A TRANSACTION EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT, (3) PURSUANT TO AN
        EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR (4) TO THE COMPANY, ANY OF THE GUARANTORS OR ANY OF THEIR SUBSIDIARIES AND (B) IN ACCORDANCE WITH ALL APPLICABLE BLUE SKY LAWS OF THE STATES OF THE UNITED STATES, AND ANY SELLER AGREES
        THAT IT WILL DELIVER TO EACH PERSON TO WHOM THIS NOTE OR AN INTEREST HEREIN IS TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND.

       

      

       B-2Pursuant to 17 CFR 229.601(b)(10)(iv),
    confidential information (indicated by [***]) has been omitted from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed.

  Exhibit 10.7

   

  Execution Version

   

  University College Dublin, National University of Ireland

   

  and-

   

  AMRYT GENETICS LIMITED

   

  LICENCE AGREEMENT

   

  
  
    	 	1	 

  

  
     

  

  
   

  THIS LICENCE AGREEMENT is made BETWEEN:

   

  		(1)	University College Dublin, National University of Ireland, dublin of Belfield, Dublin 4, Ireland (UCD) and

   

  		(2)	AMRYT GENETICS LIMITED, a company registered in Ireland under number 622577 with the Companies Registration Office, whose registered office is 90 Harcourt Street, Dublin 2, Ireland (the Licensee),

   

  (individually a Party and collectively, the Parties).

   

  WHEREAS

   

  		1.	The Parties wish to enter into this Agreement with effect from the Effective Date in accordance with the terms of this Agreement.

   

  		2.	UCD has developed a polymer technology with applications in gene therapy, which is the subject of the Application (defined below).

   

  		3.	The Licensee is a clinical stage specialty pharmaceutical company, which focuses on the development and commercialisation of medicines for the treatment for patients with rare and orphan diseases.

   

  		4.	UCD has agreed to licence certain intellectual property to the Licensee on the terms set out in this Agreement.

   

  		5.	The Parties intend to enter into a collaborative research agreement to further develop polymer technologies with applications in gene therapy subject to and in compliance with the terms of Clause 4 of this Agreement.

   

  NOW, THEREFORE, IN CONSIDERATION OF THE MUTUAL COVENANTS SET FORTH HEREIN, THE PARTIES HEREBY AGREE AS FOLLOWS:

   

  		1.	DEFINITIONS AND INTERPRETATION

   

  		1.1	In this Agreement (including the Schedules) and in the Recitals, unless the context otherwise requires or unless otherwise specified, the following terms shall have the following meanings:

   

  	Affiliate:	 	means in relation to either Party, any corporation, or other business entity which Controls, is Controlled by, or is under common Control with said Party.  
	 	 	 
	Agreement:	 	means this document including its Schedules, as amended from time to time in accordance with Clause 13.12.
	 	 	 
	API:	 	means an active pharmaceutical ingredient of a dosage form intended to furnish pharmacological activity or other direct effect in the prevention, treatment or diagnosis of disease.
	 	 	 
	Application:	 	means the patent application as set out and further described at Part 1 of Schedule 1 attached hereto, and any amendments made to same in the course of the prosecution phase for such patent application, including any
          amendments required for the prosecution at 

   

  
  
    	 	2	 

  

  
     

  

  
   

  	 	 	nationalisation stage (as applicable), and any granted Patents issuing from such patent application.
	 	 	 
	Business Day:	 	means Monday to Friday (inclusive), except bank or public holidays in the Republic of Ireland and “Business Days” shall be construed accordingly.
	 	 	 
	Combination Product:	 	means a product that is sold in the form of a combination product containing (i) the Product and (ii) at least one other API, as separate molecular entity(ies) where such API does not comprise any component of the
          Product.
	 	 	 
	Commercially Reasonable Efforts	 	means exerting such efforts and employing such resources as would normally be exerted or employed by a reasonable Third Party company for a product of similar market potential at a similar stage of its product life,
          when utilising sound and reasonable scientific and business practice and judgment in order to develop and commercialise the Product in a timely manner. 
	 	 	 
	“Control”, “Controlled by” and “under the common Control with”: 	 	mean beneficial ownership of fifty percent (50%) or more of the share capital, stock or other participating interest having the right to vote or carrying the right to distribution of profits of that Party, as the
          case may be.
	 	 	 
	Effective Date:	 	14 March 2018.
	 	 	 
	Field:	 	means gene therapy products for the treatment of any and all disorders which, for the avoidance of doubt, will include all therapeutic uses in humans and animals. 
	 	 	 
	First Commercial Sale:	 	means the first sale of the Product following the granting of a marketing authorisation by a regulatory agency in the applicable country of the Territory to a Third Party by Licensee, its sub-licensee or its
          Affiliates.
	 	 	 
	HPAE:	 	a Hyperbranched poly (β – amino ester).
	 	 	 
	Improvement:	 	means any IPR which constitutes an improvement, enhancement, alteration and/or modification in or to the Licensed IP in the Field.
	 	 	 
	IPR:	 	means any and all Patent, trade or other mark, registered design, design right, topography right, copyright, database right or any other right in the nature of any of the foregoing (or application, or right to apply
          for, any of the foregoing), and any invention, discovery, concept, idea, method improvement, design, technique, confidential process or information or know how, business or trade names, goodwill and all other intellectual property and rights of a
          similar or corresponding nature in each case subsisting anywhere in the world and whether registered, unregistered or unregisterable, and including all applications and the right 

   

  
  
    	 	3	 

  

  
     

  

  
   

  	 	 	to apply for any of the foregoing rights.
	 	 	 
	Know-How:	 	means the documented unpatented technical information, as set out and described at Part 2 of Schedule 1 attached hereto, insofar as same was created by Scientist and/or a Scientist’s Researcher (including [***])
          prior to the Effective Date.
	 	 	 
	Licensed IP:	 	means (i) the Application, and (ii) the Know-How, insofar as same was created by or on behalf of UCD prior to the Effective Date.
	 	 	 
	
          Licensee Improvement:

           

        	 	means Improvements made by or on behalf of the Licensee during the Term, but for the avoidance of doubt excludes UCD Improvements.
	 	 	 
	Material Breach:	 	means a breach of this Agreement that is material in the widest sense of having a serious effect on the benefit which the terminating Party would otherwise derive from a substantial portion of this Agreement in
          respect to the performance of this Agreement in accordance with its terms.
	 	 	 
	Milestones	 	means the specific milestones events with respect to the to use the Licensed IP for the Purpose in the Field in the Territory, as set out at Schedule 2 hereto, as may be varied or amended on the written agreement of
          the Parties.
	 	 	 
	Net Receipts:	 	
          means the amount of the following payments (excluding value added tax where payable in respect of such amount) obtained by, or due to the Licensee, or its
            Affiliates from a Third Party in relation to:

           

          (i) the grant of sub-licences (including the grant of any option over a sub-license) of any of the Licensed IP such as: up-front, and milestone payments but for
            the avoidance of doubt excluding (a) milestone payments received by the Licensee or its Affiliates from a sub-licensee which constitute payment for research or development activities related to the Product, and (b) payments received by the
            Licensee or its Affiliates from a sub-licensee for the conduct of research and development activities related to the Product, in each case to the extent that such payments do not exceed a reasonable level of payment for the conduct of such
            research and development activities; and

           

          (ii) royalty payments in relation to the sale of the Products by a sub licensee.

           

          If the royalty payment received by the Licensee relates to a Combination Product, Net Receipts shall, subject to the

        

   

  
  
    	 	4	 

  

  
     

  

  
   

  	 	 	
          provisions of Clause 6.1.3(e), be calculated by multiplying the royalties received by Licensee from the applicable sublicensee during the applicable reporting
            period by the fraction A/(A+B) where: “A” is the average sale price of the Product contained in the Combination Product when sold separately by the sublicensee in such country; and “B” is the average sale price of the other API included in the
            Combination Product when sold separately by its supplier in such country, in each case during the applicable reporting period or if sales of both the Product and/or other API did not occur in such country during such period, then in the most
            recent reporting period in which sales of both occurred.

           

          In the event that such average sale price cannot be determined for both the Product and the other API included in the Combination Product, the calculation of Net
            Receipts arising from such Combination Product shall subject to the provisions of Clause 6.1.3(e) be calculated by multiplying the royalties received by Licensee from the applicable sublicensee during the applicable reporting period by the
            fraction of C/(C+D) where: “C” is the fair market value of the Product, and “D” is the fair market value of the other API included in the Combination Product. In such event, the Parties shall negotiate in good faith to arrive at a determination
            of the respective fair market values of the Product and the other API included in the Combination Product.

           

          In circumstances where Net Receipts relate to license fees in relation to a Combination Product, the Parties shall negotiate in good faith to arrive at a
            determination of the respective fair market values of the Product and the other API included in the Combination Product.

        
	 	 	 
	Net Sales:	 	
          means the total of the gross amount invoiced for sales or other supply of the Product by the Licensee or its Affiliates to a Third Party (but for the avoidance of
            doubt excluding sales to Affiliates) in a usual arm’s length transaction from, less the following deductions from such gross amounts as are actually paid or accrued for by the Licensee, its sub-licensee or its Affiliates (as the case may be)
            including, without limitation:

           

          (i)            trade, cash or quantity discounts, retroactive price reductions or adjustments in each case actually granted, or
            billing corrections actually corrected and bad debts actually collected with respect to sales of Product;

           

          (ii)           amounts repaid, credits or allowances granted for damaged goods, defects, recalls, returns or 

        

   

  
  
    	 	5	 

  

  
     

  

  
   

  	 	 	
          rejections of the Product(s);

           

          (iii)          taxes paid by or charged to the account of the Licensee or Affiliates including without limitation; rebates and
            similar payments made with respect to sales paid for by any Third Party, governmental or regulatory authority, sales tax, value added tax, import/export duties or other similar governmental taxes or charges imposed on sales of the Product(s)
            but excluding national, state or local taxes based on income);

           

          (iv)          commercially reasonable fees payable to a distributor with respect to sales and distribution of the Products, subject
            to such fees being normal and standard within the Field in the applicable countries of the Territory; and

           

          (v)           freight, postage, shipping, customs duties and insurance charges to the extent included in the gross amount invoiced.

           

          In relation to a Combination Product, ‘Net Sales’ shall subject to the provisions of Clause 6.1.2(c) be calculated by multiplying the actual Net Sales of such
            Combination Product during the applicable reporting period, by the fraction A/(A+B) where: “A” is the average sale price of the Product contained in the Combination Product when sold separately by the Licensee or its Affiliates in such country;
            and “B” is the average sale price of the other API included in the Combination Product when sold separately by its supplier in such country, in each case during the applicable reporting period, or if sales of both the Product and/or other API
            did not occur in such country during such period, then in the most recent reporting period in which sales of both occurred.

           

          In the event that such average sale price cannot be determined for both the Product and the other API included in the Combination Product, Net Sales for the
            purpose of determining royalty payments shall be calculated by multiplying the Net Sales of the Combination Products by the fraction of C/(C+D) where “C” is the fair market value of the Product and “D” is the fair market value of the other API
            included in the Combination Product. In such event, the Parties shall negotiate in good faith to arrive at a determination of the respective fair market values of the Product and the other API included in the Combination Product.

           

          Products provided by the Licensee free of charge, for administration to patients enrolled in clinical trials or distributed through a not-for-profit foundation at
            no charge to eligible patients shall not be included in Net

        

   

  
  
    	 	6	 

  

  
     

  

  
   

  	 	 	Sales, provided that the Licensee receives no consideration from such not-for-profit foundation or from such clinical trials or such use of Products.
	 	 	 
	Orphan Drug Exclusivity:	 	means granted orphan drug exclusivity by the applicable governmental agency, where an application has been made by the Licensee or an Affiliate for orphan drug designation for the applicable Product. 
	 	 	 
	Patents:	 	means design and utility patent applications and patents including, without limitation, provisional patent applications, continuations, continuations-in-part, divisional applications and patents, reissues,
          re-examinations and revalidations of same, and extensions of any patents, patents of addition, SPCs and the like, and any foreign counterparts or equivalent protection rights in respect thereof. 
	 	 	 
	Patent Rights:	 	
          means the following Patents which are owned and/or become owned by UCD:

           

          (i)          the Application.

        
	 	 	 
	Phase I Study:	 	means a first in healthy human volunteer study.
	 	 	 
	Phase IIa Proof of Concept Study:	 	means a study in a small number of patients with the target disease that demonstrates the biological proof of concept.
	 	 	 
	Phase IIb Study: 	 	means a dose ranging study conducted in patients with the target disease.
	 	 	 
	Product:	 	means one or more gene therapy products incorporating or using a HPAE, which incorporate or utilise, or the development, manufacture, use or supply of are covered by any Valid Claim, or which makes use of any of the
          Know-How, and “Products” shall be construed accordingly.
	 	 	 
	Purpose:	 	means to use the Licensed IP to develop, manufacture, have manufactured, use, and sell, market and/or otherwise supply the Product.
	 	 	 
	Reasonable Commercial Terms:	 	means such terms and conditions as would usually be found in a licence of the IPR in question in an equivalent arm’s length transaction.
	 	 	 
	Report:	 	means the report as set out and defined in Clause 5.4, detailing the progress made and steps taken by the Licensee during the previous twelve (12) months in respect of the Licensed IP in connection with the Purpose
          in the Field in the Territory, and which shall contain such financial, technical and other information, and in such a format, as is reasonably requested by UCD. 

   

  
  
    	 	7	 

  

  
     

  

  
   

  	Reporting Period:	 	
          means

           

          (i)            with respect to the first Reporting Period, the period commencing on the Effective Date and ending on 31 December
            2018; and

           

          (ii)           with respect to each subsequent Reporting Period, a period of twelve (12) months commencing on 1 January 2019 and each
            subsequent anniversary of that date.

        
	 	 	 
	Scientist:	 	means [***] while employed by UCD and acting as principal investigator, and such principal investigator, appointed to replace [***] should [***] cease to act in such role. 
	 	 	 
	Scientist’s Researcher:	 	means any researcher working under the direction of Scientist, while any such researcher is either employed or engaged by UCD (including as an employee, contractor or consultant).
	 	 	 
	SPC:	 	means a supplementary protection certificate. 
	 	 	 
	Term:	 	means the term of this Agreement as set out in Clause 10.1.
	 	 	 
	Territory:	 	means worldwide.
	 	 	 
	Third Party:	 	means any individual or entity which is neither a Party, or an Affiliate of a Party, and “Third Parties” shall be construed accordingly.
	 	 	 
	UCD Improvement:	 	means any and all Improvements made by and/or on behalf of the Scientist and/or a Scientist’s Researcher during the Term, but which for the avoidance of doubt excludes Licensee Improvements.
	 	 	 
	Valid Claim: 	 	means a claim of any issued, unexpired Patent Rights that has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be
          taken, or with respect to which an appeal is not taken within the time allowed for appeal, and that has not been disclaimed, dedicated to the public or otherwise rendered unenforceable.

   

  		1.2	Except as otherwise provided, any references in this Agreement to clauses, paragraphs, schedules and/or Parties are references to the clauses, paragraphs, schedules and/or Parties to this Agreement.

   

  
  
    	 	8	 

  

  
     

  

  
   

  		1.3	Where applicable references to the singular shall include the plural and vice versa and reference to any gender shall include other genders.

   

  		1.4	The division of this Agreement to Clauses and sub-Clauses, and the headings used in this Agreement, are for convenience only, and shall not affect the interpretation of this Agreement.

   

  		1.5	In this Agreement, unless otherwise specified, any reference to writing includes fax transmission and email, but excludes SMS and similar means of communication.

   

  		1.6	This Agreement and all rights and obligations hereunder shall for all purposes be treated and construed as being separate and apart from any other agreement or agreements or any rights or obligations thereunder save
          only insofar as the express provision requires to the contrary.

   

  		1.7	In this Agreement, any phrase introduced by the words include, including, includes and such as are to be construed as illustrative, and shall not limit the sense of the words preceding
          those words.

   

  		1.8	In this Agreement, unless otherwise specified, any reference to a statute or statutory provision includes a reference to the statute or statutory provision as modified or re-enacted, or both, from time to time, and
          to any subordinate legislation made under it.

   

  		1.9	Any reference to a person shall be construed as a reference to any individual, firm, company, corporation, government, state or agency of a state or any association or partnership (whether or not having separate
          legal personality) of two or more of the foregoing.

   

  		2.	GRANT OF LICENCE

   

  		2.1	Subject to Clause 2.5, UCD hereby grants to the Licensee, and the Licensee hereby accepts with effect from the Effective Date:

   

  		2.1.1	an exclusive licence to the Patent Rights for the Purpose in the Field in the Territory, subject to Clause 2.5;

   

  		2.1.2	a non-exclusive licence to the Know-How for the Purpose in the Field in the Territory;

   

  		2.2	During the period of [***] commencing on the Effective Date, subject to the provisions of Clause 2.5, UCD shall not grant a licence to the Know How to any Third Party to develop or commercialise a Product in the
          Field in the Territory.

   

  		2.3	On the expiry of the Term, on a Product by Product and country by country basis, the Licensee may at its option notify UCD that it wishes to elect to negotiate a non-exclusive licence to the Know-How in the Field and
          in the applicable countries of the Territory and such licence shall be on terms to be negotiated in good faith between the Parties, having regard to the applicable provisions of the Agreement, and subject to the negotiation and conclusion of a
          separate agreement in writing between the Parties.

   

  		2.4	The Licensee may grant sub-licenses of the rights set out at Clause 2.1, provided that:

   

  		2.4.1	the Licensee shall provide UCD with a copy of each sub-license within thirty (30) Business Days after its grant;

   

  		2.4.2	to the extent applicable the Licensee shall ensure that there are included in the terms of any sub-license the obligations on the sub-licensee which are equivalent to the obligations contained in this Agreement,
          including in particular (but not limited to) Clause 3.2 (confidentiality of Know-How) and Clause 7;

   

  
  
    	 	9	 

  

  
     

  

  
   

  		2.4.3	all sub-licenses shall terminate immediately on the termination of this Agreement for any reason;

   

  		2.4.4	the payment terms of any sub-licenses shall be on terms equivalent to those that should be included in a customary arm’s length transaction;

   

  		2.4.5	all sub-licenses shall be personal to the sub-licensee and not capable of assignment or sub-sub-licensing without UCD's prior written consent; and

   

  		2.4.6	the Licensee shall at all times indemnify UCD and keep UCD indemnified against any and all actions, proceedings, costs, claims, damages, expenses and/or liabilities arising any act or omission of any sub-licensee.

   

  		2.5	Notwithstanding (i) the exclusive licence granted by UCD to the Licensee pursuant to Clauses 2.1.1 and (ii) the provisions of Clause 2.2, the Licensee agrees and acknowledges that, subject to the provisions of Clause
          3.3, UCD will at all times have an irrevocable, perpetual, royalty-free, worldwide right to use the Licensed IP for the purposes of academic teaching, publication (subject to Clauses 4.3.2 and 7.3, as applicable) and non-commercial research,
          including the right for UCD to sub-license to research collaborators (whether pursuant to a research grant or otherwise) for non-commercial research, provided that such research collaborators shall be under equivalent obligations of
          confidentiality as Clause 7. Subject to the provisions of Clause 4.3, any other access to (i) the Patent Rights in the Field in the Territory, and (ii) the Know-How in the Field in the Territory for five (5) years commencing on the Effective Date
          in accordance with Clause 2.2 will require the prior written consent of the Licensee which it may withhold at its sole discretion.

   

  		2.6	No licence is granted to the Licensee other than as expressly stated in this Clause 2. UCD reserves all other rights under the Licensed IP.

   

  		2.7	The Licensee and UCD shall execute such licences as may be necessary or appropriate for registration with intellectual property offices, patent offices or other relevant authorities in particular countries or regions
          of the Territory. In the event of any conflict in meaning between any such licence and the provisions of this Agreement, the provisions of this Agreement shall prevail. Prior to the execution of the formal licence(s) (if any) referred to in this
          Clause 2.7 the Parties shall so far as possible have the same rights and obligations towards one another as if such licence(s) had been granted. The Parties shall use reasonable endeavours to ensure that, to the extent permitted by the relevant
          authorities, this Agreement shall not form part of any public record.

   

  		2.8	The Licensee may enter into one or more sub-contracts for the Products for the Purpose in the Field in the Territory, provided that:

   

  		2.8.1	any sub-contractor shall first enter into a confidentiality agreement with the Licensee and containing terms similar to, and no less onerous than, (and in respect to observing the obligations under) the provisions in
          Clause 7 of this Agreement, in relation to the disclosure of Confidential Information to the sub-contractor and the Licensee shall procure that any subcontractor duly observes and complies with such obligations;

   

  		2.8.2	the Licensee procures that the sub-contractor acts in accordance with the obligations on the Licensee pursuant to this Agreement.

   

  		2.8.3	the Licensee shall be liable for all acts and omissions of any sub-contractor.

   

  		3.	PROVISION OF KNOW-HOW AND TECHNICAL ASSISTANCE

   

  
  
    	 	10	 

  

  
     

  

  
   

  		3.1	UCD will provide the Know-How to the Licensee as soon as practicable after the Effective Date, subject to the Licensee complying with Clause 3.2.

   

  		3.2	In consideration of the disclosure by UCD of the Know-How, the Licensee undertakes and agrees:

   

  		3.2.1	to keep the Know-How secret and in strict confidence and to use the Know-How only for the Purpose in the Field in the Territory and in the manner as set out in this Agreement, and for no other purpose;

   

  		3.2.2	to only disclose the Know-How to such employees, contractors or sub-licensees as require same for the Purpose in the Field in the Territory and provided said employees, contractors or sub-licensees have undertaken in
          writing to comply with the terms of this Agreement.

   

  		3.2.3	not to make or use any copies, synopses or summaries of any of the Know-How, except such as are strictly necessary for the Licensee’s internal communications in connection with the Purpose in the Field in the
          Territory, or as are strictly necessary for the Purpose;

   

  		3.2.4	at UCD’s written request, and in any event upon termination or expiration of this Agreement, to return to UCD (or, if requested, destroy or erase) all documents (and copies thereof) and other materials concerning or
          incorporating, or in any way recording any of the Know-How, in whatever form, which are in its possession or control, and shall make no further use or disclosure of any of the Know-How;

   

  		3.2.5	to give notice to UCD of any unauthorised misuse, disclosure, theft or loss of the Know-How as soon as possible and, in any event, no later than five (5) Business Days after becoming aware of the same; and

   

  		3.2.6	that the obligations in this Clause 3.2 shall continue to be binding on it with respect to each piece of Know-How, for so long as it remains secret and confidential, it being recognised that any particular Know-How
          shall not be deemed to be publicly known merely because other Know-How contained in the same document or embodiment becomes publicly known.

   

  		3.3	UCD shall keep the Know-How secret and in strict confidence and shall procure that other licensees of the Know-How shall also do so.

   

  		4.	IMPROVEMENTS 

   

  		4.1	UCD shall own all rights in and to the UCD Improvements.

   

  		4.2	It is envisaged as at the Effective Date, that the Parties intend to enter into good faith negotiations during the Term with a view to the negotiation and conclusion of a collaborative research agreement as between
          the Parties, to further develop HPAE polymer technologies developed by the Scientist with application in the Field and that such an agreement shall regulate such collaborative research project and the access rights of Licensee to the foreground
          intellectual property generated pursuant to such collaborative research project. The provisions of this Clause 4.2 shall not be construed to obligate either Party to enter into such a collaborative research agreement. Furthermore, any failure on
          the part of the Parties, or either Party, to so enter into such an agreement following good faith negotiations shall not constitute a breach of this Agreement.

   

  		4.3	Strictly subject to Clause 4.3.4 below, it is agreed that during the Term:

   

  
  
    	 	11	 

  

  
     

  

  
   

  		4.3.1	in the event that UCD is carrying out research in relation to HPAE polymer technology developed by the Scientist with application (including in conjunction with one or more additional technologies) in the Field, UCD
          shall prior to disclosure to any Third Party (other than a research collaborator) notify the Licensee of and, if and/or requested by Licensee, provide the Licensee with details in respect to IPR and data generated pursuant to such research and
          such other information as is reasonably required by Licensee for the Licensee to be able to evaluate such IPR and data, and that such information and/or access to and/or evaluation of such IPR and data shall be subject to the good faith
          negotiation and conclusion of a separate evaluation licence between the Parties in writing;

   

  		4.3.2	in the event that UCD proposes to publish the output of all or some of such research, UCD shall provide a copy of the proposed publication material to Licensee for review and comment at least thirty (30) Business
          Days prior to the proposed submission date for publication. UCD shall in good faith consult with Licensee and its patent advisers to consider recommended alterations or deletions to the proposed publication material that are reasonably
          appropriate in order to enable UCD to seek appropriate legal protection or registration of the IPR in respect of such output, or to facilitate the negotiation of a further agreement between the Parties. For the avoidance of doubt, UCD shall be
          under no obligation whatsoever to act in accordance with such recommendations of the Licensee and UCD may make such alterations or deletions in and/or at its sole discretion; and

   

  		4.3.3	UCD shall in good faith consider proposals made by Licensee to enter in to an evaluation licence and/or a commercialisation licence with regard to all or part of the IPR in respect to the development of the Licensed
          IP by the Scientist in the Field and such licences shall be subject to negotiation in good faith between the Parties and the conclusion of separate agreements in writing between the Parties. The provisions of this Clause 4.3.3 shall not be
          construed to obligate either Party to enter into such a licence. Furthermore, any failure on the part of the Parties, or either Party, to so enter into such a licence following good faith negotiations shall not constitute a breach of this
          Agreement.

   

  		4.3.4	The provisions of this Clause 4.3 shall be strictly subject to the extent that UCD is not prohibited by (i) law or (ii) any contractual or other obligation which UCD may have to any Third Party (including without
          limitation in respect to any contractual or other obligations in such funding agreements with one or more state agencies as may be applicable).

   

  		4.4	The Licensee shall own all rights in and to the Licensee Improvements. To the extent that it is not prohibited by law or by any contractual obligation to any Third Party, Licensee shall in good faith consider a
          request by UCD to grant to UCD a non-exclusive licence to use applicable Licensee Improvements for non-commercial research purposes only, on terms to be negotiated in good faith to include obligations of confidentiality consistent with the
          provisions of this Agreement.

   

  		5.	OBLIGATIONS ON THE Licensee 

   

  		5.1	The Licensee shall use Commercially Reasonable Efforts to develop, use and exploit the Licensed IP for the Purpose in the Field in the Territory.

   

  		5.2	Notwithstanding and without prejudice to the generality of Clause 5.1, the Licensee shall use Commercially Reasonable Efforts to achieve the Milestones by the dates as described in Schedule 2.

   

  		5.3	The Licensee shall consult with the UCD in relation to the progress being made to achieve the Milestones. Any updates and/or amendments to the Milestones shall be discussed in advance

   

  
  
    	 	12	 

  

  
     

  

  
   

  with UCD and any such updates and/or amendments shall be incorporated into this Agreement with the express written agreement of both Parties.

   

  		5.4	Without prejudice to the generality of the Licensee’s obligations pursuant to Clause 5.1, the Licensee shall provide annually to UCD an updated, written statement (the Report), at the same time as the royalty
          statements outlined in Clauses 6.9 and 6.10, which shall include details of:

   

  		5.4.1	the progress made and steps taken by the Licensee, its Affiliates and the sub-licensees since the Effective Date or the date of the previous Report (as defined and pursuant to this Clause 5.4) in respect to the
          Purpose in the Field in the Territory, including in respect to regulatory approvals and/or regulatory applications;

   

  		5.4.2	set out the dates on which the applicable Milestone(s) have been achieved and, where applicable, report on the differences between such dates and the dates as described in Schedule 2 (as may be amended) and the
          reasons for those differences; and

   

  		5.4.3	Licensee’s plans for the next twelve (12) months in relation to the Product.

   

  		5.5	Licensee shall meet UCD to discuss the contents of such Report, and will answer such questions as may be asked by UCD in respect of the progress made by the Licensee and the steps taken pursuant to this Agreement.
          The Licensee acknowledges and agrees that UCD’s receipt or approval of any Report shall not be taken to waive or qualify the Licensee’s obligations under Clause 5.1.

   

  		5.6	Referral to Expert. If UCD reasonably considers on the basis of the Report that Licensee has, without legitimate reason having put Licensee on notice that it considers Licensee to have failed to comply
          with its obligations pursuant to Clause 5.1 and/or 5.2 and given Licensee reasonable time to address UCD’s concerns, failed to comply with its obligations pursuant to Clause 5.1 and/or 5.2, UCD shall be entitled to refer the following questions
          to an Expert (as defined in Schedule 3):

   

  		5.6.1	whether taking into account the provisions of Clause 5 and Schedule 2 the Licensee has complied with its obligations pursuant to Clause 5.1 and/or Clause 5.2 (as the case may be); and if not

   

  		5.6.2	what specific action the Licensee should have taken (Specific Action) in order to have so complied.

   

  		5.7	Appointment of Expert. The Expert shall be appointed in accordance with the provisions of Schedule 3 and his decision shall be final and binding on the Parties.

   

  		5.8	Consequences of Expert’s decision. If the Expert determines that the Licensee has failed to comply with its obligations pursuant to Clause 5.1 taking into account the provisions set out in Schedule 2,
          and if the Licensee fails to take the Specific Action within six (6) months of the Expert giving his decision, UCD shall be entitled, by giving, at any time within three (3) months after the end of that six (6) month period, not less than three
          (3) months’ notice to terminate this Agreement and the licences granted to the Licensee pursuant to Clause 2.

   

  		5.9	Licensee shall report to UCD the dates of the First Commercial Sale of a Product and the First Commercial Sale of each and every subsequent Product (that is each and every subsequent Product requiring a separate
          marketing authorisation such as pursuant to a New Drug Application) in each country within the Territory within [***] of their occurrence.

   

  
  
    	 	13	 

  

  
     

  

  
   

  		5.10	The Licensee will ensure that the Products and the packaging associated with them are appropriately marked with any relevant Patent or patent application numbers to comply with the laws of each of the countries in
          which the Products are sold.

   

  		5.11	The Licensee shall procure that the manufacture of the Products are to the standard of quality and workmanship as is required by and to comply with all applicable laws and regulations in each country of the
          Territory, and the Licensee shall be responsible for compliance with all relevant regulatory and legal requirements in respect of the Licensed IP and Products.

   

  		6.	PAYMENTS 

   

  		6.1	Subject to Clause 6.2 hereto, in consideration of the rights granted pursuant to Clause 2 and Clause 3, the Licensee shall make payments to UCD in accordance with this Clause 6.1 as follows:

   

  		6.1.1	Upfront and Milestone Payments:

   

  		(a)	an upfront payment of forty thousand Euro (€40,000) [***] of the Effective Date;

   

  		(b)	development milestone payment(s) of:

   

  		(i)	one hundred thousand Euro (€100,000) on the successful completion of the first Phase IIa Proof of Concept Study; and

   

  		(ii)	one hundred thousand Euro (€100,000) on successful completion of the first Phase IIb Study; and

   

  		(c)	commercial milestone payment(s) of:

   

  		(i)	two hundred thousand Euro (€200,000) when the First Commercial Sale of a Product has been achieved; and

   

  		(ii)	two hundred thousand Euro (€200,000) in the case of the First Commercial Sale of each and every subsequent Product (that is each and every subsequent Product requiring a separate marketing authorisation such as
          pursuant to a New Drug Application).

   

  All upfront and milestone payments as set out and specified in this Clause 6.1.1 are non-creditable and non-refundable.

   

  		(d)	The milestone payments in Clause 6.1.1(b) shall only be payable if the applicable Product is covered by a Valid Claim in France, Germany, Italy, Spain, the United Kingdom, or the United States.

   

  		(e)	The milestone payments in Clause 6.1.1(c) shall only be payable if (i) the sale of the applicable Product is covered by a Valid Claim, or (ii) there is Orphan Drug Exclusivity for such a Product in the country of
          sale.

   

  		6.1.2	Royalty Payments on Net Sales:

   

  		(a)	Net Sales of Product as follows:

   

  		(i)	two per cent (2%) on Net Sales in a calendar year up to one hundred million Euro (€100,000,000); and

   

  
  
    	 	14	 

  

  
     

  

  
   

  		(ii)	three per cent (3%) on Net Sales in a calendar year in excess of one hundred million Euro (€100,000,000).

   

  		(b)	A royalty on Net Sales of the Product shall only be payable:

   

  		(i)	if at the time of sale the sale of the Product is covered by a Valid Claim in the country of sale,

   

  		(ii)	if at the time of sale there is Orphan Drug Exclusivity for the Product in the country of sale; or

   

  		(iii)	in relation to the first Product to achieve First Commercial Sale in any country of the Territory, until the last to occur of (a) the expiration of the last Valid Claim covering the Product in the country of sale,
          (b) the expiration of Orphan Drug Exclusivity for the Product in the country of sale, or (c) fifteen years (15) from the date of the First Commercial Sale of such Product in any country of the Territory, provided that such period follows the
          expiration of the last Valid Claim in the applicable country of sale.

   

  		(c)	If the royalty on Net Sales relates to a Combination Product, (i) the royalty rate in Clause 6.1.2(a)(i) shall not be reduced below [***], and (ii) the royalty rate in Clause 6.1.2(a)(ii) shall not be reduced below
          [***].

   

  		(d)	The determination as to the applicable royalty rates in this Clause 6.1.2 shall be determined during every calendar year of the period set out in Clause 6.1.2.

   

  		6.1.3	Net Receipts:

   

  		(a)	thirty per cent (30%) of Net Receipts received during that period of the Term prior to the initiation of a Phase I Study;

   

  		(b)	twenty per cent (20%) of Net Receipts received during that period of the Term commencing upon the initiation of the Phase I Study and before the completion of a Phase IIa Proof of Concept Study;

   

  		(c)	ten per cent (10%) of Net Receipts received during that period of the Term commencing upon the completion of a Phase IIa Proof of Concept Study.

   

  		(d)	A royalty on Net Receipts in relation to royalties received by Licensee or an Affiliate from a sub-licensee shall only be payable:

   

  		(i)	if at the time of sale by the sub-licensee the sale of the Product is covered by a Valid Claim in the country of sale;

   

  		(ii)	if at the time of sale by the sub-licensee there is Orphan Drug Exclusivity for the Product in the country of sale; or

   

  		(iii)	in relation to the first Product to achieve First Commercial Sale in any country of the Territory, until the last to occur of (a) the expiration of the last Valid Claim covering the Product in the country of sale,
          (b) the expiration of Orphan Drug Exclusivity for the Product in the country of sale; or (c) fifteen years (15) from the date of the First Commercial Sale of such Product in any country of the Territory, provided that such period follows the
          expiration of the last Valid Claim in the applicable country of sale.

   

  
  
    	 	15	 

  

  
     

  

  
   

  		(e)	If the royalty on Net Receipts relates to a Combination Product, the royalty rates in Clauses 6.1.3(a), (b) and (c) shall not be reduced by more than [***].

   

  General Terms re Payments:

   

  		6.2	The consideration which the Licensee and/or its Affiliates shall charge Third Parties for the supply of Product shall be on an arm’s length transaction basis on Reasonable Commercial Terms. If any prices are not
          charged on this basis, the Net Sales shall be calculated based on the price which would have been charged on an arm’s length transaction basis.

   

  		6.3	Subject to the provisions of Clause 6.4, UCD shall be responsible for and shall bear all taxes levied upon payments received by it, and UCD hereby authorises Licensee to withhold such taxes from the payments which
          are payable to UCD in accordance with this Agreement if Licensee is either required to do so pursuant to the applicable tax laws or directed to do so by any agency of the relevant government. Upon the written request of UCD, Licensee shall, with
          respect to the laws of the country from which the payments are made, reasonably support UCD in its legal efforts to minimise any such withholding taxes, and provide UCD with information about any and all documentation reasonably required to
          enable UCD to obtain appropriate relief in respect to the payment in question and, if this is not possible, to facilitate the reduction of the withholding to a legal minimum and on request to provide UCD with receipts and any other evidence from
          relevant revenue authorities which may be required by UCD for its own tax affairs in this respect.

   

  		6.4	In the event that the Licensee ceases to be tax resident in Ireland, the Parties shall in good faith review the provisions of Clause 6.3 and negotiate such amendments to Clause 6.3 as are fair and equitable between
          the Parties.

   

  		6.5	All amounts payable by the Licensee pursuant to of this Agreement shall be made in Euro, and shall be payable by cheque or by bank transfer to the account of UCD as set out in Annex 1:

   

  		6.6	All amounts payable to UCD pursuant to Clauses 6.1.2 and 6.1.3 shall be payable annually within [***] from the end of each Reporting Period and include payment of all sums payable or receivable in respect of that
          Reporting Period.

   

  		6.7	Any exchange of currency made to calculate sales or payments for the purpose of this Clause 6 will be determined as at the last Business Day of each Reporting Period with respect to which the sales or payments are
          made, using the average of the average daily buying and selling rates of such other currency as quoted by Bank of Ireland in Dublin during that Reporting Period.

   

  		6.8	If the Licensee fails to make any payment due to UCD pursuant to this Agreement by the due date, without prejudice to any other right or remedy available to UCD, UCD may charge interest both before and after any
          judgment) on the amount outstanding, on a daily basis at a rate equivalent to of [***] per annum above the ECB Rate from time to time in force. Such interest will be calculated from the payment due date to the actual date of payment, both dates
          inclusive. The Licensee will pay such interest to UCD on demand.

   

  Financial Reporting:

   

  		6.9	When making any payments to UCD pursuant to this Agreement, the Licensee shall also contemporaneously notify NovaUCD as per UCD’s perspective representative as in accordance with clause 13.2 in writing of said
          payment, and said notification shall be accompanied by a report sent to NovaUCD (hereinafter Financial Reports), certified as true and accurate by an authorised officer of the Licensee, showing such information as UCD may reasonably
          request to enable UCD to calculate the sums due to UCD pursuant to this Agreement, including, without

   

  
  
    	 	16	 

  

  
     

  

  
   

  limitation, details of how the following were calculated in respect of the payments made for the Reporting Period in question: gross revenue
    receivable by the Licensee, the sources of that revenue, the deductions made to calculate Net Sales, and all sums due to UCD.

   

  		6.10	The Licensee shall, and shall procure that its Affiliates and its sub-licensees (as applicable), keep accurate records and books of account (hereinafter Records and Accounts) showing details of all
          activities in respect of the Licensed IP for the Purpose in the Field in the Territory and such other information as would be reasonably necessary for UCD to be able to confirm the calculation of Net Sales and Net Receipts including, without
          limitation, details of sums receivable by the Licensee in respect of the Licensed IP for the Purpose in the Field in the Territory, (including in respect of Products made or sold), for at least [***] following the dates of the underlying
          transaction, and will permit UCD or its agents to inspect and audit these records and books, who shall also be entitled to take copies of or extracts from the same. In the event that any such inspection or audit reveals a discrepancy of greater
          than [***] between the sums paid from those payable to UCD pursuant to this Agreement, the Licensee shall, save where the determination of such inspection or audit is disputed in good faith by Licensee (acting reasonably), promptly (i) make up
          any shortfall plus interest at a rate of [***] per annum above the ECB Rate from time to time in force, and (ii) reimburse UCD in respect of any reasonable professional charges incurred for such audit or inspection. The provisions of this Clause
          6.10 shall continue to apply notwithstanding termination or expiry of this Agreement for whatever reason, until the payment of all outstanding sums due to UCD.

   

  		7.	CONFIDENTIALITY

   

  		7.1	Confidential Information shall mean:

   

  		7.1.1	the provisions of this Agreement and information, know-how or data that is disclosed by one Party to the other Party for the purposes of this Agreement before, on or after the date of this Agreement relating to the
          operations, business, research of a Party which if disclosed in writing shall be marked ‘Confidential’, or if first disclosed otherwise, shall within thirty (30) Business Days of such disclosure be reduced to writing by the Party, as the case may
          be, and sent to the other Party. For the avoidance of doubt Know-How shall be treated as Confidential Information of UCD and shall be subject to the applicable confidentiality restrictions in Clause 3. Furthermore, all information relating to the
          Application disclosed by UCD to the Licensee shall be treated as Confidential Information of UCD and the provisions of this Clause 7 shall be construed accordingly;

   

  		7.1.2	Confidential Information shall exclude information which:

   

  		(a)	is publicly available or subsequently becomes publicly available other than in a breach of this Agreement;

   

  		(b)	the recipient can demonstrate by way of contemporaneous written documentation was already lawfully known to the recipient on a non-confidential basis before being disclosed by the recipient; or

   

  		(c)	is rightly acquired from a Third Party who is not in breach of an agreement to keep such information confidential

   

  		7.1.3	Subject to the provisions of Clause 7.2, each Party shall (i) keep the Confidential Information confidential at all times; (ii) not disclose the Confidential Information or allow it to be disclosed in whole or in
          part to any Third Party without the prior written consent of the other Party such consent not to be unreasonably withheld, conditioned or delayed, except in accordance with

   

  
  
    	 	17	 

  

  
     

  

  
   

  the provisions of this Agreement; (iii) not to use the Confidential Information in whole or in part for any purpose, other than for the sole
    purpose of performing its obligations under this Agreement; (iv) to take all proper and reasonable measures to ensure the confidentiality of the Confidential Information; (v) to inform the other Party immediately if it becomes aware of the possession,
    use, or knowledge of any of the Confidential Information by an unauthorized person, and to provide any reasonable assistance in relation to such unauthorized possession, use, or knowledge that the other Party shall require; (vi) to refrain from using
    the Confidential Information for any purposes outside the scope of this Agreement either for the other Party’s benefit or for the benefit of any of its Agents; and (vii) not disclose Confidential Information of the other Party to others (except to its
    employees, agents or consultants who are bound to the applicable Party by a like obligation of confidentiality) without the express written permission of other Party, except that the Party shall not be prevented from using or disclosing any of the
    Confidential Information of the other Party that:

   

  		(a)	such Party can demonstrate by written records was previously known to it;

   

  		(b)	is now, or becomes in the future, public knowledge other than through acts or omissions of such Party;

   

  		(c)	is lawfully obtained by such Party from sources independent of the other Party; or

   

  		(d)	is required to be disclosed by law, a court of competent jurisdiction or a relevant stock exchange, in which case the Party will (i) inform the other Party of the full circumstances of the disclosure and the
          information that shall be disclosed; (ii) consult with the other Party prior to such disclosure as to possible steps to avoid or limit disclosure and take those steps where they would not result in significant adverse consequences; (iii) ask the
          court or other public body to treat the Confidential Information as confidential; and (iv) in the event disclosure of the Confidential Information is made, only disclose the minimum amount necessary to comply with the court or public body’s
          request.

   

  		7.2	The Financial Reports, Records and Accounts and Report shall be treated as Confidential Information of the Licensee, but notwithstanding the provisions of Clause 7.1, UCD may identify the sums received from the
          Licensee in UCD’s annual report and similar publications, in consideration of the disclosure by the Licensee of the Financial Reports, Records and Accounts and Report to UCD, provided that UCD agrees:

   

  		7.2.1	to keep such Financial Reports, Records and Accounts and Report strictly confidential and to use such Financial Reports, Records and Accounts and Reports solely in connection with and for the purposes of this
          Agreement and in the manner as set out in this Agreement, and for no other purpose;

   

  		7.2.2	to only disclose such Financial Reports, Records and Accounts and Report (in relation to the financial aspects of the Report only) (and for the avoidance of doubt, unless otherwise required by a funding agency,
          ensuring all technical and other information relating to the Licensed IP is not disclosed) to such employees, contractors or sub-licensees as require same only for the purposes of this Agreement;

   

  		7.3	In relation to the proposed publication of material relating to the Licensed IP:

   

  		7.3.1	UCD shall provide a copy of proposed publication material relating to the Licensed IP to the Licensee for review and comment at least [***] prior to the proposed submission date for publication (Review Period);

   

  
  
    	 	18	 

  

  
     

  

  
   

  		7.3.2	during the Review Period UCD shall in good faith consult with Licensee and its patent advisers to consider recommended alterations or deletions to the proposed publication material that are reasonably appropriate in
          order to enable UCD to seek appropriate legal protection or registration of such Licensed IP, but UCD shall not be obliged whatsoever to make such alterations or deletions, and such alterations or deletions may be made by UCD in and/or at UCD’s
          sole discretion;

   

  		7.3.3	if, during the Review Period, the Licensee (acting reasonably) requests alterations to the proposed publication material so that it does not disclose any (i) Confidential Information of the Licensee, or (ii)
          proprietary information owned by Licensee, the publication will be amended as requested; and

   

  		7.3.4	if, during the Review Period, the Licensee reasonably requests it and to the extent the proposed publication material contains IPR owned by the Licensee, UCD may also be required by the Licensee to delay publication
          for a period not exceeding [***] in order to enable the Licensee (as the case may be in accordance with this Agreement) to seek appropriate legal protection or registration of such IPR as owned by the Licensee.

   

  		7.4	The obligations of each Party with respect to Confidential Information shall continue for a period ending [***] from the termination or expiry of this Agreement, excepting in respect to Know-How, which shall be
          treated as Confidential Information of UCD and which is and shall be subject to the confidentiality and secrecy restrictions as set out in and in accordance with Clause 3 and which obligations shall continue to be binding on the Parties (as
          applicable) in accordance with the relevant provisions of Clause 3.

   

  		8.	MANAGEMENT AND PROTECTION OF LICENSED IP

   

  Management of Licensed IP:

   

  		8.1	Within [***] of the Effective Date, Licensee shall reimburse UCD in respect of all of the vouched Third Party costs and expenses UCD has incurred for the filing, prosecuting, maintaining, protecting and all other
          actions and costs in respect of the Application, including the professional and associated costs therewith (Past Patent Costs). Such Past Patent Costs shall be paid by the Licensee to the UCD within [***] of receiving an invoice from
          and/or on behalf of the UCD, dated after the Effective Date. During the Term, the Licensee will be entitled to and shall be responsible for taking, and shall take, all actions and pay all costs associated with the filing, prosecution,
          maintenance, protection and all other actions and costs in respect of the Application, including the professional and associated costs therewith.

   

  		8.2	During the Term, the Licensee, shall appoint and be the point of contact with patent agents mutually agreed between the Licensee and UCD in respect of all aspects of filing, prosecuting and maintaining the Patent
          Rights, but. Licensee shall ensure UCD receives a copy of material correspondence to and from the relevant patent offices and shall consult with UCD in respect of the filing, prosecution and maintenance of the Patent Rights, including the
          designation of all countries, unless the Parties agree otherwise in writing.

   

  		8.3	UCD shall provide the Licensee all reasonable assistance in the filing, and prosecution of the Patent Rights, and the maintenance of the Patent Rights when granted, at the expense of the Licensee.

   

  		8.4	The Licensee and UCD shall cooperate fully in the preparation, filing, prosecution and maintenance of the Patent Rights in the Territory by executing all papers and instruments so as

   

  
  
    	 	19	 

  

  
     

  

  
   

  to enable the Licensee to apply for, to prosecute and to maintain patent applications and Patents in UCD’s name in any country, including the
    execution of documents by applicable employees and students of UCD. Each Party shall promptly notify the other Party as to all matters which come to its attention and which may affect the filing, prosecution, maintenance and protection of the Patent
    Rights.

   

  		8.5	UCD shall provide such assistance as is reasonably required by the Licensee to obtain all available SPC(s) in relation to the Patent Rights. If a Party has an option to extend the patent term for only one of several
          granted Patents pursuant to the Patent Rights, the Parties will consult before making the election. If more than one granted Patent pursuant to the Patent Rights is eligible for extension, SPC or patent term restoration, the Parties will discuss
          and agree upon a strategy that will maximise patent protection for the Patent Rights. All filings of such SPC(s) will be the responsibility of the Licensee with all reasonable assistance from UCD and shall be owned by UCD.

   

  		8.6	The Licensee shall pay the costs of all SPC filings and payment shall be made by the Licensee directly to the patent agent mutually agreed between the Licensee and UCD to be responsible for the drafting and filing of
          such SPCs.

   

  		8.7	Licensee agrees and acknowledges that, save as specified in this Clause 8, UCD shall be under no other obligation to do any other acts or things, or pay any sums, to prosecute, maintain, defend or in any other way
          protect the Patent Rights.

   

  		8.8	Notwithstanding Clause 8.2, Licensee shall not permit any Patent Rights (or if granted, any Patent) to lapse or be abandoned in [***], without giving UCD at least thirty (30) Business Days’ notice prior to any such
          lapse or abandonment, of its intention to do so, in order that UCD has an opportunity to assume full responsibility for the continued prosecution and maintenance of same in the applicable country or countries, including the payment of all costs
          associated therewith. In the event that the Licensee elects not to do any particular act specified in this Clause 8.8 and UCD elects (in its sole discretion) to take said action, then UCD’s rights in the Patent Rights for the applicable country
          or countries shall be deemed to be excluded from the licence granted to the Licensee in this Agreement, the Licensee’s responsibility for the future costs will terminate in respect of the Patent Rights in question in the applicable country or
          countries on the date of UCD’s receipt of the Licensee’s notice, and UCD shall have the sole and exclusive right to use and exploit all rights in the applicable Patent Rights in the applicable country or countries. It is understood that UCD shall
          have the right, but not the obligation, to assume such responsibility under this provision.

   

  		8.9	Infringement by Third Parties

   

  		8.9.1	The Licensee shall promptly give UCD full information of any actual, threatened or suspected infringement by a Third Party of the Licensed IP or of any declaratory judgment, opposition, or similar action alleging the
          invalidity, unenforceability or non-infringement of any of the Licensed IP including as follows: (i) that any aspects of the Licensed IP is being attacked whether through validity challenge, revocation application, nullity action, opposition,
          interference or otherwise; or (ii) that any application for a Patent is made by, or any Patent is granted to, a Third Party by reason of which the Third Party in a Party’s opinion may be granted or may have been granted rights which conflict with
          any of the rights granted to the Licensee under the Licensed IP; or (iii) of any infringement/misappropriation or potential infringement/misappropriation of any of the Licensed IP; or (iv) that any application is made for a compulsory licence
          under any granted Patent (collectively Third Party Infringement) of which the Licensee becomes aware.

   

  
  
    	 	20	 

  

  
     

  

  
   

  		8.9.2	If a Third Party Infringement occurs, then the Parties will consult in good faith with each other as to the appropriate course of action to be taken and to decide the best way to respond to such alleged infringement.
          The Licensee may, in its sole discretion, take such action as is commercially and legally reasonable in accordance with the advice and resources available to it with respect to the Third Party Infringement. In any event, before starting any legal
          action under this Clause 8.9.2, the Licensee shall consult with UCD as to the advisability of the action or settlement, its adverse effect on the good name of UCD, how the action should be conducted, and in addition, if the alleged infringement
          is both within and outside the Field, the Parties shall also co-operate with UCD’s other licensees (if any) in relation to any such action. Such action will be brought in the Licensee’s own name and at the Licensee’s cost, and the Licensee will
          retain all damages awarded or settlement amounts received to reimburse Licensee for all costs and expenses incurred relating to such proceedings which have not already been reimbursed in such court judgment. At the request of the Licensee, UCD
          shall provide reasonable assistance to the Licensee in connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action.

   

  		8.9.3	The Licensee indemnifies UCD against all actions, claims, loss, damage, cost or expenses and awards, which UCD may incur, suffer or become liable to, arising out of or in connection with any proceedings or action
          taken by the Licensee in relation to a Third Party Infringement.

   

  		8.9.4	The Licensee shall keep UCD advised of the progress of such proceedings and provide UCD with copies of documents used in or prepared for such proceedings (subject to ensuring that any legal professional privilege in
          any documents is maintained).

   

  		8.9.5	If UCD wishes, in its sole discretion, to join or assist the Licensee in prosecuting such proceedings, UCD will notify the Licensee of such wish and in such event shall contribute to the costs and expenses of the
          proceedings as agreed between the Parties, and if no agreement is reached as to costs and expenses as between the Parties, then UCD shall have no obligation to contribute to the costs and expenses of the proceedings.

   

  		8.9.6	If the Licensee:

   

  		(a)	determines it will not take action or, once some action has been engaged in, not commence proceedings, the Licensee will promptly notify UCD in writing that it is unwilling to take action or proceedings against a
          Third Party with respect to a Third Party Infringement; or

   

  		(b)	fails to take any action or agree a course of action with UCD, within a period of [***] after notification of the Third Party Infringement pursuant to Clause 8.9.1,

   

  unless the Parties agree alternative arrangements, then UCD may institute and prosecute an action in its own name, in which case UCD will retain all damages
    awarded or settlement amounts received.

   

  		8.10	Third Party claims

   

  		8.10.1	If proceedings are threatened or commenced by a Third Party against UCD, or the Licensee in the Territory on the ground that the exploitation of any Licensed IP or Product pursuant to this Agreement infringes IPR
          owned by a Third Party, then:

   

  		(a)	the Party threatened or sued shall promptly notify the other Party and provide full information. The Parties shall promptly consult with each other in good faith;

   

  
  
    	 	21	 

  

  
     

  

  
   

  		(b)	the Parties will refer the matter to the Licensee’s patent lawyer for advice on the action, or settlement thereof and how the action should be conducted;

   

  		(c)	each Party will co-operate in providing the necessary information and documents and attend meetings to assist the preparation of that advice; and

   

  		(d)	the Licensee will pay for the cost of that advice.

   

  		8.10.2	Subject to Clause 8.10.1, if proceedings are threatened or commenced against the Licensee, the Licensee will, in consultation with UCD, be responsible for the defence of those proceedings.

   

  		8.10.3	A Party will not be required to defend any infringement proceedings brought by a Third Party where advice obtained pursuant to Clause 8.10.1(b) is to the effect that it would be imprudent to defend such proceedings.

   

  		8.10.4	Each Party agrees to keep the other Party advised of the progress of any proceedings in which it is a defendant and (subject to ensuring that any legal professional privilege in any documents is maintained) provide
          the other Party with copies of documents used in or prepared for such proceedings.

   

  		8.11	If during the Term of this Agreement, the Licensee acting in a commercially reasonable manner considers it necessary to obtain a licence from any Third Party (a Third Party Licence) in order to avoid
          infringing a Third Party’s Patent(s) resulting from the exploitation of the Patent Rights, the Licensee shall be entitled to offset [***] of the amount paid pursuant to the Third Party Licence against the royalty payments otherwise payable to UCD
          pursuant to Clauses 6.1.2 and 6.1.3 of this Agreement, provided that such royalty payments payable to UCD shall not be reduced by more than [***] of the royalty payment otherwise payable pursuant to Clauses 6.1.2 and 6.1.3 of this Agreement. The
          offset referred to in this Clause 8.11 shall only be made where the infringement of the Third Party’s Patents arises from the use of the Patent Rights in accordance with the provisions of this Agreement, and not from the use of any other IPR that
          the Licensee chooses to use in the manufacture or sale of any Product.

   

  		8.11.1	In the event that the Licensee is required to make a payment of any amount to a Third Party in connection with a Third Party claim resulting from the exploitation of the Patent Rights in order to avoid infringing a
          Third Party’s Patent(s), by way of damages, pursuant to a court order, settlement or otherwise, the Licensee shall be entitled to offset [***] of the amount paid pursuant to the Third Party Licence against the royalty payments otherwise payable
          to UCD pursuant to this Agreement, provided that the royalty payments payable to UCD shall not be reduced by more than [***] of the royalty payments otherwise payable.

   

  		8.11.2	The Licensee shall have the right to carry forward any amounts of the credit which are not or have not been off set against the royalty payments paid in any given calendar year to the following or subsequent calendar
          years (if applicable) as against payments otherwise payable by Licensee pursuant to Clause 6.1.2 or 6.1.3.

   

  		9.	WARRANTIES AND LIABILITY

   

  		9.1	Each of the Parties acknowledges that, in entering into this Agreement, it has not relied on any warranty, representation or undertaking and each Party waives any claim for breach of any warranty, representation or
          undertaking which is not expressly contained in this Agreement as a warranty.

   

  
  
    	 	22	 

  

  
     

  

  
   

  		9.2	Subject to the provisions of Clause 9.4 and Clause 9.6, Licensee acknowledges that UCD is providing the Licensed IP on an ‘as is’ basis, without warranty or representations, including, by way of example, without any
          warranty or representation:

   

  		9.2.1	as to merchantability, fitness for a particular purpose, accuracy, efficacy, completeness, capabilities or safety; or

   

  		9.2.2	as to the efficacy or usefulness of any of the Licensed IP; or

   

  		9.2.3	that the Application will proceed to grant or, if granted, shall be valid; or

   

  		9.2.4	that the use of any of the Licensed IP, or the manufacture, use or supply of any Products, or the exercise of any of the rights granted pursuant to this Agreement will not infringe any IPR or other rights of any
          other person; or

   

  		9.2.5	that any Products will be of satisfactory quality or fit for the purpose for which the Licensee (or its sub-licensees or customers) intended, and all warranties, conditions, terms, undertakings and obligations with
          respect to the Licensed IP and any Products, whether express or implied by statute, common law, custom, trade usage, course of dealing or in any other way, are hereby excluded to the greatest extent permitted by law.

   

  		9.3	Subject to the provisions of Clause 9.12, the total aggregate liability of UCD in respect of the Licensed IP or arising in any other way out of the subject matter of this Agreement shall not exceed the total amounts
          paid by Licensee to UCD pursuant to this Agreement.

   

  		9.4	Warranties by UCD

   

  UCD represents and warrants to the Licensee that, except as otherwise disclosed by UCD in writing, and as far as UCD is aware (but without
    having carried out any searches or investigations in this regard, including without limitation in respect to the existence of any Third Party rights that may affect any of the Licensed IP, each of the following warranties is correct as at the Effective
    Date:

   

  		9.4.1	UCD is the owner of the Patent Rights and has the right to grant the licences pursuant to this Agreement to the Licensee;

   

  		9.4.2	all necessary licenses, consents, permits and authorities (public and private), have been obtained to enable UCD to properly perform its obligations pursuant to this Agreement;

   

  		9.4.3	the execution and performance of this Agreement by UCD does not breach any agreements that it has with Third Parties;

   

  		9.4.4	in relation to the agreement entered into by UCD on [***] with a Third Party pursuant to which UCD granted a non-exclusive licence to the certain of the Licensed IP to the Third Party to facilitate a project to be
          conducted in conjunction with [***] (as an SFI Fellow)(Fellowship Agreement), and such non-exclusive licence in respect to such Licensed IP granted to such Third Party will be terminated in accordance with and pursuant to the terms and
          conditions of such Fellowship Agreement, and that following such termination the said Third Party shall have no rights to the Licensed IP;

   

  		9.4.5	there is no action or proposed action by any other person to challenge, threaten or cancel any IPR in the Licensed IP;

   

  
  
    	 	23	 

  

  
     

  

  
   

  		9.4.6	there is no claim against any person relating to or alleging infringement of any of the Licensed IP;

   

  		9.4.7	no claim or legal proceeding has been served on UCD, nor, is any claim or legal proceeding threatened, by any person alleging (and there is no basis for any claim, whether or not asserted) that:

   

  		(a)	the Licensed IP are invalid or unenforceable; or

   

  		(b)	the Licensed IP violates or infringes the IPR of any Third Party;

   

  		9.4.8	there are no judgments against UCD or settlements to which UCD is a party concerning the Licensed IP;

   

  		9.4.9	the Know-How was generated by employees of UCD, and in each case the terms of employment vested in UCD, all right, title, and interest in and to any intellectual property generated by them in respect of such
          Know-How; and UCD is not aware that any Third Party has rights in any Know-How that would adversely affect the Licensee’s rights pursuant to this Agreement.

   

  		9.5	Mutual warranties

   

  Each Party warrants that at the Effective Date:

   

  		9.5.1	it has full corporate power and authority to enter into, perform and observe its obligations and duties pursuant to this Agreement and that the execution and performance of this Agreement by it has been duly and
          validly authorised by all necessary corporate action;

   

  		9.5.2	this Agreement and the transactions contemplated by this Agreement do not contravene its constituent documents or any law, regulation or official directive or any of its obligations or undertakings by which it or any
          of its assets are bound or cause a limitation on its powers or of its directors and officers to be exceeded; and

   

  		9.5.3	its obligations pursuant to this Agreement are valid and binding and enforceable against it in accordance with their terms.

   

  		9.6	Licensee’s warranties

   

  		9.6.1	The Licensee acknowledges and agrees that the Licensee, its Affiliates, and its Sub-licensees exploit the Licensed IP at their own risk.

   

  		9.6.2	The Licensee warrants to UCD that each sub-licence agreement will be enforceable in accordance with its terms.

   

  		9.7	Neither Party shall be liable to the other Party for any death or injury unless it is caused by the negligence of that Party or its agents.

   

  		9.8	Indemnity by the Licensee

   

  The Licensee agrees to indemnify and hereby indemnifies and keeps indemnified UCD and its respective directors, officers, employees and agents
    (each an Indemnified Party) against all liability, loss, costs, damages or expense (including legal costs and expenses) incurred or suffered by UCD (except any claim caused by breach of this Agreement, negligence, malpractice, wrongful acts or
    omissions or breach of statutory duty of UCD), as a result of:

   

  		9.8.1	wilful misconduct, negligent act or omission or wilful failure to act on the part of the Licensee;

   

  
  
    	 	24	 

  

  
     

  

  
   

  		9.8.2	the development, manufacture, use, marketing or sale of, or any other dealing in any of the Products by the Licensee or other entity involved in the development, manufacture, use, marketing or sale of, or any other
          dealing in any of the Products under its authority;

   

  		9.8.3	the use by a Third Party of any Product manufactured by the Licensee or other entities involved in the manufacture by the Licensee;

   

  		9.8.4	the use of any of the Licensed IP by the Licensee; and

   

  		9.8.5	and/or arising out of any act or omission of any sub-contractor, including (i) pursuant to the provisions of Clause 2.8, and (ii) in relation to any product liability claim relating to Products manufactured by the
          subcontractor.

   

  		9.9	Continuing obligations

   

  The indemnities in this Agreement are enforceable as debts and are continuing obligations, independent from the other obligations pursuant to
    this Agreement and continue after this Agreement ends. Upon UCD becoming aware of any claim or other circumstance that may give rise to it seeking to rely on an indemnity set out in this clause, UCD shall provide the Licensee with full details of the
    action, claim, proceeding, or demand.

   

  		9.10	Enforcement of indemnities and conduct of claims

   

  It is not necessary for UCD to incur expense or make payment before enforcing a right of indemnity conferred by this Agreement. Before making
    any demand for performance of the indemnity UCD shall allow the Licensee sufficient time as is reasonable in the circumstance to investigate its alleged liability and to negotiate a settlement of or defend the action, claim, proceeding or demand. In
    particular, UCD will permit the Licensee and its insurer, at Licensee’s expense, to assume or participate in the defence of any such claims or suits. UCD will co-operate with Licensee and its insurers in such defence when reasonably requested to do so
    and will not compromise or settle the claim or suit without Licensee’s prior written consent.

   

  		9.11	Limitation of Liability

   

  Subject to Clause 9.12 and notwithstanding anything to the contrary in this Agreement and excluding the indemnity provided by the Licensee to
    UCD pursuant to Clause 9.8, neither Party shall not be liable to the other Party by reason of any representation or warranty, indemnity, condition or other term or any duty of common law, or under the express terms of this Agreement, for any
    consequential or special or incidental or punitive loss or damage (whether for loss of current or future profits, loss of enterprise value or otherwise), or loss of opportunity, and whether occasioned by the breach of contract or the negligence or
    other wrongdoing of the responsible Party, its employees or agents or otherwise.

   

  		9.12	Nothing in this Agreement shall limit or exclude the liability of either Party for:

   

  		9.12.1	death or personal injury resulting from negligence;

   

  		9.12.2	fraud or fraudulent misrepresentation; and

   

  		9.12.3	any breach of this Agreement that results from the wilful act or wilful omission of that Party or its employees, agents or sub-contractors.

   

  		9.13	On the written request of UCD, the Licensee shall provide a copy of the insurance cover secured by the Licensee. Licensee shall obtain and maintain at its own cost and expense, the same level 

        

   

  
  
    	 	25	 

  

  
     

  

  
   

  	 	 	of insurance during the Term, and for any period thereafter where any Product utilising any of the Licensed IP is being commercially developed or sold. 

        
	 	 	 
		10.	TERM AND TERMINATION

   

  		10.1	This Agreement shall commence on the Effective Date and will continue in full force on a Product-by-Product and country-by-country basis until the later of (a) the expiration of the last to expire Valid Claim of the
          Patent Rights; (b) the expiration of Orphan Drug Exclusivity; or (c) fifteen (15) years after the First Commercial Sale of the first Product in the Territory by the Licensee, its Affiliates or sub-licensees (the Term), unless terminated
          earlier in accordance with the remainder of this Clause 10.

   

  		10.2	UCD may terminate this Agreement by giving at least thirty (30) Business Days’ prior written notice to the Licensee if:

   

  		10.2.1	the Licensee is in Material Breach of any provision of this Agreement and after receiving written notice from UCD identifying a Material Breach by Licensee of its obligations pursuant to this Agreement, fails to cure
          such Material Breach within [***], then UCD may give written notice of default (Notice of Default) to Licensee. If Licensee fails to cure the default [***] of the Notice of Default, UCD may terminate this Agreement and the license granted
          herein by a second written notice (Notice of Termination) to Licensee; or

   

  		10.2.2	the Licensee becomes insolvent, or if an interim order is applied for or made, or a voluntary arrangement approved, or a voluntary arrangement is proposed or approved or an administration order is made, or a receiver
          or administrative receiver is appointed of any of the Licensee's assets or undertaking or a winding-up resolution or petition is passed or presented (otherwise than for the purposes of reconstruction or amalgamation), or if any circumstances
          arise which entitle the court or a creditor to appoint a receiver, administrative receiver or administrator or to prevent a winding-up petition or make a winding-up order, or other similar or equivalent action is taken against or by the Licensee
          by reason of its insolvency or in consequence of debt, or if the Licensee makes any arrangement with its creditors;

   

  		10.2.3	the Licensee shall dispose of all or a substantial part of its business involving the licensing of the Licensed IP, for the Purpose in the Field in the Territory in circumstances where it does not enter into a
          novation agreement pursuant to Clause 13.5;

   

  		10.2.4	the Licensee or its Affiliates challenge the validity of the Application(s) when granted),or assists any Third Party to commence legal proceedings to challenge such validity;

   

  		10.2.5	pursuant to Clause 5.8; or

   

  		10.2.6	if the Licensee fails to pay any amount due pursuant to this Agreement (including payments due pursuant to Clause 6 of this Agreement) within [***] from Licensee receiving written notice from UCD of its failure to
          pay, and such failure to pay is not subject to a good faith dispute between the Parties.

   

  		10.3	The Licensee may terminate this Agreement by giving UCD not less than sixty (60) Business Days’ written notice at any time, provided that the Licensee shall continue to pay any invoices received within sixty (60)
          Business Days’ after the effective date of termination.

   

  		11.	CONSEQUENCES OF TERMINATION and expiry

   

  		11.1	On termination or expiry, of this Agreement for whatever reason:

   

  
  
    	 	26	 

  

  
     

  

  
   

  		11.1.1	all rights and licenses granted to the Licensee pursuant to this Agreement shall terminate forthwith and the Licensee shall not use any of the Licensed IP for any purpose;

   

  		11.1.2	subject to the provisions of Clause 11.1.5 the Licensee shall procure that all sub-licenses of any of the Licensed IP shall terminate forthwith;

   

  		11.1.3	the Licensee shall co-operate with UCD and provide such assistance as is necessary to cancel all or any licences registered pursuant to this Agreement;

   

  		11.1.4	the Licensee shall not be reimbursed for any payments made pursuant to this Agreement, and shall pay all outstanding payments properly accrued and/or payable to UCD up to and including the date of termination or
          expiry within [***] of the date of termination or expiry in accordance with Clause 6.1 (Payments); and

   

  		11.1.5	the Licensee and any sub-licensee shall have the right to dispose of all stocks of the Products in its possession and all Products in the course of manufacture at the date of termination, provided that any sums
          payable pursuant to the provisions of Clause 6.1 (as if such stocks shall have been supplied at the date of termination) shall be received within a period of [***] following termination.

   

  		11.2	Termination or expiry of this Agreement for whatever reason shall not extinguish or otherwise affect any obligations and/or rights of either Party to this Agreement which:

   

  		11.2.1	accrued prior to the date of termination or expiry; or

   

  		11.2.2	otherwise relate to or may arise at any future time from any breach or non-observance of obligations pursuant to this Agreement which arose prior to the date of termination or expiry.

   

  		11.3	Notwithstanding expiry or termination of this Agreement for whatever reason, the following terms shall continue to be binding on the Parties (to the extent applicable for the applicable period): Clause 2.3 (on
          expiry), Clause 3.2, Clause 4.1, Clause 4.4 (first sentence), Clause 6.10, Clause 7, Clause 8.11.2, Clause 9.2, Clause 9.6.1, Clauses 9.8 to 9.13, Clause 11, and Clause 13 as applicable.

   

  		12.	FORCE MAJEURE

   

  If the performance by either Party of any of its obligations pursuant to this Agreement (except a payment obligation) is made impossible,
    delayed or prevented by circumstances beyond its reasonable control including but not limited to war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other serious labour disputes; and floods,
    fires, explosions, or other natural disasters , that Party will not be in breach of this Agreement because of that delay in performance. When such events have abated, the non-performing Party’s obligations herein shall resume.

   

  		13.	GENERAL

   

  		13.1	Publicity: Neither UCD nor the Licensee will use the other’s name or logo in any press release or product advertising, or for any other promotional purpose, without first obtaining the other's written consent,
          except that UCD may identify the sums received from the Licensee in UCD’s annual report and similar publications.

   

  		13.2	Notices: Any notice to be given pursuant to this Agreement shall be in writing, may be delivered to the other Party by any of the methods set out in the left hand column below, and will be deemed to be
          received on the corresponding day set out in the right hand column:

   

  
  
    	 	27	 

  

  
     

  

  
   

  	Method of service 	Deemed day of receipt
	 	 
	By hand or courier	the day of delivery
	 	 
	By pre-paid first class post	the second Business Day after posting
	 	 
	By recorded delivery post	the next Business Day after posting

   

  The Parties’ respective representatives for the receipt of notices are, until changed by notice given in accordance with this Clause 13.2, as follows:

   

  	For UCD:	For the Licensee:
	 	 
	
          Name: Director of NovaUCD

           

          Address: NovaUCD,

          University College Dublin,

          Dublin 4

        	
          Name: Dr. Joseph Wiley

           

          Address: Amryt Genetics Limited,

            90 Harcourt Street, Dublin 2.

        

   

  		13.3	Headings: The headings in this Agreement are for ease of reference only; they do not affect its construction or interpretation.

   

  		13.4	Assignment by either Party: The rights of each Party pursuant to this Agreement are personal. Subject to the provisions of this Clause 13.4 and Clause 13.5, neither Party may assign, charge, transfer or
          otherwise encumber or dispose of any of their rights pursuant to this Agreement unless the prior written consent of the other Party has been obtained (such consent not to be unreasonably conditioned, withheld or delayed) SAVE THAT UCD may
          assign its rights and obligations pursuant to this Agreement to an entity that acquires its business or assets by way of public sector reorganization.

   

  		13.5	Novation by Licensee

   

  Excepting where the Licensee is insolvent or any other circumstance described in Clause 10.2 applies to the Licensee:

   

  		13.5.1	The Licensee may novate all (but not a portion) of its rights and obligations pursuant to this Agreement to an Affiliate, subject to entering into a deed of novation with that Affiliate which binds the Affiliate to
          the relevant terms and conditions of this Agreement; and

   

  		13.5.2	The Licensee may novate all (but not a portion) its rights and obligations pursuant to this Agreement together with its rights in the Licensed IP in an arm’s length transaction to any company to which it transfers
          all or substantially all of its assets or business or all or substantially all of its assets or business to which this Agreement relates, provided that the company is in a position to enter into (and actually enters into) a deed of novation which
          binds such company to the relevant terms and conditions of this Agreement.

   

  		13.6	Illegal/unenforceable provisions:  Each of the provisions of this Agreement is separate and severable and enforceable accordingly. If at any time any of the provisions is held to be void or unenforceable in
          law, including the laws of the European Union, the remainder of such provision and all other provisions of this Agreement shall remain valid and enforceable to the

   

  
  
    	 	28	 

  

  
     

  

  
   

  fullest extent permissible by law, and such provision shall be deemed to be omitted from this Agreement to the extent of such invalidity or
    unenforceability and the Parties shall negotiate in good faith to replace the invalid or unenforceable provision with a valid, legal and enforceable provision which achieves to the greatest extent possible the economic, legal and commercial objectives
    of the invalid or unenforceable provision.

   

  		13.7	Construction: This Agreement will be considered drafted by all Parties and it will not be construed against any one Party because that Party or its solicitors drafted it.

   

  		13.8	Waiver of rights:  If a Party fails to enforce, or delays in enforcing, an obligation of the other Party, or fails to exercise, or delays in exercising, a right pursuant to this Agreement, that failure or
          delay will not affect its right to enforce that obligation or constitute a waiver of that right, nor shall any single or partial enforcement or exercise of any obligation or right prevent any further or other enforcement or exercise thereof. Any
          waiver of any provision of this Agreement will not, unless expressly stated to the contrary, constitute a waiver of that provision on a future occasion.

   

  		13.9	No agency: Nothing in this Agreement creates, implies or evidences any partnership or joint venture between the Parties, or the relationship between them of principal and agent. Neither Party has any authority
          to make any representation or commitment, or to incur any liability, on behalf of the other.

   

  		13.10	Entire agreement: The Parties agree that this Agreement constitutes the entire agreement between the Parties relating to its subject matter and supersedes all previous agreements, discussions and arrangements
          between the Parties relating to the subject matter hereof.

   

  		13.11	Further Assurances: Each Party undertakes, at the reasonable request of the other Party at any time in the future, and at the requesting Party’s expense, to execute all such documents, give such assistance
          and do such acts and things as may in the opinion of the requesting Party be necessary to give effect to the terms of this Agreement.

   

  		13.12	Amendments:  No variation or amendment of this Agreement will be effective unless it is made in writing and signed by each Party's representative.

   

  		13.13	Governing law: This Agreement is governed by and is to be construed in accordance with Irish law. Subject to the provisions of Clauses 5.6, 5.7, 5.8, and 13.14, the Irish Courts will have exclusive
          jurisdiction to deal with any dispute which has arisen or may arise out of, or in connection with, this Agreement.

   

  		13.14	Disputes: If the Parties are unable to reach agreement on any issue concerning this Agreement within [***] after one Party has notified the other of that issue, the matter shall be referred to the Director of
          NovaUCD and the CEO of the Licensee. In the event these two (2) individuals cannot reach agreement within [***] of the matter being referred to them, the matter shall be subject to the jurisdiction of the Irish Courts. The provisions of this
          Clause 13.14 shall not apply in the event that a Party considers it necessary to seek injunctive relief.

   

  		13.15	Certain changes of Control: In the event of a change of Control of Licensee which results in a Third Party being in a position to change the composition of the board of directors of the Licensee, the Licensee
          shall give written notice thereof to UCD as soon as is practicable following such change of Control.

   

  		13.16	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original, and which together shall constitute one and the same

   

  
  
    	 	29	 

  

  
     

  

  
   

  Agreement. This Agreement shall become effective and be dated (and each counterpart shall be dated) on the date first written above between the
    parties which have executed and delivered a counterpart. Immediate evidence that a counterpart engrossment has been executed may be provided by transmission of such counterpart engrossment by fax machine or a scanned version thereof by email with the
    original executed counterpart engrossment to be put in the post as soon as practicable thereafter.

   

  
  
    	 	30	 

  

  
     

  

  
   

  Schedule 1

   

  Licensed IP

    

  

  
    	 	31	 

  

  
      

  

  
   

  Schedule 2

   

  MILESTONES

   

  		1.	As of the Effective Date and as part of the Licensee’s obligations pursuant to Clause 5.2, the Licensee agrees to meet the following milestones, either by itself and/or either directly or indirectly through its
          Affiliate(s) and/or its sub-licensee(s):

   

  		1.1.1	[***];

   

  		1.1.2	initiate the first Phase IIa clinical trial of a Product by [***];

   

  		1.1.3	initiate the first Phase IIb clinical trial of a Product by [***];

   

  		1.1.4	initiate the first pivotal clinical study of a Product by [***];

   

  		1.1.5	[***].

   

  		2.	The Parties acknowledge and accept that the estimated timelines set out above may have to be adjusted for a number of reasons, such as, the requirements of one or more regulatory agencies, supply chain issues or
          issues in connection with the conduct of the clinical study. In such event any updates and/or amendments to the Milestones shall be discussed in advance with UCD and any such updates and/or amendments shall be incorporated into this Agreement
          with the express written agreement of both Parties.

   

  		3.	For the purposes of this Schedule 2, initiation of a “clinical trial” and/or “clinical study” (as the case may be) shall mean the effective date of the clinical trial and/or clinical study research agreement (as the
          case may be) in which the first patient or subject is to be treated with Product pursuant to a protocol approved both by an appropriate institutional review board and by an appropriate drug regulatory agency with a therapeutic agent or process
          that has been manufactured according to the applicable good manufacturing practices (GMP) guidelines provided by the relevant regulatory agency.

   

  
  
    	 	32	 

  

  
     

  

  
   

  Schedule 3

   

  Appointment of expert

   

  		1.	Pursuant to Clause 5.5, UCD may serve notice on the Licensee (Referral Notice) that it wishes to refer to an expert who shall be independent, impartial and a leading authority in the Field, (the Expert)
          the questions set out in Clause 5.5.

   

  		2.	The Parties shall mutually agree the identity of the Expert who shall have at least ten (10) years’ experience of at least senior at vice president level in a engaged in the development and commercialisation of
          innovative pharmaceutical or biotechnology products. In the absence of such agreement within sixty (60) Business Days of the Referral Notice, the questions shall be referred to an Expert appointed by the President of Law Society of Ireland who
          shall have the experience referred to in this paragraph 2.

   

  		3.	Sixty (60) Business Days after the giving of a Referral Notice, both parties shall exchange simultaneously statements of case, and each side shall simultaneously send a copy of its statement of case to the Expert.

   

  		4.	Each Party may, within thirty (30) Business Days of the date of exchange of statement of case pursuant to paragraph 3 of this Schedule 3, serve a reply to the other side's statement of case of not more than 10,000
          words, or alternatively not to exceed such other word count as may be mutually agreed between the Parties in writing. A copy of any such reply shall be simultaneously sent to the Expert.

   

  		5.	The Expert shall make his decision on the said questions on the basis of written statements and supporting documentation only and there shall be no oral hearing. The Expert shall issue his decision in writing within
          thirty (30) Business Days of the date of service of the last reply pursuant to paragraph 4 of this Schedule 3, or in the absence of receipt of any replies, within sixty (60) Business Days of the date of exchange pursuant to paragraph 3 of this
          Schedule 3.

   

  		6.	The Expert's decision shall be final and binding on the Parties.

   

  		7.	The Expert's charges shall be borne equally by the Parties.

   

  
  
    	 	33	 

  

  
     

  

  
   

  Annex 1

   

  Bank Account Details 

   

   
  
  
    	 	34	 

  

  
     

  

  
   

  IN WITNESS WHEREOF, the Parties have hereto have signed this Agreement on the date set out above:

   

  	SIGNED on behalf of University College Dublin, National University of Ireland, DUBLIN:	 	SIGNED on behalf of AMRYT GENETICS LIMITED:
	 	 	 
	Ciaran O’Beirne	 	Joseph Wiley
	Name	 	Name
	 	 	 
	Manager, Technology Transfer	 	 
	Position	 	Position
	 	 	 
	/s/ Ciaran O’Beirne	 	/s/ Joseph Wiley
	Signature	 	Signature

   

  	Dated: 	14th March 2018	 	 	Dated:	 14th March 2018	 

   

  

  
  
    	 	35

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]